Form 8-K

8-K — Aditxt, Inc.

Accession: 0001213900-26-067421

Filed: 2026-06-10

Period: 2026-06-10

CIK: 0001726711

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0294307-8k_aditxt.htm (Primary)

EX-2.1 — BUSINESS COMBINATION AGREEMENT, DATED AS OF JUNE 10, 2026, BY AND AMONG COPLEY ACQUISITION CORP., IGNITE PROTEOMICS HOLDINGS, INC., IGNITE MERGER SUB I INC., IGNITE MERGER SUB II LLC, IGNITE PROTEOMICS, LLC (ea029430701ex2-1.htm)

EX-10.1 — FORM OF SELLER SUPPORT AGREEMENT (ea029430701ex10-1.htm)

EX-10.2 — AMENDMENT TO LETTER AGREEMENT, DATED AS OF JUNE 10, 2026, BY AND AMONG COPLEY ACQUISITION CORP., COPLEY ACQUISITION SPONSORS, LLC, IGNITE PROTEOMICS HOLDINGS, INC., IGNITE PROTEOMICS, LLC, AND THE OTHER PARTIES SIGNATORY THERETO (ea029430701ex10-2.htm)

EX-10.3 — SIDE LETTER AND GUARANTY AGREEMENT, DATED JUNE 10, 2026, BY AND AMONG ADITXT, INC. AND COPLEY ACQUISITION CORP (ea029430701ex10-3.htm)

EX-99.1 — PRESS RELEASE, DATED JUNE 9, 2026 (ea029430701ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0294307-8k_aditxt.htm · Sequence: 1

false

0001726711

2026-06-10

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section

13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date

of earliest event reported): June 10, 2026

ADITXT, INC.

(Exact name of registrant

as specified in its charter)

Delaware

(State or other jurisdiction

of incorporation)

001-39336

82-3204328

(Commission File Number)

(I.R.S. Employer Identification No.)

2569 Wyandotte Street, Suite

101

Mountain

View, California 94043

(Address of principal

executive offices, including zip code)

(650) 870-1200

(Registrant’s

telephone number, including area code)

N/A

(Former name or former

address, if changed since last report)

Check the appropriate

box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following

provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section

12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

ADTX

The Nasdaq Stock Market LLC

Indicate by check mark

whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule

12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth

company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or

revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive

Agreement.

Business Combination Agreement

General Description of the Business

Combination Agreement

June 10, 2026, Ignite Proteomics, LLC, a Delaware LLC ( “Ignite”) and a wholly-owned subsidiary of Aditxt, Inc., a

Delaware corporation (the “Corporation”), entered into a Business Combination Agreement (the “Business Combination

Agreement”) with (i) Copley Acquisition Corp, a Cayman Islands exempted company (together with its successors, including after

the Conversion in the State of Delaware (as defined below), “SPAC”), (ii) Ignite Proteomics Holdings, Inc., a Delaware

corporation (“Pubco”), (iii) Ignite Merger Sub I Inc., a Delaware corporation and a wholly-owned subsidiary of Pubco

(“SPAC Merger Sub”), (iv) Ignite Merger Sub II LLC, a Delaware limited liability company and a wholly-owned subsidiary

of Pubco (“Company Merger Sub” and together with SPAC Merger Sub, the “Merger Subs”, and together

with Pubco and SPAC, the “SPAC Parties”), (v) Chibo Tang, solely in the capacity as the representative from and after

the Effective Time (as defined below) for SPAC shareholders as of immediately prior to the Effective Time and their successors and assigns

(other than the Sellers) in accordance with the terms and conditions of the Business Combination Agreement (the “SPAC Representative”),

and (vi) Jeffrey M. Busch, solely in the capacity as the representative from and after the Effective Time for the Sellers as of immediately

prior to the Effective Time (and their successors and assigns) in accordance with the terms and conditions of the Business Combination

Agreement (the “Seller Representative”). Capitalized terms used in this Current Report on Form 8-K but not otherwise

defined herein have the meanings given to them in the Business Combination Agreement.

Prior

to the consummation (the “Closing”) of the transactions contemplated by the Business Combination Agreement (the “Transactions”),

SPAC shall transfer by way of continuation out of the Cayman Islands and into the State of Delaware so as to re-domicile as and become

a Delaware corporation. At the Closing, (i) SPAC Merger Sub will merge with and into SPAC, with SPAC continuing as the surviving entity

(the “SPAC Merger”) and as a result of which each issued and outstanding security of SPAC immediately prior to the

effective time of the SPAC Merger shall no longer be outstanding and shall automatically be cancelled in exchange for which the security

holders of SPAC shall receive substantially equivalent securities of Pubco and (ii) Company Merger Sub will merge with and into Ignite,

with Ignite continuing as the surviving entity (the “Company Merger”, and together with the SPAC Merger, the “Mergers”),

and as a result of which each issued and outstanding security of Ignite immediately prior to the effective time of the Company Merger

shall no longer be outstanding and shall automatically be cancelled in exchange for which the security holders of Ignite shall receive

shares of common stock of Pubco and (iii) as a result of which Mergers, SPAC and Ignite will become wholly-owned subsidiaries of Pubco

and Pubco will become a publicly traded company. As used herein, “Effective Time” means 5:00 P.M. on the date

of the Closing (or such other date and/or time as may be agreed in writing by Ignite and SPAC), at which time each of the Mergers shall

be consummated simultaneously by the filing of appropriate certificates of merger with the Secretary of State of the State of Delaware.

Consideration

The aggregate consideration to be paid to holders of the Company Interests

as of the Effective Time (collectively, the “Sellers”) pursuant to the Company

Merger shall consist of a number of newly issued shares of Pubco Common Stock equal to One Hundred and Fifty Million U.S. Dollars ($150,000,000)

divided by Ten U.S. Dollars ($10.00) (the “Merger Consideration”). At the

Effective Time, the Company Interests (excluding the Excluded Interests, if any), issued and outstanding as of immediately prior to the

Effective Time shall be automatically canceled and extinguished and converted into the right for the respective Sellers to receive their

respective Percentage Merger Consideration in the form of Pubco Common Stock; provided, however, that Ignite may elect, in its sole discretion,

prior to the Effective Time to receive in lieu of all or any number of shares of Pubco Common Stock issuable as Merger Consideration to

Sellers the same number of Pubco Common Stock Equivalents. Pubco will also pay Copley Acquisition Sponsors Limited, $4,000,000 U.S. Dollars.

Representations

and Warranties

The Business Combination

Agreement contains representations and warranties reasonably customary for similar transactions, made by the parties as of the date of

the Business Combination Agreement or other specified dates, solely for the benefit of certain of the parties to the Business Combination

Agreement, and in certain cases are subject to specified exceptions and qualifications, such as materiality, the absence of a Material

Adverse Effect (as defined below), knowledge and other exceptions and qualifications contained in the Business Combination Agreement or

in information provided pursuant to certain disclosure schedules to the Business Combination Agreement. As used in the Business Combination

Agreement, “Material Adverse Effect” means, with respect to any specified person or entity, any fact, event,

occurrence, change or effect that has had or would reasonably be expected to have, individually or in the aggregate, a material adverse

effect upon the business, assets, liabilities, results of operations, prospects or condition (financial or otherwise) of such person or

entity and its subsidiaries, taken as a whole, or the ability of such person or entity or any of its subsidiaries on a timely basis to

consummate the transactions contemplated by the Business Combination Agreement or the ancillary documents to which it is a party or bound

or to perform its obligations thereunder, in each case subject to certain customary exceptions.

No Survival

The representations and

warranties of the parties contained in the Business Combination Agreement will not survive the closing of the Transactions and there are

no indemnification rights for another party’s breach. The covenants and agreements of the parties contained in the Business Combination

Agreement do not survive the Closing, except those covenants and agreements to be performed after the Closing, which covenants and agreements

will survive until fully performed.

Covenants

Each party to the Business Combination Agreement has agreed to use

commercially reasonable efforts to consummate the Transactions. The Business Combination Agreement also contains certain customary covenants

by each of the parties that apply during the period between the signing of the Business Combination Agreement and the earlier of the Closing

or the termination of the Business Combination Agreement (the “Interim Period”),

including (i) the provision of access to the applicable party’s properties, books and personnel; (ii) the operation of the parties’

respective businesses in the ordinary course of business; (iii) SPAC’s public filings; (iv) no insider trading; (v) notifications

to the other parties of certain breaches, consent requirements and other matters; (vi) obtaining third party and regulatory approvals;

(vii) tax matters; (viii) further assurances; (ix) public announcements; (x) confidentiality; and other covenants. The Business Combination

Agreement also contains certain customary post-Closing covenants, including in regard to (1) tax matters; (2) the maintenance of books

and records; (3) the indemnification of directors and officers; (4) the use of proceeds from SPAC’s trust account; and other covenants.

Additionally:

Each of SPAC and Ignite will not solicit or enter into a competing

alternative transaction, in accordance with customary terms and provisions set forth in the Business Combination Agreement.

SPAC will not change, withdraw, withhold, qualify or modify its recommendation

to its shareholders for approval of the Business Combination Agreement and the Transactions (a “Change

in Recommendation”); provided, however, that if at any time prior to (but not after) obtaining the approval of the SPAC shareholders,

the SPAC board determines in good faith, in response to an “Intervening Event”

(including any material event, fact, development, circumstance or occurrence following the date of the Business Combination that was not

reasonably foreseeable to, or the consequences or magnitude of which were reasonably foreseeable to, the board of SPAC, except for changes

relating to the Transactions, changes in the price or trading volume of Class A ordinary shares, par value $0.0001 per share, of SPAC

(“SPAC Class A Ordinary Shares”), certain changes specified in the definition

of Material Adverse Effect and certain other changes) after consultation with its outside legal counsel, that the failure to make a Change

in Recommendation would be a breach of its fiduciary duties under applicable law, then the board may make a Change in Recommendation,

provided that SPAC delivers, pursuant to procedures set forth in the Business Combination Agreement, written notice advising Ignite that

the SPAC board proposes to take such action and containing the material facts underlying the board’s determination. If requested

by Ignite, SPAC will use its reasonable best efforts to engage in good faith negotiations with Ignite to make adjustments in the terms

and conditions of the Business Combination Agreement that obviate the need for a Change in Recommendation.

SPAC, Ignite and Pubco will, as promptly as practicable after the date

of the Business Combination Agreement, prepare and file with the U.S. Securities and Exchange Commission (the “SEC”),

a registration statement on Form S-4 (as amended, the “Registration Statement”) in connection with the registration

under the Securities Act of 1933, as amended (the “Securities Act”), of the Pubco Common Stock to be issued pursuant

to the Transactions, and containing a proxy statement/prospectus for the solicitation of proxies from SPAC shareholders to approve the

Business Combination Agreement, the Transactions and related matters at an extraordinary general meeting of SPAC’s shareholders,

and providing SPAC’s public shareholders with an opportunity to request redemption of their public shares in connection with the

Transactions, as required by SPAC’s amended and restated memorandum and articles of association and SPAC’s initial public

offering prospectus (the “Redemption”).

Ignite will call a meeting

of its members in order to obtain the requisite vote of its members to approve the Business Combination Agreement and each of the ancillary

documents to which Ignite is or is required to be a party or bound and the consummation of the transactions contemplated thereby (the

“Ignite Member Approval”) and use its reasonable best efforts to solicit proxies from its members prior to such meeting

and to take all other actions necessary or advisable to secure the Ignite Member Approval, including enforcing the Seller Support Agreement

(as described below). At the request of SPAC, Ignite shall make the members of its management reasonably available to participate in management

presentations, “road shows,” rating agency presentations, meetings with financing sources and similar events in connection

with obtaining the approval of SPAC shareholders, any “share recycling” efforts by SPAC and the obtaining of any debt or equity

financing, ratings or governmental or other third-party approvals.

The parties shall take all action necessary so that, effective at the

Closing, the post-Closing board of directors of Pubco will consist of seven (7) individuals, one (1) of whom will be Ignite’s Chief

Executive Officer, and at least four (4) of whom shall be independent directors in accordance with the requirements of The New York Stock

Exchange (“NYSE”). The parties shall also take all action necessary so that

the individuals serving as the chief executive officer and chief financial officer, respectively, of Pubco immediately after the Closing

will be the same individuals (in the same office) as that of Ignite immediately prior to the Closing (unless, at its sole discretion,

Ignite desires to appoint another qualified person to either such role, in which case, such other person(s) identified by Ignite shall

serve in such role or roles).

During the Interim Period,

(i) SPAC shall use its best efforts to obtain up to $20,000,000 in Transaction Financing, and (ii) Ignite shall use its best efforts to

obtain up to $10,000,000 in Transaction Financing. These financings may be structured as one, or a combination of, common equity,

preferred equity, convertible equity or debt, non-redemption or backstop arrangements with respect to SPAC’s trust account, a committed

equity facility, debt facility and/or other sources of cash or cash equivalents, in each case, whether such investment is into SPAC, Ignite

or Pubco.

Closing Conditions

Under the Business Combination

Agreement, the obligations of the parties to consummate the Transactions are subject to a number of conditions customary in transactions

undertaken by special purpose acquisition companies, including, among others: (i) the receipt of the approval of SPAC’s shareholders

of the Business Combination Agreement and the transactions contemplated thereby; (ii) the consummation of the Business Combination not

being prohibited by applicable law; (iii) the effectiveness of the Registration Statement; (iv) the shares of Pubco Common Stock and Pubco

Warrants having been approved for listing on NYSE; (v) the adoption of the Pubco incentive plan; and (vi) the consummation of the SPAC’s

conversion from a Cayman Islands exempted company to a Delaware corporation.

Unless waived by Ignite,

the obligations of Ignite, Pubco, SPAC Merger Sub and Company Merger Sub to consummate the Transactions are also subject to the satisfaction

of the following closing conditions, in addition to customary closing certificates and other closing deliveries: (i) the representations

and warranties of SPAC being true and correct, subject where applicable to the materiality standards contained in the Business Combination

Agreement; (ii) compliance by SPAC with its pre-closing covenants, subject where applicable to the materiality standards contained in

the Business Combination Agreement; (iii) certain specified ancillary documents being in full force and effect; and (iv) the sum of cash

proceeds available for release from SPAC’s trust account after giving effect to redemptions, plus net proceeds of any Transaction

Financings conducted by SPAC, equaling or exceeding $15.0 million.

Unless waived by SPAC,

the obligations of SPAC to consummate the Transactions are also subject to the satisfaction of the following closing conditions, in addition

to customary closing certificates and other closing deliveries: (i) the representations and warranties of Ignite, Pubco, SPAC Merger Sub

and Company Merger Sub being true and correct, subject where applicable to the materiality standards contained in the Business Combination

Agreement; (ii) compliance by Ignite, Pubco, SPAC Merger Sub and Company Merger Sub with their respective pre-closing covenants, subject

where applicable to the materiality standards contained in the Business Combination Agreement; (iii) no occurrence of a Material Adverse

Effect with respect to Ignite or Pubco since the date of the Business Combination Agreement; (iv) certain specified ancillary documents,

including employment agreements between Pubco and each of Jeffrey M. Busch, Faith Zaslavsky and Ronald Tam, respectively, being in full

force and effect; (v) the net proceeds of any Transaction Financings conducted by Ignite equaling or exceeding $7.5 million; (vi) all

indebtedness of Ignite having been repaid, forgiven, discharged or otherwise satisfied in full on or prior to the Closing, or arrangements

having been made for such repayment, forgiveness, discharge or satisfaction in form and substance reasonably satisfactory to SPAC; and

(vii) customary intellectual property assignment agreements having been executed by each Ignite employee engaged in the development of

intellectual property for Ignite.

The Business Combination Agreement also requires Ignite to deliver

audited consolidated financial statements for the six months ended December 31, 2024 and the twelve months ended December 31, 2025, audited

by a PCAOB-qualified auditor, no later than ten business days after the date of the Business Combination Agreement. SPAC has a termination

right if Ignite does not deliver such audited financial statements within that timeframe.

Termination

The Business Combination

Agreement contains certain termination rights, including, among others, the following: (i) upon the mutual written consent of SPAC and

Ignite; (ii) by either SPAC or Ignite if the closing conditions pursuant to the Business Combination Agreement have not been satisfied

or waived by September 30, 2026, subject to certain automatic and discretionary extensions; (iii) by SPAC or Ignite if a Governmental

Authority shall have issued an Order or taken any other action permanently restraining, enjoining or otherwise prohibiting the Transactions;

(iv) by Ignite for SPAC’s material breach of the Business Combination Agreement, if the breach would result in the failure of the

related condition to Closing and the breach or inaccuracy is incapable of being cured or is not cured in accordance with the terms of

the Business Combination Agreement; (v) by SPAC in connection with a breach of a representation, warranty, covenant or other agreement

by Ignite, Pubco, SPAC Merger Sub, Company Merger Sub or the Seller Representative, if the breach would result in the failure of the related

condition to Closing and the breach or inaccuracy is incapable of being cured or is not cured in accordance with the terms of the Business

Combination Agreement; (vi) by SPAC if there shall have been a Material Adverse Effect on Ignite following the date of the Business Combination

Agreement which is uncured and continuing; (vii) by either SPAC or Ignite if the SPAC shareholder meeting is held and the SPAC shareholder

approval is not received; and (viii) by SPAC if Ignite has not delivered its required audited financial statements to SPAC within 10 days

from the date of the Business Combination Agreement.

If the Business Combination

Agreement is terminated in accordance with the terms of the Business Combination Agreement, all further obligations of the parties under

the Business Combination Agreement (except for certain obligations related to public announcements, confidentiality, the effect of termination,

fees and expenses, the trust fund waiver and customary miscellaneous provisions) will terminate and no party to the Business Combination

Agreement will have any further liability to any other party thereto except for liability for fraud or for willful breach of the Business

Combination Agreement prior to termination.

Trust Account Waiver

Ignite has agreed that

it and its affiliates will not have any right, title, interest or claim of any kind in or to any monies in SPAC’s trust account

held for its public shareholders, and has agreed not to, and has waived any right to, make any claim against the trust account (including

any distributions therefrom).

Governing Law

The Business Combination Agreement is governed by Delaware law. The

parties are subject to the exclusive jurisdiction of federal and state courts located in Wilmington, Delaware (and any appellate courts

thereof).

The foregoing description of the Business Combination Agreement does

not purport to be complete and is qualified in its entirety by reference to the complete text of the Business Combination Agreement, a

copy which is filed hereto as Exhibit 2.1.

Related Agreements

Seller Support

Agreements

Simultaneously with the execution of the Business Combination Agreement,

each Seller entered into a seller support agreement (each, a “Seller Support Agreement”), pursuant to which, among

other things, such Seller has agreed to vote its membership interests in favor of the adoption of the Business Combination Agreement,

the ancillary documents, the approval of the Transactions and any amendments to Ignite’s organizational documents in connection

therewith, subject to certain customary conditions. Each Seller also agreed to take certain

other actions in support of the Business Combination Agreement and the Transactions (and any actions required in furtherance thereof)

and refrain from taking actions that would adversely affect their ability to perform such Seller’s obligations under the Seller

Support Agreement. Each Seller also agreed not to transfer their membership interests in Ignite during the period from and including the

date of the Seller Support Agreement and the first to occur of the date of Closing or the date on which the Seller Support Agreement is

terminated. The foregoing description of the Seller Support Agreement does not purport to be complete and is qualified in its entirety

by reference to the complete text of the Seller SupportAgreement, a copy which is filed hereto as Exhibit 10.1.

Insider Letter

Amendment

Simultaneously with the execution of the Business Combination Agreement,

SPAC, Pubco, Ignite, on the one hand, and Copley Acquisition Sponsors, LLC (the “Sponsor”) and SPAC’s directors

and officers, on the other hand, entered into an amendment (the “Insider Letter Amendment”) to the letter agreement

that was entered into in connection with SPAC’s initial public offering (the “Insider Letter”) to (i) add Pubco

and Ignite as parties to the Insider Letter, (ii) revise the terms of the Insider Letter to reflect the Transactions, including the issuance

of Pubco securities in exchange for SPAC securities, and have Pubco assume and be assigned the rights and obligations of SPAC under the

Insider Letter, and (iii) amend the terms of the lock-up set forth in the Insider Letter to conform with the lock-up terms in the Lock-Up

Agreements described above. The foregoing description of the Inside Letter Amendment does not purport to be complete and is qualified

in its entirety by reference to the complete text of the Inside Letter Amendment, a copy which is filed hereto as Exhibit 10.2.

Side Letter and Guaranty Agreement

Simultaneously with the execution of the Business Combination Agreement,

the Corporation and SPAC entered into a Side Letter and Guaranty Agreement (the “Side Letter”), pursuant to which the Corporation

agreed to guarantee certain obligations of Ignite under the Business Combination Agreement and agreements ancillary thereto, including

(i) the payment of all expenses required to be paid by or on behalf of Ignite pursuant to the Business Combination Agreement; (ii) the

repayment, forgiveness, discharge or other satisfaction in full of all Indebtedness of Ignite as required by Section 7.3(g) of the Business

Combination Agreement; (iii) the performance of all covenants and agreements of Ignite contained in the Business Combination Agreement,

including under Article VI thereof; (iv) any reimbursement or indemnification obligations of Ignite arising under the Business Combination

Agreement; and (v) any other monetary or performance obligations of Ignite arising under the Business Combination Agreement or any ancillary

document to which Ignite is a party. The foregoing description of the Side Letter does not purport to be complete and is qualified in

its entirety by reference to the complete text of the Side Letter, a copy which is filed hereto as Exhibit 10.3.

Lock-Up and Non-Competition Agreements

At or prior to the Effective Time, the Sellers and the directors and

officers of Ignite shall each enter into a Lock-Up Agreement in form and substance reasonably satisfactory to SPAC and Ignite. At or prior

to the Effective Time, SPAC, Pubco and Ignite shall enter into a Non-Competition and Non-Solicitation Agreement in favor of Pubco and

Ignite with Jeffrey M. Busch, in form and substance reasonably satisfactory to SPAC and Ignite (collectively, the “Non-Competition

Agreements”), which will be effective as of Closing and will provide for a restricted period from the Closing until the third anniversary

of the Closing Date.

Additional Information

and Where to Find It

SPAC, Ignite and Pubco

intend to file relevant materials with the SEC, including a Registration Statement on Form S-4 (as may be amended, the “Registration

Statement”), which will include a proxy statement of SPAC and a prospectus in connection with Business Combination, referred

to as a proxy statement/prospectus. The definitive proxy statement and other relevant documents will be mailed to shareholders of SPAC

as of a record date to be established for voting on SPAC’s proposed Business Combination with Ignite. SHAREHOLDERS OF SPAC AND OTHER

INTERESTED PARTIES ARE URGED TO READ, WHEN AVAILABLE, THE REGISTRATION STATEMENT, THE PRELIMINARY PROXY STATEMENT AND AMENDMENTS THERETO,

THE DEFINITIVE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH SPAC’S

SOLICITATION OF PROXIES FOR THE EXTRAORDINARY GENERAL MEETING OF ITS SHAREHOLDERS TO BE HELD TO APPROVE THE BUSINESS COMBINATION BECAUSE

THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT SPAC, IGNITE, PUBCO AND THE BUSINESS COMBINATION.

Forward-Looking Statements

The information in this

Current Report on Form 8-K includes “forward-looking statements” within the meaning of the federal securities laws. Forward-looking

statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,”

“intend,” “may,” “will,” “expect,” “continue,” “should,” “would,”

“anticipate,” “believe,” “seek,” “target,” “predict,” “potential,”

“seem,” “future,” “outlook” or other similar expressions that predict or indicate future events or

trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking.

These forward-looking statements include, but are not limited to, references with respect to the anticipated benefits and timing of the

completion of the Business Combination; statements about Ignite’s market opportunity and the potential growth of that market; Ignite’s

strategy, outcomes and growth prospects; trends in Ignite’s industry and markets; the competitive environment in which Ignite operates;

the ability for Ignite to raise funds to support its business; the sources and uses of cash of the Business Combination; and the anticipated

capitalization and enterprise value of the Pubco following the consummation of the Business Combination. These statements are based on

various assumptions, whether or not identified in this Current Report on Form 8-K, and on the current expectations of Ignite’s and

SPAC’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative

purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction

or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ

from assumptions. Many actual events and circumstances are beyond the control of Ignite and SPAC.

These forward-looking

statements (including projections) are predictions, and other statements about future events or conditions that are based on current expectations,

estimates and assumptions and, as a result, are subject to risks and uncertainties, including the occurrence of any event, change or other

circumstances that could give rise to the termination of the Business Combination Agreement; the risk that the Business Combination disrupts

Ignite’s current plans and operations as a result of the announcement and consummation of the Business Combination; the inability

of the parties to recognize the anticipated benefits of the Business Combination; the ability to maintain the listing of SPAC’s

securities on a national securities exchange; the ability to obtain or maintain the listing of the Pubco’s securities on NYSE following

the Business Combination, including having the requisite number of shareholders; costs related to the Business Combination; changes in

business, market, financial, political and legal conditions; Ignite’s limited operating history, lack of history of operating as

a public company and the rapidly evolving industry in which it operates; Ignite’s use and reporting of business and operational

metrics; uncertainties surrounding Ignite’s business model; Ignite’s expectations regarding future financial performance,

capital requirements and unit economics; Ignite’s competitive landscape; capital market, interest rate and currency exchange risks;

Ignite’s ability to manage growth and expand its operations; Ignite’s dependence on members of its senior management and its

ability to attract and retain qualified personnel; uncertainty or changes with respect to taxes, trade conditions and the macroeconomic

and geopolitical environment; the risk that the Business Combination may not be completed in a timely manner or at all, which may adversely

affect the price of SPAC’s securities; the risk that the Business Combination may not be completed by SPAC’s business combination

deadline and the potential failure to obtain an extension of the business combination deadline if sought by SPAC; the failure to satisfy

the conditions to the consummation of the Business Combination; the outcome of any legal proceedings that may be instituted against Ignite,

SPAC, Pubco or others following announcement of the proposed Business Combination and the transactions contemplated thereby; the risk

that shareholders of SPAC could elect to have their shares redeemed, leaving Pubco with insufficient cash to execute its business plans;

past performance by Ignite management team may not be indicative of the future performance of Pubco after the Business Combination; the

risk that an active market for the securities of Pubco after the Business Combination may not develop; and those risk factors discussed

in documents of the Corporation, SPAC, Ignite and Pubco filed, or to be filed, with the SEC. If any of these risks materialize or the

assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There

may be additional risks that neither SPAC nor Ignite presently know or can anticipate or that SPAC and Ignite currently believe are immaterial

that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements

reflect the Corporation’s, SPAC’s, Ignite’s and Pubco’s expectations, plans or forecasts of future events and

views as of the date of this Current Report on Form 8-K. SPAC, Ignite and Pubco anticipate that subsequent events and developments will

cause the Corporation’s, SPAC’s, Ignite’s and Pubco’s assessments to change. However, while the Corporation, SPAC,

Ignite and Pubco may elect to update these forward-looking statements at some point in the future, the Corporation, SPAC, Ignite and Pubco

specifically disclaim any obligation to do so. Readers are referred to the most recent reports filed with the SEC by the Corporation and

SPAC. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and

the Corporation, SPAC, Ignite and Pubco undertake no obligation to update or revise the forward-looking statements, whether as a result

of new information, future events or otherwise.

Participants in the

Solicitation

the Corporation, SPAC,

Ignite and Pubco and their respective directors and executive officers may be deemed under SEC rules to be participants in the solicitation

of proxies from SPAC’s shareholders in connection with the Business Combination. A list of the names of such directors and executive

officers, and information regarding their interests in the Business Combination and their ownership of SPAC’s securities are, or

will be, contained in filings with the SEC relating to the Business Combination. Additional information regarding the interests of the

persons who may, under SEC rules, be deemed participants in the solicitation of proxies of SPAC’s shareholders in connection with

the Business Combination, including the names and interests of Ignite’s directors and executive officers, will be set forth in the

proxy statement/prospectus included in the Registration Statement for the Business Combination.

No Offer or Solicitation

This Current Report on

Form 8-K shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the

Business Combination. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any

securities pursuant to the Business Combination or otherwise, nor shall there be any sale of securities in any jurisdiction in which the

offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of

1933, as amended, or an exemption therefrom.

NEITHER THE SEC NOR ANY

STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE BUSINESS COMBINATION DESCRIBED HEREIN, PASSED UPON THE MERITS OR FAIRNESS

OF THE BUSINESS COMBINATION OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS REPORT. ANY

REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

Item 7.01 Regulation FD Disclosure

Attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated

into this Item 7.01 by reference is the press release (“Press Release”) issued by Aditxt on June 8, 2026, announcing the Business

Combination Agreement described above. The Press Release is intended to be furnished and shall not be deemed “filed” for purposes

of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities

of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as

expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

2.1*†

Business Combination Agreement, dated as of June 10, 2026, by and among Copley Acquisition Corp., Ignite Proteomics Holdings, Inc., Ignite Merger Sub I Inc., Ignite Merger Sub II LLC, Ignite Proteomics, LLC, Chibo Tang, as SPAC Representative, and Jeffrey M. Busch, as Seller Representative.

10.1†

Form of Seller Support Agreement.

10.2

Amendment to Letter Agreement, dated as of June 10, 2026, by and among Copley Acquisition Corp., Copley Acquisition Sponsors, LLC, Ignite Proteomics Holdings, Inc., Ignite Proteomics, LLC, and the other parties signatory thereto.

10.3†

Side Letter and Guaranty Agreement, dated June 10, 2026, by and among Aditxt, Inc. and Copley Acquisition Corp.

99.1

Press Release, dated June 9, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADITXT, INC.

Date: June 10, 2026

By:

/s/ Jeffrey M. Busch

Name:

Jeffrey M. Busch

Title:

Interim Chief Executive Officer

EX-2.1

Filename: ea029430701ex2-1.htm · Sequence: 2

Exhibit 2.1

BUSINESS COMBINATION AGREEMENT

by and among

Copley Acquisition Corp,

as SPAC,

Ignite Proteomics Holdings, Inc.,

as Pubco,

Ignite Merger Sub I Inc.,

as SPAC Merger Sub,

Ignite Merger Sub II LLC,

as Company Merger Sub,

Jeffrey M. Busch,

as Seller Representative,

Chibo Tang,

as SPAC Representative

and

Ignite Proteomics, LLC,

as the Company

Dated as of June 10, 2026

TABLE OF CONTENTS

Page

I. MERGER

1.1. The SPAC

Merger

1.2. The Company

Merger

1.3. Effective Time

1.4. Effect of the Mergers

1.5. Governing Documents

1.6. Directors, Officers and Managers of the Surviving Subsidiaries

1.7. Conversion of SPAC

1.8. Merger Consideration

1.9. Effect of

SPAC Merger on Issued Securities of SPAC and SPAC Merger Sub

1.10. Effect of Company Merger on Issued Securities of the Company and Company Merger Sub

1.11. Effect of

Mergers on Issued and Outstanding Securities of Pubco

1.12. Sponsor

Payment

1.13. Tax

Consequences

1.14. Taking of

Necessary Action; Further Action

II. CLOSING

2.1. Closing

III. representations and warranties of SPAC

3.1. Organization and Standing

3.2. Authorization; Binding Agreement

3.3. Governmental Approvals

3.4. Non-Contravention

3.5. Capitalization

3.6. SEC Filings and SPAC Financials

3.7. Absence of Certain Changes

3.8. Compliance with Laws

3.9. Actions; Orders; Permits

3.10. Taxes and Returns

3.11. Employees and Employee Benefit Plans

3.12. Properties

3.13. Material Contracts

3.14. Transactions with Affiliates

3.15. Investment Company Act

3.16. Finders and Brokers

3.17. Certain Business Practices

3.18. SPAC Trust Account

3.19. Exclusivity of Representations

3.20. Information Supplied

IV. representations and warranties of pubco AND THE MERGER SUBS

4.1. Organization and Standing

4.2. Authorization; Binding Agreement

4.3. Governmental Approvals

4.4. Non-Contravention

4.5. Capitalization

4.6. Ownership of Pubco Common Stock

v. representations and warranties of THE COMPANY

5.1. Organization and Standing

5.2. Authorization; Binding Agreement

5.3. Capitalization

5.4. Subsidiaries

5.5. Governmental Approvals

5.6. Non-Contravention

5.7. Financial Statements

5.8. Absence of Certain Changes

5.9. Compliance with Laws

5.10. Company Permits

5.11. Litigation

5.12. Material Contracts

5.13. Intellectual Property

5.14. Taxes and Returns

5.15. Real Property

5.16. Personal Property

5.17. Title to and Sufficiency of Assets

5.18. Employee Matters

5.19. Benefit Plans

5.20. Environmental Matters

5.21. Transactions with Related Persons

5.22. Insurance

5.23. Top Customers and Suppliers

5.24 Certain Business Practices

5.25 Privacy and Data Security

5.26 Healthcare Compliance

5.27 Investment Company Act

5.28. Finders and Brokers

5.29. Exclusivity of Representations

5.30. Information Supplied

VI. COVENANTS

6.1. Access and Information

6.2. Conduct of Business of the Company

6.3. Conduct of Business of SPAC

6.4. Additional Financial Information

6.5. SPAC Public Filings

6.6. No Solicitation; Change in Recommendation

6.7. No Trading

6.8. Notification of Certain Matters

6.9. Efforts

6.10. Tax Matters

6.11. Further Assurances

6.12. The Registration Statement

6.13. Company Member Meeting

6.14. Public Announcements

6.15. Confidential Information

6.16. Documents and Information

6.17. Post-Closing Board of Directors and Executive Officers

6.18. Indemnification of Officers and Directors; Tail Insurance

6.19. Trust Account Proceeds

6.20. Transaction Financing

6.21. Qualification to do Business

VII. Closing conditions

7.1. Conditions of Each Party’s Obligations

7.2. Conditions to Obligations of the Company

7.3. Conditions to Obligations of SPAC

7.4. Frustration of Conditions

VIII. TERMINATION AND EXPENSES

8.1. Termination

8.2. Effect of Termination

8.3. Fees and Expenses

Ix. WAIVERS and releases

9.1. Waiver of Claims Against Trust

x. MISCELLANEOUS

10.1. Notices

10.2. Binding Effect; Assignment

10.3. Third Parties

10.4. Governing Law; Jurisdiction

10.5. WAIVER OF JURY TRIAL

10.6. Specific Performance

10.7. Severability

10.8. Amendment

10.9. Waiver

10.10. Entire Agreement

10.11. Interpretation

10.12. Counterparts

10.13. SPAC Representative

10.14. Counterparts

10.15. Legal Representation

XI DEFINITIONS

11.1. Certain Definitions

11.2. Section References

INDEX OF EXHIBITS

Exhibit

Description

Exhibit A

Seller Support Agreement

Exhibit B

Insider Letter Amendment

iii

BUSINESS COMBINATION AGREEMENT

This Business Combination

Agreement (this “Agreement”) is made and entered into as of June 10, 2026 by and among (i) Copley Acquisition

Corp, a Cayman Islands exempted company (together with its successors, including after the Conversion in the State of Delaware (as

defined below), “SPAC”), (ii) Ignite Proteomics Holdings, Inc., a Delaware corporation (“Pubco”),

(iii) Ignite Merger Sub I Inc., a Delaware corporation and a wholly-owned subsidiary of Pubco (“SPAC Merger Sub”),

(iv) Ignite Merger Sub II LLC, a Delaware limited liability company and a wholly-owned subsidiary of Pubco (“Company

Merger Sub” and together with SPAC Merger Sub, the “Merger Subs”, and together with Pubco and

SPAC, the “SPAC Parties”), (v) Ignite Proteomics, LLC, a Delaware limited liability company (the “Company”),

(vi) Chibo Tang, solely in the capacity as the representative from and after the Effective Time (as defined herein) for SPAC shareholders

as of immediately prior to the Effective Time and their successors and assigns (other than the Sellers) in accordance with the terms and

conditions of this Agreement (the “SPAC Representative”), and (vii) Jeffrey M. Busch, solely in the capacity

as the representative from and after the Effective Time for the Sellers as of immediately prior to the Effective Time (and their successors

and assigns) in accordance with the terms and conditions of this Agreement (the “Seller Representative”). SPAC,

Pubco, SPAC Merger Sub, Company Merger Sub, Company, SPAC Representative and Seller Representative are sometimes referred to herein individually

as a “Party” and, collectively, as the “Parties”.

RECITALS:

A. The

Company is in the business of delivering pathway-level protein analytics to guide precision oncology (the “Company Business”);

B. Pubco

is a newly incorporated Delaware corporation that is owned entirely by one or more managers or officers of the Sponsor, and Pubco owns

all of the issued and outstanding equity interests of SPAC Merger Sub and Company Merger Sub, each of which is a newly organized entity

formed for the sole purpose of effecting the Mergers (as defined below);

C. Upon

the terms and subject to the conditions set forth herein, the Parties desire and intend to effect a business combination transaction pursuant

to which (i) SPAC Merger Sub will merge with and into SPAC, with SPAC continuing as the surviving entity (the “SPAC Merger”)

and as a result of which each issued and outstanding security of SPAC immediately prior to the effective time of the SPAC Merger shall

no longer be outstanding and shall automatically be cancelled in exchange for which the security holders of SPAC shall receive substantially

equivalent securities of Pubco and (ii) Company Merger Sub will merge with and into the Company, with the Company continuing as the surviving

entity (the “Company Merger”, and together with the SPAC Merger, the “Mergers”), and

as a result of which each issued and outstanding security of the Company immediately prior to the effective time of the Company Merger

shall no longer be outstanding and shall automatically be cancelled in exchange for which the security holders of the Company shall receive

shares of common stock of Pubco and (iii) as a result of which Mergers, SPAC and the Company will become wholly-owned subsidiaries of

Pubco and Pubco will become a publicly traded company;

D. Prior

to the consummation of the Mergers, SPAC shall transfer by way of continuation out of the Cayman Islands and into the State of Delaware

so as to re-domicile as and become a Delaware corporation pursuant to the Companies Act (as Revised) of the Cayman Islands (as amended,

the “Act”) and the applicable provisions of the Delaware General Corporation Law (as amended, the “DGCL”);

E. The

boards of directors of Pubco, SPAC and SPAC Merger Sub have each (i) determined that the respective Mergers to which they are a party

are fair, advisable and in the best interests of their respective companies and stockholders or shareholders (as relevant), (ii) approved

this Agreement and the transactions contemplated hereby, including, with respect to Pubco, the Conversion and the respective Mergers to

which they are a party, upon the terms and subject to the conditions set forth herein, and (iii) determined to recommend to their respective

stockholders, shareholders or class or stockholders or shareholders (as relevant) the approval and adoption of this Agreement and the

transactions contemplated hereby, including, with respect to Pubco, the Conversion and the respective Mergers to which they are a party

(in case of the recommendation of the board of directors of SPAC, the “SPAC Board Recommendation”);

F. The

board of managers (or manager or managing member(s), as applicable) of the Company has (i) determined that the Company Merger is fair,

advisable and in the best interests of the Company and its members, (ii) approved this Agreement and the transactions contemplated hereby,

including the Company Merger, upon the terms and subject to the conditions set forth herein, and (iii) determined to recommend to its

members the approval and adoption of this Agreement and the transactions contemplated hereby, including the Company Merger;

G. Contemporaneously

with the execution and delivery of this Agreement, SPAC has received voting and support agreements in the form attached as Exhibit

A hereto (collectively, the “Seller Support Agreements”) signed by the Company and the Sellers with respect

to the Company Interests (as defined herein) held by them sufficient to approve the adoption of this Agreement and approve the Company

Merger and the other transactions contemplated by this Agreement;

H. At

or prior to the Effective Date, the Sellers and the directors and officers of the Company shall have each entered into a Lock-Up Agreement

in form and substance reasonably satisfactory to SPAC and the Company (each, a “Lock-Up Agreement”);

I. Contemporaneously

with the execution and delivery of this Agreement, SPAC, the Company, Pubco and the IPO Underwriter have entered into an amendment to

the Insider Letter Agreement with the Sponsor and SPAC’s directors and officers, a copy of which is attached as Exhibit B

hereto (the “Insider Letter Amendment”), pursuant to which, among other matters, effective as of the Closing,

(a) Pubco shall assume and be assigned the rights and obligations of SPAC under the Insider Letter and (b) revise the existing lock-up

restrictions, subject to and contingent upon the Closing;

J. At

or prior to the Effective Date, SPAC, Pubco and the Company shall have entered into a Non-Competition and Non-Solicitation Agreement in

favor of Pubco and the Company with Jeffrey M. Busch, in form and substance reasonably satisfactory to SPAC and the Company (collectively,

the “Non-Competition Agreements”), which will be effective as of Closing and will provide for a restricted period

from the Closing until the third anniversary of the Closing Date;

K. Contemporaneously

with the Closing, SPAC, Pubco, the Sponsor and the Sellers, will execute and deliver an amendment and restatement of the Founder Registration

Rights Agreement, in form and substance reasonably satisfactory to SPAC and the Company (the “Amended Registration Rights

Agreement”), to, among other matters, have Pubco assume the registration obligations of SPAC under the Founder Registration

Rights Agreement, have such rights apply to the shares Pubco Common Stock, and to provide Sellers with registration rights thereunder;

L. Promptly

following the date hereof, Pubco intends to enter into employment agreements with SPAC and each of Jeffrey M. Busch, Faith Zaslavavsky

and Ronald Tam (collectively, the “Employment Agreements”), in each case to be effective as of Closing;

M. The

Parties hereby agree and acknowledge that for U.S. federal income Tax purposes, the Mergers are intended to qualify as an exchange described

in Section 351 of the Code, and each of the Parties acknowledges and agrees that each is responsible for paying its own Taxes, including

any adverse Tax consequences that may result if the Mergers do not qualify under Section 351 of the Code (as defined herein); and

N. Certain

capitalized terms used herein are defined in Article XI hereof.

NOW, THEREFORE, in

consideration of the premises set forth above, which are incorporated in this Agreement as if fully set forth below, and the representations,

warranties, covenants and agreements contained in this Agreement, and intending to be legally bound hereby, the Parties hereto agree as

follows:

Article

MERGER

1.1 The

SPAC Merger. At the Effective Time and subject to and upon the terms and conditions of this Agreement, and following the Conversion

(as described in Section 1.7), and in accordance with the applicable provisions of the DGCL, SPAC Merger Sub and SPAC shall consummate

the SPAC Merger, pursuant to which SPAC Merger Sub shall be merged with and into SPAC, following which the separate corporate existence

of SPAC Merger Sub shall cease and SPAC shall continue as the surviving corporation in the SPAC Merger. SPAC as the surviving corporation

after the SPAC Merger is hereinafter sometimes referred to as “SPAC Surviving Subsidiary” (provided, that references

to SPAC for periods after the Effective Time shall include SPAC Surviving Subsidiary).

1.2 The

Company Merger. At the Effective Time and subject to and upon the terms and conditions of this Agreement and in accordance with the

applicable provisions of the Delaware Limited Liability Company Act (“DLLCA”), Company Merger Sub and the Company

shall consummate the Company Merger, pursuant to which Company Merger Sub shall be merged with and into the Company, following which the

separate limited liability company existence of Company Merger Sub shall cease and the Company shall continue as the surviving limited

liability company in the Company Merger. The Company as the surviving limited liability company after the Company Merger is hereinafter

sometimes referred to as “Company Surviving Subsidiary” (provided, that references to the Company for periods

after the Effective Time shall include Company Surviving Subsidiary), and together with SPAC Surviving Subsidiary, the “Surviving

Subsidiaries” (provided, that notwithstanding the Company Merger, the Company will not be included within the meaning of

the term SPAC Parties for purposes of this Agreement).

1.3 Effective

Time. Subject to the conditions of this Agreement, and following the Conversion (as described in Section 1.7), the Parties

shall (i) cause the SPAC Merger to be consummated by filing a certificate of merger in form and substance reasonably acceptable to the

Company and SPAC (the “SPAC Certificate of Merger”) with the Secretary of State of the State of Delaware in

accordance with the applicable provisions of the DGCL, and (ii) cause the Company Merger to be consummated by filing a certificate of

merger in form and substance reasonably acceptable to the Company and SPAC (the “Company Certificate of Merger”)

with the Secretary of State of the State of Delaware in accordance with the applicable provisions of the DLLCA, with each of the Mergers

to be consummated and effective simultaneously at 5:00 p.m. New York City time on the Closing Date or at such other date and/or time as

may be agreed in writing by the Company and SPAC and specified in each of the SPAC Certificate of Merger and the Company Certificate of

Merger (the “Effective Time”).

1.4 Effect

of the Mergers. At the Effective Time, the effect of the Mergers shall be as provided in this Agreement and the applicable provisions

of the DGCL, DLLCA and other applicable Law. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time

all the property, rights, agreements, privileges, powers and franchises of SPAC Merger Sub and Company Merger Sub shall vest in SPAC Surviving

Subsidiary and Company Surviving Subsidiary, respectively, and all debts, liabilities, obligations and duties of SPAC Merger Sub and Company

Merger Sub shall become the debts, liabilities, obligations and duties of SPAC Surviving Subsidiary and Company Surviving Subsidiary,

respectively, including in each case the rights and obligations of each such Party under this Agreement and the Ancillary Documents from

and after the Effective Time.

1.5 Governing

Documents. At the Effective Time, (i) each of the certificate of incorporation and bylaws of SPAC Merger Sub shall become the certificate

of incorporation and bylaws of SPAC Surviving Subsidiary, respectively, (ii) the name of the SPAC Surviving Subsidiary shall be amended

to be such name as is determined by Pubco and (iii) each of the certificate of formation and operating agreement of Company Merger Sub

shall become the certificate of formation and operating agreement of Company Surviving Subsidiary, respectively, except that the name

of Company Surviving Subsidiary in such certificate of formation and operating agreement shall be as mutually agreed between SPAC and

the Company.

1.6 Directors,

Officers and Managers of the Surviving Subsidiaries. At the Effective Time, (i) the board of directors and executive officers of SPAC

Surviving Subsidiary shall be the same as the post-Closing board of directors and executive officers of Pubco, after giving effect to

Section 6.17, each to hold office in accordance with the organizational documents of SPAC Surviving Subsidiary until their successors

are duly elected or appointed and qualified or their earlier death, resignation, or removal, and (ii) the board of managers and executive

officers of Company Surviving Subsidiary shall be designated by the Company, each to hold office in accordance with the organizational

documents of the Company Surviving Subsidiary until their successors are duly elected or appointed and qualified or their earlier death,

resignation, or removal.

1.7 Conversion

of SPAC. Prior to the Effective Time and prior to consummating the SPAC Merger, and subject to (i) obtaining the approval of the holders

of the SPAC Ordinary Shares in accordance with SPAC’s Organizational Documents, the Act and the DGCL and (ii) SPAC duly filing (1)

the Cayman Conversion Documents with the Cayman Islands Registrar of Companies (the “Cayman Registrar”) and

(2) the Delaware Conversion Documents with the State of Delaware, SPAC shall adopt Delaware Organizational Documents in a form satisfactory

to SPAC (the “Conversion Organizational Documents”) (with such changes as may be agreed in writing by SPAC and

the Company), SPAC shall transfer by way of continuation out of the Cayman Islands and into the State of Delaware so as to convert into

and become a Delaware corporation pursuant to the Act and the applicable provisions of the DGCL (the “Conversion”).

In connection with the Conversion, all of the issued and outstanding SPAC Securities shall remain outstanding and become substantially

identical securities of SPAC as a Delaware corporation (including the Class A Ordinary Shares and Class B Ordinary Shares becoming simple

common stock of SPAC as a Delaware corporation).

1.8 Merger

Consideration. The aggregate consideration to be paid to holders of the Company Interests as of the Effective Time (collectively,

the “Sellers”) pursuant to the Company Merger shall consist of a number of newly issued shares of Pubco Common

Stock equal to One Hundred and Fifty Million U.S. Dollars ($150,000,000) divided by Ten U.S. Dollars ($10.00) (the “Merger

Consideration”). At the Effective Time, the Company Interests (excluding the Excluded Interests, if any), issued and outstanding

as of immediately prior to the Effective Time shall be automatically canceled and extinguished and converted into the right for the respective

Sellers to receive their respective Percentage Merger Consideration in the form of Pubco Common Stock; provided, however, that

the Company may elect, in its sole discretion, prior to the Effective Time to receive in lieu of all or any number of shares of Pubco

Common Stock issuable as Merger Consideration to Sellers the same number of Pubco Common Stock Equivalents; provided, further,

that in no event shall the aggregate number of shares of Pubco Common Stock and Pubco Common Stock Equivalents issued pursuant to this

Section 1.8 exceed the total number of shares that would otherwise constitute the Merger Consideration.

1.9 Effect

of SPAC Merger on Issued and Outstanding Securities of SPAC and SPAC Merger Sub. At the Effective Time, by virtue of the SPAC Merger

and following the Conversion, and without any action on the part of any Party or the holders of securities of any SPAC Party or the Company:

(a) SPAC

Public Units. At the Effective Time, each issued and outstanding SPAC Public Unit shall be automatically detached and the holder thereof

shall be deemed to hold one share of SPAC Common Stock and one-half (1/2) of one SPAC Public Warrant in accordance with the terms of the

applicable SPAC Public Unit, which underlying SPAC Securities shall then be converted in accordance with the applicable terms of this

Section 1.9 below.

(b) SPAC

Common Stock. At the Effective Time, each issued and outstanding share of SPAC Common Stock (other than those described in Section

1.9(d) below, but including those described in Section 1.9(a) above) shall be converted automatically into and thereafter represent

the right to receive one share of Pubco Common Stock; following which, all shares of SPAC Common Stock shall cease to be outstanding and

shall automatically be canceled and shall cease to exist.

Warrants. At the Effective Time, each issued and outstanding SPAC Public Warrant shall be converted into one Pubco Public Warrant

and each issued and outstanding SPAC Private Warrant shall be converted into one Pubco Private Warrant. At the Effective Time, SPAC Warrants

shall cease to be outstanding and shall automatically be canceled and retired and shall cease to exist. Each of the Pubco Public Warrants

shall have, and be subject to, substantially the same terms and conditions set forth in SPAC Public Warrants, and each of the Pubco Private

Warrants shall have, and be subject to, substantially the same terms and conditions set forth in SPAC Private Warrants, except that in

each case they shall represent the right to acquire shares of Pubco Common Stock in lieu of shares of SPAC Common Stock. At or prior to

the Effective Time, Pubco shall take all corporate action necessary to reserve for future issuance, and shall maintain such reservation

for so long as any of the Pubco Public Warrants or Pubco Private Warrants remain outstanding, a sufficient number of shares of Pubco Common

Stock for delivery upon the exercise of such Pubco Public Warrants or Pubco Private Warrants, as applicable.

(d) Treasury

Stock. At the Effective Time, if there are any shares of capital stock of SPAC that are owned by SPAC as treasury shares or by any

direct or indirect Subsidiary of SPAC, such shares shall be canceled and extinguished without any conversion thereof or payment therefor.

(e) SPAC

Merger Sub Stock. At the Effective Time, each share of common stock of SPAC Merger Sub outstanding immediately prior to the Effective

Time shall be converted into an equal number of shares of common stock of SPAC Surviving Subsidiary, with the same rights, powers and

privileges as the shares so converted and shall constitute the only outstanding shares of capital stock of SPAC Surviving Subsidiary.

1.10 Effect

of Company Merger on Issued Securities of the Company and Company Merger Sub. At the Effective Time, by virtue of the Company Merger

and without any action on the part of any Party or the holders of securities of any SPAC Party or the Company:

(a) Company

Interests. At the Effective Time, each Company Interest issued and outstanding immediately prior to the Effective Time (other than

the Company Interests described in Section 1.10(b) below) will be cancelled and cease to exist in exchange for the right to receive

the Merger Consideration as described in Section 1.8. As of the Effective Time, each holder of Company Interests shall cease to

have any other rights with respect to the Company Interests, except as otherwise required under applicable Law.

(b) Treasury

Interests. At the Effective Time, if there are any equity securities of the Company that are owned by the Company in treasury or any

equity securities of the Company owned by any direct or indirect Subsidiary of the Company immediately prior to the Effective Time, such

equity interests (collectively, the “Excluded Interests”) shall be canceled and shall cease to exist without

any conversion thereof or payment therefor.

Convertible Securities. Any outstanding Company Convertible Security, if not exercised or converted prior to the Effective Time, shall

be cancelled, retired and terminated and cease to represent a right to acquire, be exchanged for or convert into Company Interests.

(d) Company

Merger Sub Interests. At the Effective Time, each membership interest of Company Merger Sub outstanding immediately prior to the

Effective Time shall be converted into an equal number of membership interests of Company Surviving Subsidiary, with the same rights,

powers and privileges as the membership interests so converted and shall constitute the only equity interests in Company Surviving Subsidiary.

1.11 Effect

of Mergers on Issued and Outstanding Securities of Pubco. At the Effective Time, by virtue of the Mergers and without any action on

the part of any Party or the holders of securities of any SPAC Party or the Company, all of the shares of Pubco issued and outstanding

immediately prior to the Effective Time shall be canceled and extinguished without any conversion thereof or payment therefor.

1.12 Sponsor

Payment. At the Closing, Pubco shall pay to Copley Acquisition Sponsors Limited, a British Virgin Islands company limited by shares

incorporated under the laws of the British Virgin Islands, in cash by wire transfer of immediately available funds, an amount equal to

Four Million U.S. Dollars ($4,000,000) (the “Sponsor Payment”).

1.13 Tax

Consequences. It is intended by the Parties that the Mergers shall, collectively, constitute a transaction described in Section 351

of the Code.

1.14 Taking

of Necessary Action; Further Action. If, at any time after the Effective Time, any further action is necessary or desirable to carry

out the purposes of this Agreement and to vest SPAC Surviving Subsidiary or Company Surviving Subsidiary with full right, title and possession

to all assets, property, rights, agreements, privileges, powers and franchises of SPAC Merger Sub and Company Merger Sub, respectively,

the then current officers and directors of SPAC Surviving Subsidiary and Pubco, and the then officers and board of managers of Company

Surviving Subsidiary shall take all such lawful and necessary action, so long as such action is not inconsistent with this Agreement.

Article

CLOSING

2.1 Closing.

Subject to the satisfaction or waiver of the conditions set forth in Article VII, the consummation of the transactions contemplated

by this Agreement (the “Closing”) shall take place at the offices of Winston Taylor, LLP (“Winston”),

counsel to SPAC, 800 Capitol St., Suite 2400, Houston, TX 77002, on a date and at a time to be agreed upon by SPAC and the Company, which

date shall be no later than the second (2nd) Business Day after all the Closing conditions to this Agreement have been satisfied

or waived, or at such other date, time or place (including remotely) as SPAC and the Company may agree (the date and time at which the

Closing is actually held being the “Closing Date”).

Article

III

REPRESENTATIONS AND WARRANTIES OF SPAC

Except as set forth in (i)

the disclosure schedules delivered by SPAC to the Company on the date hereof (the “SPAC Disclosure Schedules”),

the Section numbers of which are numbered to correspond to the Section numbers of this Agreement to which they refer, or (ii) the SEC

Reports that are available on the SEC’s website through EDGAR, SPAC represents and warrants to the Company, as follows:

3.1 Organization

and Standing. SPAC is an exempted company duly incorporated, validly existing and in good standing under the Laws of the Cayman Islands.

SPAC has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as now being

conducted. SPAC is duly qualified or licensed and in good standing to do business in each jurisdiction in which the character of the property

owned, leased or operated by it or the nature of the business conducted by it makes such qualification or licensing necessary, except

where the failure to be so qualified or licensed or in good standing can be cured without material cost or expense. SPAC has heretofore

made available to the Company accurate and complete copies of its Organizational Documents, as currently in effect. SPAC is not in violation

of any provision of its Organizational Documents in any material respect.

3.2 Authorization;

Binding Agreement. SPAC has all requisite corporate power and authority to execute and deliver this Agreement and each Ancillary Document

to which it is a party, to perform SPAC’s obligations hereunder and thereunder and to consummate the transactions contemplated hereby

and thereby, subject to obtaining the Required SPAC Shareholder Approval. The execution and delivery of this Agreement and each Ancillary

Document to which it is a party and the consummation of the transactions contemplated hereby and thereby (a) have been duly and validly

authorized by the board of directors of SPAC and (b) other than the Required SPAC Shareholder Approval, no other corporate proceedings,

other than as set forth elsewhere in the Agreement, on the part of SPAC are necessary to authorize the execution and delivery of this

Agreement and each Ancillary Document to which it is a party or to consummate the transactions contemplated hereby and thereby. This Agreement

has been, and each Ancillary Document to which SPAC is a party shall be when delivered, duly and validly executed and delivered by SPAC

and, assuming the due authorization, execution and delivery of this Agreement and such Ancillary Documents by the other parties hereto

and thereto, constitutes, or when delivered shall constitute, the valid and binding obligation of SPAC, enforceable against SPAC in accordance

with its terms, except to the extent that enforceability thereof may be limited by applicable bankruptcy, insolvency, reorganization and

moratorium laws and other laws of general application affecting the enforcement of creditors’ rights generally or by any applicable

statute of limitation or by any valid defense of set-off or counterclaim, and the fact that equitable remedies or relief (including the

remedy of specific performance) are subject to the discretion of the court from which such relief may be sought (collectively, the “Enforceability

Exceptions”).

3.3 Governmental

Approvals. No Consent of or with any Governmental Authority, on the part of SPAC is required to be obtained or made in connection

with the execution, delivery or performance by SPAC of this Agreement and each Ancillary Document to which it is a party or the consummation

by SPAC of the transactions contemplated hereby and thereby, other than (a) pursuant to Antitrust Laws, (b) such filings as contemplated

by this Agreement, (c) any filings required with NYSE or the SEC with respect to the transactions contemplated by this Agreement, (d)

applicable requirements, if any, of the Securities Act, the Exchange Act, and/ or any state “blue sky” securities Laws, and

the rules and regulations thereunder, (e) the filing of the Conversion Organizational Documents with the Cayman Registrar and the Delaware

Conversion Documents with the Delaware Secretary of State pursuant to the DGCL and (f) where the failure to obtain or make such Consents

or to make such filings or notifications, would not reasonably be expected to have a Material Adverse Effect on SPAC.

3.4 Non-Contravention.

The execution and delivery by SPAC of this Agreement and each Ancillary Document to which it is a party, the consummation by SPAC of the

transactions contemplated hereby and thereby, and compliance by SPAC with any of the provisions hereof and thereof, will not (a) conflict

with or violate any provision of SPAC’s Organizational Documents, (b) contravene or conflict with or constitute a violation

of any provisions of Law or Order binding upon or applicable to SPAC, (c) subject to obtaining the Consents from Governmental Authorities

referred to in Section 3.3 hereof, and the waiting periods referred to therein having expired, and any condition precedent

to such Consent or waiver having been satisfied, conflict with or violate any Law, Order or Consent applicable to SPAC or any of its properties

or assets, or (d) (i) violate, conflict with or result in a breach of, (ii) constitute a default (or an event which, with notice or lapse

of time or both, would constitute a default) under, (iii) result in the termination, withdrawal, suspension, cancellation or modification

of, (iv) accelerate the performance required by SPAC under, (v) result in a right of termination or acceleration under, (vi) give rise

to any obligation to make payments or provide compensation under, (vii) result in the creation of any Lien upon any of the properties

or assets of SPAC under, (viii) give rise to any obligation to obtain any third party Consent or provide any notice to any Person or (ix)

give any Person the right to declare a default, exercise any remedy, claim a rebate, chargeback, penalty or change in delivery schedule,

accelerate the maturity or performance, cancel, terminate or modify any right, benefit, obligation or other term under, any of the terms,

conditions or provisions of, any SPAC Material Contract, except for any deviations from any of the foregoing clauses (c) or (d) that would

not reasonably be expected to have a Material Adverse Effect on SPAC.

3.5 Capitalization.

(a) SPAC’s

authorized share capital is comprised of: (i) 166,500,000 SPAC Ordinary Shares, consisting of 150,000,000 SPAC Class A Ordinary Shares,

par value $0.0001 per share, of which 17,978,393 SPAC Class A Ordinary Shares are issued and outstanding as of the date of this Agreement,

and 15,000,000 SPAC Class B Ordinary Shares, par value $0.0001 per share, of which 5,750,000 SPAC Class B Ordinary Shares are issued and

outstanding as of the date of this Agreement, and (ii) 1,500,000 SPAC Preference Shares, par value $0.0001 per share, of which no shares

are issued and outstanding as of the date of this Agreement. All outstanding SPAC Securities are duly authorized, validly issued, fully

paid and non-assessable and are not subject to or issued in violation of any purchase option, right of first refusal, preemptive right,

subscription right or any similar right under any provision of the Act (prior to the Conversion), SPAC’s Organizational Documents

or any Contract to which SPAC is a party. None of the outstanding SPAC Securities has been issued in violation of any applicable securities

Laws.

(b) Except

as set forth on Schedule 3.5(a) or Schedule 3.5(b) there are no (i) outstanding options, warrants, puts, calls, convertible

securities, preemptive or similar rights, (ii) bonds, debentures, notes or other Indebtedness having general voting rights or that are

convertible or exchangeable into securities having such rights or (iii) subscriptions or other rights, agreements, arrangements, Contracts

or commitments of any character (other than this Agreement and the Ancillary Documents), (A) relating to the issued or unissued shares

of SPAC or (B) obligating SPAC to issue, transfer, deliver or sell or cause to be issued, transferred, delivered, sold or repurchased

any options or shares or securities convertible into or exchangeable for such shares, or (C) obligating SPAC to grant, extend or enter

into any such option, warrant, call, subscription or other right, agreement, arrangement or commitment for such capital shares. Other

than the Redemption or as expressly set forth in this Agreement, there are no outstanding obligations of SPAC to repurchase, redeem or

otherwise acquire any shares of SPAC or to provide funds to make any investment (in the form of a loan, capital contribution or otherwise)

in any Person. Except as set forth on Schedule 3.5(b), there are no shareholders agreements, voting trusts or other agreements

or understandings to which SPAC is a party with respect to the voting of any shares of SPAC.

Indebtedness of SPAC as of the date of this Agreement is disclosed on Schedule 3.5(c). No Indebtedness of SPAC contains any restriction

upon (i) the prepayment of any of such Indebtedness, (ii) the incurrence of Indebtedness by SPAC or (iii) the ability of SPAC to grant

any Lien on its properties or assets.

(d) Since

the date of formation of SPAC, and except as contemplated by this Agreement, SPAC has not declared or paid any distribution or dividend

in respect of its shares and has not repurchased, redeemed or otherwise acquired any of its shares, and SPAC’s board of directors

has not authorized any of the foregoing.

3.6 SEC

Filings and SPAC Financials.

(a) SPAC,

since the IPO, has filed all forms, reports, schedules, statements, registration statements, prospectuses and other documents required

to be filed or furnished by SPAC with the SEC under the Securities Act and/or the Exchange Act, together with any amendments, restatements

or supplements thereto, and will file all such forms, reports, schedules, statements and other documents required to be filed subsequent

to the date of this Agreement and SPAC has not taken any action prohibited by Section 402 of SOX regarding this Section 3.6(a).

Except to the extent available on the SEC’s web site through EDGAR, SPAC has delivered to the Company copies in the form filed with

the SEC of all of the following: (i) SPAC’s annual reports on Form 10-K for each fiscal year of SPAC beginning with the first year

SPAC was required to file such a form, (ii) SPAC’s quarterly reports on Form 10-Q for each fiscal quarter that SPAC filed such reports

to disclose its quarterly financial results in each of the fiscal years of SPAC referred to in clause (i) above, (iii) all other forms,

reports, registration statements, prospectuses and other documents (other than preliminary materials) filed by SPAC with the SEC since

the beginning of the first fiscal year referred to in clause (i) above (the forms, reports, registration statements, prospectuses and

other documents referred to in clauses (i), (ii) and (iii) above, whether or not available through EDGAR, are, collectively, the “SEC

Reports”) and (iv) all certifications and statements required by (A) Rules 13a-14 or 15d-14 under the Exchange Act, and

(B) 18 U.S.C. §1350 (Section 906 of SOX) with respect to any report referred to in clause (i) above (collectively, the “Public

Certifications”). As of their respective dates, the SEC Reports (x) were prepared in all material respects in accordance

with the requirements of the Securities Act and the Exchange Act, as the case may be, and the rules and regulations thereunder and (y)

did not, as of their respective effective dates (in the case of SEC Reports that are registration statements filed pursuant to the requirements

of the Securities Act) and at the time they were filed with the SEC (in the case of all other SEC Reports) contain any untrue statement

of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements made therein,

in the light of the circumstances under which they were made, not misleading. As of the date of this Agreement, (A) SPAC Public Units,

SPAC Class A Ordinary Shares, and SPAC Public Warrants are listed on NYSE, (B) SPAC has not received any written deficiency notice from

NYSE relating to the continued listing requirements of such SPAC Securities, (C) there are no Actions pending or, to the Knowledge of

SPAC, threatened against SPAC by the Financial Industry Regulatory Authority with respect to any intention by such entity to suspend,

prohibit or terminate the quoting of such SPAC Securities on NYSE and (D) such SPAC Securities are in compliance with all of the applicable

corporate governance rules of NYSE.

(b) SPAC

maintains disclosure controls and procedures required by Rules 13a-15 or Rule 15d-15 under the Exchange Act; such controls and procedures

are reasonably designed to ensure that all material information concerning SPAC and other material information required to be disclosed

by SPAC in the reports and other documents that it files or furnishes under the Exchange Act is made known on a timely basis to the individuals

responsible for the preparation of SPAC’s SEC filings and other public disclosure documents.

financial statements and notes of SPAC contained or incorporated by reference in the SEC Reports (the “SPAC Financials”),

fairly present in all material respects the financial position and the results of operations, changes in shareholders’ equity, and

cash flows of SPAC at the respective dates of and for the periods referred to in the SPAC Financials, all in accordance with (i) GAAP

methodologies applied on a consistent basis throughout the periods involved and (ii) Regulation S-X or Regulation S-K, as applicable (except

as may be indicated in the notes thereto and for the omission of notes and audit adjustments in the case of unaudited quarterly financial

statements to the extent permitted by Regulation S-X or Regulation S-K, as applicable).

(d) Except

to the extent reflected or reserved against in SPAC Financials, SPAC has not incurred any Liabilities or obligations of the type required

to be reflected on a balance sheet in accordance with GAAP that are not adequately reflected or reserved on or provided for in SPAC Financials,

other than Liabilities of the type required to be reflected on a balance sheet in accordance with GAAP that have been incurred since SPAC’s

formation in the ordinary course of business. The SPAC has no off-balance sheet arrangements.

(e) There

are no outstanding loans or other extensions of credit made by SPAC to any executive officer (as defined in Rule 3b-7 under the Exchange

Act) or director of SPAC.

3.7 Absence

of Certain Changes. As of the date of this Agreement, SPAC has, (a) since its formation, conducted no business other than its formation,

the public offering of its securities (and the related private offerings), public reporting and its search for an initial Business Combination

as described in the IPO Prospectus (including the investigation of the Target Companies and the negotiation and execution of this Agreement)

and related activities and (b) since December 31, 2025 through the date of this Agreement, not been subject to a Material Adverse Effect

on SPAC.

3.8 Compliance

with Laws. SPAC is, and has since its formation been, in compliance with all Laws applicable to it and the conduct of its business

except for such noncompliance which would not reasonably be expected to have a Material Adverse Effect on SPAC, and SPAC has not received

written notice alleging any violation of applicable Law in any material respect by SPAC.

3.9 Actions;

Orders; Permits. There is no pending or, to the Knowledge of SPAC, threatened material Action to which SPAC is subject which would

reasonably be expected to have a Material Adverse Effect on SPAC. There is no material Action that SPAC has pending against any other

Person. SPAC is not subject to any material Orders of any Governmental Authority, nor are any such Orders pending. SPAC holds all material

Permits necessary to lawfully conduct its business as presently conducted, and to own, lease and operate its assets and properties, all

of which are in full force and effect, except where the failure to hold such Consent or for such Consent to be in full force and effect

would not reasonably be expected to have a Material Adverse Effect on SPAC.

3.10 Taxes

and Returns.

(a) SPAC

has timely filed, or caused to be timely filed, all material Tax Returns required to be filed by it, which Tax Returns are accurate and

complete in all material respects, and has paid, collected or withheld, or caused to be paid, collected or withheld, all material Taxes

required to be paid, collected or withheld, other than such Taxes for which adequate reserves in SPAC Financials have been established

in accordance with GAAP. Schedule 3.10(a) sets forth each jurisdiction where SPAC files or is required to file a Tax Return. There

are no audits, examinations, investigations or other proceedings pending against SPAC in respect of any Tax, and SPAC has not been notified

in writing of any proposed Tax claims or assessments against SPAC (other than, in each case, claims or assessments for which adequate

reserves in SPAC Financials have been established in accordance with GAAP or are immaterial in amount). There are no Liens with respect

to any Taxes upon any of SPAC’s assets, other than Permitted Liens. SPAC has no outstanding waivers or extensions of any applicable

statute of limitations to assess any material amount of Taxes. There are no outstanding requests by SPAC for any extension of time within

which to file any Tax Return or within which to pay any Taxes shown to be due on any Tax Return.

(b) Since

the date of its incorporation, SPAC has not (i) changed any Tax accounting methods, policies or procedures except as required by a change

in Law, (ii) made, revoked or amended any material Tax election, (iii) filed any amended Tax Returns or claim for refund or (iv) entered

into any closing agreement affecting or otherwise settled or compromised any material Tax Liability or refund.

the Knowledge of SPAC, there are no facts or circumstances that would reasonably be expected to prevent the Mergers from qualifying as

an exchange described in Section 351 of the Code.

3.11 Employees

and Employee Benefit Plans. SPAC does not (a) have any paid employees or (b) maintain, sponsor, contribute to or otherwise have any

Liability under, any Benefit Plans.

3.12 Properties.

SPAC does not own, license or otherwise have any right, title or interest in any material Intellectual Property. SPAC does not own or

lease any material real property or material Personal Property.

3.13 Material

Contracts.

(a) Except

as set forth on Schedule 3.13(a), other than this Agreement and the Ancillary Documents, there are no Contracts to which SPAC is

a party or by which any of its properties or assets may be bound, subject or affected, which creates or imposes a Liability greater than

$250,000 (each, a “SPAC Material Contract”). All SPAC Material Contracts have been made available to the Company

other than those that are exhibits to the SEC Reports.

(b) With

respect to each SPAC Material Contract: (i) the SPAC Material Contract was entered into at arms’ length and in the ordinary course

of business, (ii) the SPAC Material Contract is legal, valid, binding and enforceable in all material respects against SPAC and, to the

Knowledge of SPAC, the other parties thereto, and is in full force and effect (except, in each case, as such enforcement may be limited

by the Enforceability Exceptions),(iii) SPAC is not in breach or default in any material respect, and no event has occurred that with

the passage of time or giving of notice or both would constitute such a breach or default in any material respect by SPAC, or permit termination

or acceleration by the other party, under such SPAC Material Contract, and (iv) to the Knowledge of SPAC, no other party to any SPAC Material

Contract is in breach or default in any material respect, and no event has occurred that with the passage of time or giving of notice

or both would constitute such a breach or default by such other party, or permit termination or acceleration by SPAC under any SPAC Material

Contract.

3.14 Transactions

with Affiliates. Schedule 3.14 sets forth a true, correct and complete list of the Contracts and arrangements that are in existence

as of the date of this Agreement under which there are any existing or future Liabilities or obligations between SPAC and any (a) present

or former director, officer or employee or Affiliate of SPAC, or any immediate family member of any of the foregoing, or (b) record or

beneficial owner of more than ten percent (10%) of SPAC’s outstanding capital stock as of the date hereof.

3.15 Investment

Company Act. SPAC is not an “investment company” or a Person directly or indirectly “controlled” by or acting

on behalf of an “investment company”, or required to register as an “investment company”, in each case within

the meaning of the Investment Company Act of 1940, as amended (the “Investment Company Act”).

3.16 Finders

and Brokers. Except as set forth on Schedule 3.16, no broker, finder or investment banker is entitled to any brokerage, finder’s

or other fee or commission from SPAC, the Target Companies or any of their respective Affiliates in connection with the transactions contemplated

hereby based upon arrangements made by or on behalf of SPAC.

3.17 Certain

Business Practices.

(a) Neither

SPAC, nor, to the Knowledge of SPAC, any of its Representatives acting on its behalf, has (i) used any funds for unlawful contributions,

gifts, entertainment or other unlawful expenses relating to political activity, (ii) made any unlawful payment to foreign or domestic

government officials or employees, to foreign or domestic political parties or campaigns or violated any provision of the U.S. Foreign

Corrupt Practices Act of 1977 or any other local or foreign anti-corruption or bribery Law, (iii) made any other unlawful payment or (iv)

since the formation of SPAC, directly or indirectly, given or agreed to give any unlawful gift or similar benefit in any material amount

to any customer, supplier, governmental employee or other Person who is or may be in a position to help or hinder SPAC or assist it in

connection with any actual or proposed transaction.

(b) The

operations of SPAC are and have been conducted at all times in material compliance with money laundering statutes in all applicable jurisdictions,

the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by

any Governmental Authority, and no Action involving SPAC with respect to any of the foregoing is pending or, to the Knowledge of SPAC,

threatened.

of SPAC or any of its directors or officers, or, to the Knowledge of SPAC, any other Representative acting on behalf of SPAC is currently

(i) identified on the specially designated nationals or other blocked person list or otherwise currently subject to any U.S. sanctions

administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”), the U.S. Department

of State, or other applicable Governmental Authority; (ii) organized, resident, or located in, or a national of a comprehensively sanctioned

country; or (iii) in the aggregate, fifty percent (50%) or greater owned, directly or indirectly, or otherwise controlled, by a person

identified in (i) or (ii); and SPAC has not, directly or indirectly, used any funds, or loaned, contributed or otherwise made available

such funds to any Subsidiary, joint venture partner or other Person, in connection with any sales or operations in any other country sanctioned

by OFAC or for the purpose of financing the activities of any Person currently subject to, or otherwise in violation of, any U.S. sanctions

administered by OFAC or the U.S. Department of State in the last five (5) fiscal years.

3.18 SPAC

Trust Account. As of March 31, 2026, the Trust Account had a balance of $179,525,293.60. Such monies are invested solely in United

States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act or money market funds

meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act, and held in trust by the Trustee pursuant to

the Trust Agreement. The Trust Agreement is valid and in full force and effect and enforceable in accordance with its terms (subject to

the Enforceability Exceptions) and has not been amended or modified. SPAC has complied in all material respects with the terms of the

Trust Agreement and is not in material breach thereof or material default thereunder and there does not exist under the Trust Agreement

any event which, with the giving of notice or the lapse of time, would constitute such a material breach or material default by SPAC or,

to the Knowledge of SPAC, by the Trustee. There are no separate contracts, agreements, side letters or other agreements or understandings

(whether written or unwritten, express or implied) between SPAC and the Trustee that would cause the description of the Trust Agreement

in the SEC Reports to be inaccurate in any material respect and/or that would entitle any Person (other than the underwriters of the IPO,

Public Shareholders who shall have elected to redeem their SPAC Class A Ordinary Shares pursuant to SPAC Organizational Documents (or

in connection with an extension of SPAC’s deadline to consummate a Business Combination) or Governmental Authorities for Taxes)

to any portion of the proceeds in the Trust Account. Prior to the Closing, none of the funds held in the Trust Account may be released

except as described in the Trust Agreement and the IPO Prospectus. There are no Actions pending or, to the knowledge of SPAC, threatened

with respect to the Trust Account.

3.19 Exclusivity

of Representations.

(a) Neither

the Company nor its Representatives has made any representation or warranty as to the Target Companies, or this Agreement, except as expressly

set forth in this Agreement (including the related portions of the Company Disclosure Schedules) or in any certificate delivered to SPAC

pursuant hereto, or with respect to the information provided by or on behalf of the Company for the Registration Statement.

(b) Company

specifically disclaims that it is relying upon or has relied upon any other representations and warranties that may have been made by

any Person and acknowledges and agrees that SPAC, Pubco and the Merger Subs have specifically disclaimed any such other representations

and warranties.

3.20 Information Supplied.

None of the information supplied or to be supplied by SPAC expressly for inclusion or incorporation by reference: (a) in any current

report on Form 8-K, and any exhibits thereto or any other report, form, registration or other filing made with any Governmental Authority

or stock exchange with respect to the transactions contemplated by this Agreement or any Ancillary Documents; (b) in the Registration

Statement; or (c) in the mailings or other distributions to SPAC’s shareholders and/or prospective investors with respect to the

consummation of the transactions contemplated by this Agreement or in any amendment to any of documents identified in (a) through (c),

will, when filed, made available, mailed or distributed, as the case may be, contain any untrue statement of a material fact or omit

to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances

under which they are made, not misleading (provided, if such information is revised by any subsequently filed amendment or supplement

to the Registration Statement prior to the time the Registration Statement is declared effective by the SEC, this clause (a) shall solely

refer to the time of such subsequent revision or supplement). None of the information supplied or to be supplied by SPAC expressly for

inclusion or incorporation by reference in any of the Signing Press Release, the Signing Filing, the Closing Press Release and the Closing

Filing will, when filed or distributed, as applicable, contain any untrue statement of a material fact or omit to state any material

fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they

are made, not misleading. Notwithstanding the foregoing, SPAC makes no representation, warranty or covenant with respect to any information

supplied by or on behalf of the Target Companies or its Affiliates.

Article

REPRESENTATIONS AND WARRANTIES OF

PUBCO AND THE MERGER SUBS

Each of Pubco and the Merger

Subs, jointly and severally, represents and warrants to the Company, as follows:

4.1 Organization

and Standing. Pubco and SPAC Merger Sub are each corporations duly incorporated, validly existing and in good standing under the Laws

of the State of Delaware and Company Merger Sub is a limited liability company duly organized, validly existing and in good standing under

the Laws of Delaware. Each of Pubco and the Merger Subs has all requisite corporate or limited liability power, as applicable, and authority

to own, lease and operate its properties and to carry on its business as now being conducted. Each of Pubco and the Merger Subs is duly

qualified or licensed and in good standing to do business in each jurisdiction in which the character of the property owned, leased or

operated by it or the nature of the business conducted by it makes such qualification or licensing necessary, except where the failure

to be so qualified or licensed would not individually or in the aggregate reasonably be expected to have a material impact on the ability

of Pubco or any Merger Sub on a timely basis to consummate the transactions contemplated by this Agreement. Pubco has heretofore made

available to SPAC and the Company accurate and complete copies of the Organizational Documents of Pubco and the Merger Subs, each as currently

in effect. Neither Pubco nor any Merger Sub is in violation of any provision of its Organizational Documents in any material respect.

4.2 Authorization;

Binding Agreement. Subject to the adoption of the Amended Pubco Charter, each of Pubco and the Merger Subs has all requisite corporate

or limited liability power, as applicable, and authority to execute and deliver this Agreement and each Ancillary Document to which it

is a party, to perform its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The

sole stockholder of Pubco, Pubco in its capacity as sole stockholder of SPAC Merger Sub and Pubco in its capacity as sole member and manager

of Company Merger Sub has authorized the execution, delivery and performance of this Agreement and the Ancillary Documents and the consummation

of the Mergers and the other transactions contemplated by this Agreement. The execution and delivery of this Agreement and each Ancillary

Document to which it is a party and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized

by the board of directors of Pubco and SPAC Merger Sub and no other corporate proceedings, other than as expressly set forth elsewhere

in this Agreement (including the adoption of the Amended Pubco Charter and the approval by the equity holders of Pubco and each Merger

Sub), on the part of Pubco or Merger Subs are necessary to authorize the execution and delivery of this Agreement and each Ancillary Document

to which it is a party or to consummate the transactions contemplated hereby and thereby. This Agreement has been, and each Ancillary

Document to which Pubco or the Merger Subs is a party has been or shall be when delivered, duly and validly executed and delivered by

such Party and, assuming the due authorization, execution and delivery of this Agreement and such Ancillary Documents by the other parties

hereto and thereto, constitutes, or when delivered shall constitute, the valid and binding obligation of such Party, enforceable against

such Party in accordance with its terms, subject to the Enforceability Exceptions.

4.3 Governmental

Approvals. No Consent of or with any Governmental Authority, on the part of Pubco or the Merger Subs is required to be obtained or

made in connection with the execution, delivery or performance by such Party of this Agreement and each Ancillary Document to which it

is a party or the consummation by such Party of the transactions contemplated hereby and thereby, other than (a) pursuant to Antitrust

Laws, (b) such filings as contemplated by this Agreement, (c) any filings required with NYSE or the

SEC with respect to the transactions contemplated by this Agreement, (d) applicable requirements, if any, of the Securities Act, the Exchange

Act, and/ or any state “blue sky” securities Laws, and the rules and regulations thereunder, and (e) where the failure to

obtain or make such Consents or to make such filings or notifications, would not, individually or in the aggregate, reasonably be expected

to have a material impact on the ability of Pubco on a timely basis to consummate the transactions contemplated by this Agreement.

4.4 Non-Contravention.

The execution and delivery by Pubco and the Merger Subs of this Agreement and each Ancillary Document to which it is a party, the consummation

by such Party of the transactions contemplated hereby and thereby, and compliance by such Party with any of the provisions hereof and

thereof, will not (a) subject to the adoption of the Amended Pubco Charter, conflict with or violate any provision of such Party’s

Organizational Documents, (b) subject to obtaining the Consents from Governmental Authorities referred to in Section 4.3 hereof,

and any condition precedent to such Consent or waiver having been satisfied, conflict with or violate any Law, Order or Consent applicable

to such Party or any of its properties or assets, or (c) (i) violate, conflict with or result in a breach of, (ii) constitute a default

(or an event which, with notice or lapse of time or both, would constitute a default) under, (iii) result in the termination, withdrawal,

suspension, cancellation or modification of, (iv) accelerate the performance required by such Party under, (v) result in a right of termination

or acceleration under, (vi) give rise to any obligation to make payments or provide compensation under, (vii) result in the creation of

any Lien upon any of the properties or assets of such Party under, (viii) give rise to any obligation to obtain any third party Consent

or provide any notice to any Person or (ix) give any Person the right to declare a default, exercise any remedy, claim a rebate, chargeback,

penalty or change in delivery schedule, accelerate the maturity or performance, cancel, terminate or modify any right, benefit, obligation

or other term under, any of the terms, conditions or provisions of, any material Contract of such Party, except for any deviations from

any of the foregoing clauses (a), (b) or (c) that would not, individually or in the aggregate, reasonably be expected to have a material

impact on the ability of Pubco on a timely basis to consummate the transactions contemplated by this Agreement.

4.5 Capitalization.

As of the Closing Date, Pubco and the Merger Subs will have the capitalization stated in their respective Organizational Documents. Prior

to giving effect to the transactions contemplated by this Agreement, other than the Merger Subs, Pubco does not have any Subsidiaries

or own any equity interests in any other Person.

4.6 Ownership

of Pubco Common Stock. (i) All shares of Pubco Common Stock to be issued and delivered in accordance with Article I to the

Sellers shall be, upon issuance and delivery of such shares, duly authorized, validly issued, fully paid, non-assessable and free and

clear of all Liens, and (ii) upon issuance and delivery of such shares to the Sellers, each Seller shall have good and valid title to

its portion of such shares, in each case of clauses (i) and (ii), other than restrictions arising from applicable securities Laws, the

Ancillary Documents, the Amended Pubco Charter, the provisions of this Agreement and any Liens incurred by the Sellers, and (iii) the

issuance and sale of such shares pursuant hereto will not be subject to or give rise to any preemptive rights or rights of first refusal.

4.7 Pubco

and Merger Sub Activities. Since their formation, Pubco and the Merger Subs have not engaged in any business activities other than

as contemplated by this Agreement, do not own directly or indirectly any ownership, equity, profits or voting interest in any Person (other

than Pubco’s one hundred percent (100%) ownership of the Merger Subs) and have no assets or Liabilities except those incurred in

connection with this Agreement and the Ancillary Documents to which they are a party and the transactions contemplated by this Agreement,

and, other than this Agreement and the Ancillary Documents to which they are a party, Pubco and the Merger Subs are not party to or bound

by any Contract.

Article

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

Except as set forth in the

disclosure schedules delivered by the Company to SPAC on the date hereof (the “Company Disclosure Schedules”),

the Section numbers of which are numbered to correspond to the Section numbers of this Agreement to which they refer (provided, however,

that an item disclosed in any Section of the Company Disclosure Schedules shall be deemed to have been disclosed with respect to all other

Sections of this Article V to which the relevance of such disclosure is reasonably apparent on its face), the Company hereby represents

and warrants to SPAC, as of the date hereof and as of the Closing, as follows:

5.1 Organization

and Standing. The Company is a limited liability company duly organized, validly existing and in good standing under the Laws of the

State of Delaware and has all requisite limited liability power and authority to own, lease and operate its properties and to carry on

its business as now being conducted. Each Subsidiary of the Company is a corporation or other entity duly organized, validly existing

and in good standing under the Laws of its jurisdiction of organization and has all requisite corporate or limited liability company power

and authority, as applicable, to own, lease and operate its properties and to carry on its business as now being conducted. Each Target

Company is duly qualified or licensed and in good standing in the jurisdiction in which it is incorporated or registered and in each other

jurisdiction where it does business or operates to the extent that the character of the property owned, or leased or operated by it or

the nature of the business conducted by it makes such qualification or licensing necessary, except where failure to be so qualified or

licensed or in good standing can be cured without material cost or expense. Schedule 5.1 lists all jurisdictions in which any Target

Company is qualified to conduct business and all names other than its legal name under which any Target Company does business. The Company

has provided to SPAC accurate and complete copies of its Organizational Documents and the Organizational Documents of each of its Subsidiaries,

each as amended to date and as currently in effect. No Target Company is in violation of any provision of its Organizational Documents

in any material respect.

5.2 Authorization;

Binding Agreement. The Company has all requisite limited liability company power and authority to execute and deliver this Agreement

and each Ancillary Document to which it is or is required to be a party, to perform the Company’s obligations hereunder and thereunder

and to consummate the transactions contemplated hereby and thereby, subject to obtaining the Required Company Member Approval. The execution

and delivery of this Agreement and each Ancillary Document to which the Company is or is required to be a party and the consummation of

the transactions contemplated hereby and thereby, (a) have been duly and validly authorized by the Company’s board of managers (or

manager or managing member(s), as applicable) in accordance with the Company Operating Agreement any other applicable Law or any Contract

to which the Company or any of its equity holders is a party or by which it or its securities are bound and (b) other than the Required

Company Member Approval, no other corporate proceedings on the part of the Company are necessary to authorize the execution and delivery

of this Agreement and each Ancillary Document to which it is a party or to consummate the transactions contemplated hereby and thereby.

This Agreement has been, and each Ancillary Document to which the Company is or is required to be a party has been or shall be when delivered,

duly and validly executed and delivered by the Company and assuming the due authorization, execution and delivery of this Agreement and

any such Ancillary Document by the other parties hereto and thereto, constitutes, or when delivered shall constitute, the legal, valid

and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions.

The Company’s board of managers (or manager or managing member(s), as applicable), by resolutions duly adopted at a meeting duly

called and held or by unanimous written consent (i) determined that this Agreement and the Mergers and the other transactions contemplated

hereby are advisable, fair to, and in the best interests of, the Company and its members, (ii) approved this Agreement and the Mergers

and the other transactions contemplated by this Agreement in accordance with the DLLCA, (iii) directed that this Agreement and the other

matters required for member approval be submitted to the Company’s members for adoption and (iv) resolved to recommend that the

Company’s members adopt and approve this Agreement and the other matters requiring such member approval. The Seller Support Agreements

delivered by the Company include holders of Company Interests representing at least the Required Company Member Approval, and such Seller

Support Agreements are in full force and effect.

5.3 Capitalization.

(a) All

of the issued and outstanding Company Interests are set forth on Schedule 5.3(a), along with the beneficial and record owners thereof,

all of which Company Interests and other equity interests are owned free and clear of any Liens other than those imposed under the Company

Operating Agreement or by applicable securities Laws. The issued and outstanding Company Interests constitute all of the outstanding equity

interests of the Company. All of the outstanding Company Interests and other equity interests of the Company have been duly authorized,

are fully paid and non-assessable and not in violation of any purchase option, right of first refusal, preemptive right, subscription

right or any similar right under any provision of the DLLCA, any other applicable Law, the Company Operating Agreement or any Contract

to which the Company is a party or by which it or its securities are bound. The Company does not directly or indirectly hold any Company

Interests or other equity interests of the Company in its treasury. All of the Company’s securities have been granted, offered,

sold and issued in compliance with all applicable securities Laws. The rights, privileges and preferences of the Company Interests are

as stated in the Company Operating Agreement and as provided by the DLLCA.

(b) There

are no Company Convertible Securities, or preemptive rights or rights of first refusal or first offer, nor are there any Contracts, commitments,

arrangements or restrictions to which the Company or any of its equity holders is a party or bound relating to any equity securities of

the Company, whether or not outstanding. There are no issued, reserved for issuance, outstanding or authorized option, restricted unit

award, restricted interest award, profits interest, profit participation, equity appreciation, phantom equity, or equity-based award or

similar rights with respect to the Company. Except as set forth on Schedule 5.3(b), there are no voting trusts, proxies, shareholder

agreements or any other agreements or understandings with respect to the voting of the Company’s equity interests. Except as set

forth in the Company Operating Agreement, there are no outstanding contractual obligations of the Company to repurchase, redeem or otherwise

acquire any equity interests or securities of the Company, nor has the Company granted any registration rights to any Person with respect

to the Company’s equity securities. All of the Company’s securities have been granted, offered, sold and issued in compliance

with all applicable securities Laws. As a result of the consummation of the transactions contemplated by this Agreement, no equity interests

of the Company are issuable and no rights in connection with any interests, warrants, rights, options or other securities of the Company

accelerate or otherwise become triggered (whether as to vesting, exercisability, convertibility or otherwise).

January 1, 2025, the Company has not declared or paid any distribution or dividend in respect of its equity interests and has not repurchased,

redeemed or otherwise acquired any equity interests of the Company, and the members of the Company have not authorized any of the foregoing.

5.4 Subsidiaries.

Schedule 5.4 sets forth the name of each Subsidiary of the Company, and with respect to each Subsidiary (a) its jurisdiction of

organization, (b) its authorized shares or other equity interests (if applicable), (c) the number of issued and outstanding shares or

other equity interests and the record holders and beneficial owners thereof and (d) its Tax election to be treated as a corporate or a

disregarded entity under the Code and any state or applicable non-U.S. Tax laws, if any. All of the outstanding equity securities of each

Subsidiary of the Company are duly authorized and validly issued, fully paid and non-assessable (if applicable), and were offered, sold

and delivered in compliance with all applicable securities Laws, and owned by one or more of the Target Companies free and clear of all

Liens (other than those, if any, imposed by such Subsidiary’s Organizational Documents or by applicable securities Laws). There

are no Contracts to which the Company or any of its Affiliates is a party or bound with respect to the voting (including voting trusts

or proxies) of the equity interests of any Subsidiary of the Company other than the Organizational Documents of any such Subsidiary. Except

as listed on Schedule 5.4, there are no outstanding or authorized options, warrants, rights, agreements, subscriptions, convertible

securities or commitments to which any Subsidiary of the Company is a party or which are binding upon any Subsidiary of the Company providing

for the issuance or redemption of any equity interests of any Subsidiary of the Company. There are no issued, reserved for issuance, outstanding

or authorized option, restricted unit award, restricted interest award, profits interest, equity appreciation, phantom equity, profit

participation, or equity-based award or similar rights granted by any Subsidiary of the Company. No Target Company has any limitation,

whether by Contract, Order or applicable Law, on its ability to make any distributions or dividends to its equity holders or repay any

debt owed to another Target Company. Except for the equity interests of the Subsidiaries listed on Schedule 5.4(a), the Company

does not own or have any rights to acquire, directly or indirectly, any equity interests of, or otherwise Control, any Person. None of

the Company or its Subsidiaries is a participant in any joint venture, partnership or similar arrangement. There are no outstanding contractual

obligations of a Target Company to provide funds to, or make any investment (in the form of a loan, capital contribution or otherwise)

in, any other Person.

5.5 Governmental

Approvals. Except as otherwise described on Schedule 5.5, no Consent of or with any Governmental Authority on the part of any

Target Company is required to be obtained or made in connection with the execution, delivery or performance by the Company of this Agreement

or any Ancillary Documents or the consummation by the Company of the transactions contemplated hereby or thereby other than (a) such filings

as are expressly contemplated by this Agreement or (b) pursuant to Antitrust Laws.

5.6 Non-Contravention.

Except as otherwise described on Schedule 5.6, the execution and delivery by the Company (or any other Target Company, as applicable)

of this Agreement and each Ancillary Document to which any Target Company is or is required to be a party or otherwise bound, and the

consummation by any Target Company of the transactions contemplated hereby and thereby and compliance by any Target Company with any of

the provisions hereof and thereof, will not (a) conflict with or violate any provision of any Target Company’s Organizational Documents,

(b) subject to obtaining the Consents from Governmental Authorities referred to in Section 5.5 hereof, the waiting periods referred

to therein having expired, and any condition precedent to such Consent or waiver having been satisfied, conflict with or violate any Law,

Order or Consent applicable to any Target Company or any of its Company Permits, material properties or assets, or (c) (i) violate, conflict

with or result in a breach of, (ii) constitute a default (or an event which, with notice or lapse of time or both, would constitute a

default) under, (iii) result in the termination, withdrawal, suspension, cancellation or modification of, (iv) accelerate the performance

required by any Target Company under, (v) result in a right of termination or acceleration under, (vi) give rise to any obligation to

make payments or provide compensation under, (vii) result in the creation of any Lien upon any of the properties or assets of any Target

Company under, (viii) give rise to any obligation to obtain any third party Consent or provide any notice to any Person or (ix) give any

Person the right to declare a default, exercise any remedy, claim a rebate, chargeback, penalty or change in delivery schedule, accelerate

the maturity or performance, cancel, terminate or modify any right, benefit, obligation or other term under, any of the terms, conditions

or provisions of any Company Permit or Company Material Contract, except for any deviations from any of the foregoing clauses (a), (b)

or (c) that would not, individually or in the aggregate, reasonably be expected to have a material impact on the ability of the Company

on a timely basis to consummate the transactions contemplated by this Agreement.

5.7 Financial

Statements.

(a) Schedule

5.7(a) contains true and correct copies of the Unaudited Financial Statements. The Unaudited Financial Statements (A) were prepared

from the books and records of the Target Companies as of the times and for the periods referred to therein, (B) were prepared in accordance

with GAAP, consistently applied throughout and among the periods involved (except as may be indicated in the notes thereto), and (C) fairly

present in all material respects the consolidated financial position of the Target Companies as of the respective dates thereof and the

consolidated results of the operations of the Target Companies for the periods indicated.

(b) The

Target Companies do not have any Indebtedness other than the Indebtedness set forth on Schedule 5.7(b), which schedule sets forth

the amounts (including principal and any accrued but unpaid interest or other obligations) with respect to such Indebtedness. Except as

disclosed on Schedule 5.7(b), no Indebtedness of any Target Company contains any restriction upon (i) the prepayment of any of

such Indebtedness, (ii) the incurrence of Indebtedness by any Target Company, or (iii) the ability of the Target Companies to grant any

Lien on their respective properties or assets.

of the financial books and records of the Target Companies are complete and accurate in all material respects and have been maintained

in the ordinary course consistent with past practice and in accordance with applicable Laws. No Target Company has been subject to or

involved in any material fraud that involves management or other employees who have a significant role in the internal controls over financial

reporting of any Target Company. To the Knowledge of the Company, no Target Company employee has engaged in any material fraud with respect

to the business activities or operations of any Target Company. In the past three (3) years, no Target Company or its Representatives

has received any written complaint, allegation, assertion or claim regarding the accounting or auditing practices, procedures, methodologies

or methods of any Target Company or its internal accounting controls, including any material written complaint, allegation, assertion

or claim that any Target Company has engaged in questionable accounting or auditing practices.

(d) Except

as set forth on Schedule 5.7(d), no Target Company is subject to any Liabilities or obligations required to be reflected on a balance

sheet prepared in accordance with GAAP, except for those that are either (i) adequately reflected or reserved on or provided for in the

consolidated balance sheet of the Company and its Subsidiaries as of December 31, 2025 and contained in the Company Financials or (ii)

not material and that were incurred after December 31, 2025 in the ordinary course of business consistent with past practice (other than

Liabilities for breach of any Contract or violation of any Law).

(e) All

accounts, notes and other receivables, whether or not accrued, and whether or not billed, of the Target Companies (the “Accounts

Receivable”) arose from sales actually made or services actually performed in the ordinary course of business and represent

valid obligations to a Target Company arising from its business.

5.8 Absence

of Certain Changes. Except as set forth on Schedule 5.8, since December 31, 2025, each Target Company has (a) conducted its

business only in the ordinary course of business consistent with past practice, (b) not been subject to a Material Adverse Effect and

(c) has not taken any action or committed or agreed to take any action that would be prohibited by Section 6.2(b) (without giving

effect to Schedule 6.2) if such action were taken on or after the date hereof without the consent of SPAC.

5.9 Compliance

with Laws. Since January 1, 2023, no Target Company is or has been in material conflict or material non-compliance with, or in material

default or violation of, nor has any Target Company received, since January 1, 2023, any written or, to the Knowledge of the Company,

oral notice of any material conflict or non-compliance with, or material default or violation of, any applicable Laws by which it or any

of its properties, assets, employees, business or operations are or were bound or affected.

5.10 Company

Permits. Each Target Company (and its employees or contractors who are legally required to be licensed by a Governmental Authority

in order to perform his or her duties with respect to his or her employment or engagement with any Target Company), holds all Permits

necessary to lawfully conduct in all material respects its business as presently conducted, and as currently contemplated to be conducted,

and to own, lease and operate its assets and properties (collectively, the “Company Permits”). The Company has

made available to SPAC true, correct and complete copies of all material Company Permits, all of which material Company Permits are listed

on Schedule 5.10. All of the Company Permits are in full force and effect, and no suspension or cancellation of any of the Company

Permits is pending or threatened in writing. No Target Company is in violation in any material respect of the terms of any Company Permit,

and no Target Company has received any written notice of any Actions relating to the revocation or modification, of any Company Permit.

5.11 Litigation.

Except as described on Schedule 5.11, there is no (a) Action of any nature currently pending or threatened in writing, and no such

Action has been brought or threatened in writing in the past three (3) years; or (b) Order now pending or outstanding or that was rendered

by a Governmental Authority in the past three (3) years, in either case of (a) or (b) by or against any Target Company, its current or

former directors, managers or officers (provided, that any litigation involving the directors or officers of a Target Company must be

related to the Target Company’s business, equity securities or assets), its business, equity securities or assets. The items listed

on Schedule 5.11, if finally determined adversely to the Target Companies, will not have, either individually or in the aggregate,

a Material Adverse Effect upon the Target Companies taken as a whole. In the past three (3) years, none of the current officers, senior

management, managers or directors of any Target Company have been charged with, indicted for, arrested for, or convicted of any felony

or any crime involving fraud.

5.12 Material

Contracts.

(a) Schedule

5.12(a) sets forth a true, correct and complete list of, and the Company has made available to SPAC true, correct and complete copies

of, each Contract to which any Target Company is a party or by which any Target Company, or any of its properties or assets are bound

or affected (each Contract required to be set forth on Schedule 5.12(a), a “Company Material Contract”)

that:

(i) contains

covenants that limit the ability of any Target Company (A) to compete in any line of business or with any Person or in any geographic

area or to sell, or provide any service or product or solicit any Person, including any non-competition covenants, employee and customer

non-solicit covenants, exclusivity restrictions, rights of first refusal or most-favored pricing clauses or (B) to purchase or acquire

an interest in any other Person;

(ii) involves

any joint venture, profit-sharing, partnership, limited liability company or other similar agreement or arrangement relating to the formation,

creation, operation, management or control of any partnership or joint venture (other than the Company Operating Agreement);

(iii) involves

any exchange traded, over the counter or other swap, cap, floor, collar, futures contract, forward contract, option or other derivative

financial instrument or Contract, based on any commodity, security, instrument, asset, rate or index of any kind or nature whatsoever,

whether tangible or intangible, including currencies, interest rates, foreign currency and indices;

(iv) evidences

Indebtedness (whether incurred, assumed, guaranteed or secured by any asset) of any Target Company having an outstanding principal amount

in excess of $200,000;

(v) involves

the acquisition or disposition, directly or indirectly (by merger or otherwise), of assets with an aggregate value in excess of $200,000

(other than in the ordinary course of business consistent with past practice) or shares or other equity interests of any Target Company

or another Person;

(vi) relates

to any merger, consolidation or other business combination with any other Person or the acquisition or disposition of any other entity

or its business or material assets or the sale of any Target Company, its business or material assets;

(vii) by

its terms, individually or with all related Contracts, resulted, during the twelve (12)-month period prior to the date hereof, in aggregate

payments or receipts to or by the Target Companies under such Contract or Contracts of at least $100,000 or $200,000 in the aggregate;

(viii) is

with any Top Customer or Top Supplier;

(ix) obligates

the Target Companies to provide continuing indemnification or a guarantee of obligations of a third party after the date hereof in excess

of $200,000;

(x) is

between any Target Company and any directors, officers or employees of a Target Company (other than at-will employment arrangements with

employees entered into in the ordinary course of business consistent with past practice), including all non-competition, severance and

indemnification agreements, or any Related Person;

(xi) obligates

the Target Companies to make any capital commitment or expenditure in excess of $200,000 (including pursuant to any joint venture);

(xii) relates

to a material settlement entered into within three (3) years prior to the date of this Agreement or under which any Target Company has

outstanding obligations (other than customary confidentiality obligations);

(xiii) provides

another Person (other than another Target Company or any manager, director or officer of any Target Company) with a power of attorney;

(xiv) relates

to the development, ownership, licensing or use of any material Intellectual Property by, to or from any Target Company, other than Off-the-Shelf

Software;

(xv) that

will be required to be filed with the Registration Statement under applicable SEC requirements or would otherwise be required to be filed

by the Company as an exhibit for a Form S-1 pursuant to Items 601(b)(1), (2), (4), (9) or (10) of Regulation S-K under the Securities

Act as if the Company was the registrant; or

(xvi) is

otherwise material to the Target Companies taken as a whole and not described in clauses (i) through (xv) above.

(b) Except

as disclosed on Schedule 5.12(b), with respect to each Company Material Contract: (i) such Company Material Contract is valid and

binding and enforceable in all material respects against the Target Company party thereto and, to the Knowledge of the Company, each other

party thereto, and is in full force and effect (except, in each case, as such enforcement may be limited by the Enforceability Exceptions),

(ii) the consummation of the transactions contemplated by this Agreement will not affect the validity or enforceability of any Company

Material Contract in any material respect, (iii) no Target Company is in breach or default in any material respect, and no event has occurred

that with the passage of time or giving of notice or both would constitute a material breach or default by any Target Company, or permit

termination or acceleration by the other party thereto, under such Company Material Contract; (iv) to the Knowledge of the Company,

no other party to such Company Material Contract is in breach or default in any material respect, and no event has occurred that with

the passage of time or giving of notice or both would constitute such a material breach or default by such other party, or permit termination

or acceleration by any Target Company, under such Company Material Contract; (v) no Target Company has received written notice of an intention

by any party to any such Company Material Contract that provides for a continuing obligation by any party thereto to terminate such Company

Material Contract or amend the terms thereof, other than modifications in the ordinary course of business that do not adversely affect

any Target Company in any material respect; and (vi) no Target Company has waived any material rights under any such Company Material

Contract.

5.13 Intellectual

Property.

(a) Schedule

5.13(a)(i) sets forth: (i) all U.S. and foreign registered Patents, Trademarks, Copyrights and Internet Assets and applications owned

by a Target Company or otherwise used or held for use by a Target Company in which a Target Company is the owner, applicant or assignee

(“Company Registered IP”), specifying as to each item, as applicable: (A) the nature of the item, including

the title, (B) the owner of the item, (C) the jurisdictions in which the item is issued or registered or in which an application for issuance

or registration has been filed and (D) the issuance, registration or application numbers and dates and (ii) all material unregistered

Intellectual Property owned or purported to be owned by a Target Company. Schedule 5.13(a)(ii) sets forth all Intellectual Property

licenses, sublicenses and other agreements or permissions (“Company IP Licenses”) (other than “shrink

wrap,” “click wrap” and “off the shelf” software agreements and other agreements for Software commercially

available on reasonable terms to the public generally with license, maintenance, support and other fees of less than $10,000 per year

(collectively, “Off-the-Shelf Software”), which are not required to be listed, although such licenses are “Company

IP Licenses” as that term is used herein), under which a Target Company is a licensee or otherwise is authorized to use or practice

any Intellectual Property, and such Company IP Licenses describe all such Intellectual Property licensed under such Company IP Licenses.

Each Target Company owns, free and clear of all Liens (other than Permitted Liens), has valid and enforceable rights in, and has the unrestricted

right to use, sell, license, transfer or assign, all Intellectual Property currently used, licensed or held for use by such Target Company,

except for the Intellectual Property that is the subject of the Company IP Licenses. No item of Company Registered IP that consists of

a pending Patent application fails to identify all pertinent inventors, and for each Patent and Patent application in the Company Registered

IP, the Target Companies have obtained valid assignments of inventions from each inventor. Except as set forth on Schedule 5.13(a)(iii),

all Company Registered IP is owned exclusively by the applicable Target Company without obligation to pay royalties, licensing fees or

other fees, or otherwise account to any third party with respect to such Company Registered IP, and such Target Company has recorded assignments

of all Company Registered IP with any applicable Intellectual Property offices or Governmental Authorities.

(b) Each

Target Company has a valid and enforceable license to use all Intellectual Property that is the subject of the Company IP Licenses applicable

to such Target Company. The Company IP Licenses include all of the licenses, sublicenses and other agreements or permissions necessary

to operate the Target Companies as presently conducted. Each Target Company has performed all obligations imposed on it in the Company

IP Licenses, has made all payments required to date, and such Target Company is not, nor, to the Knowledge of the Company, is any other

party thereto, in breach or default thereunder, nor has any event occurred that with notice or lapse of time or both would constitute

a default thereunder. The continued use by the Target Companies of the Intellectual Property that is the subject of the Company IP Licenses

in the same manner that it is currently being used is not restricted by any applicable license of any Target Company other than by any

applicable terms regarding term and renewal of such licenses. All registrations for Copyrights, Patents, Trademarks and Internet Assets

that are owned by or exclusively licensed to any Target Company are valid, in force and in good standing with all required fees and maintenance

and/or renewal fees having been paid with no Actions pending, and all current applications to register any Copyrights, Patents and Trademarks

are pending and in good standing, all without challenge of any kind other than office actions that may be issued by the applicable Intellectual

Property office or governmental agency in the ordinary course of filing and prosecuting such applications. No Target Company is party

to any Contract that requires a Target Company to assign to any Person all of its rights in any Intellectual Property developed by a Target

Company under such Contract.

5.13(c) sets forth all licenses, sublicenses and other agreements or permissions under which a Target Company is the licensor (each,

an “Outbound IP License”). Each Target Company has performed all obligations imposed on it in the Outbound IP

Licenses, and such Target Company is not, nor, to the Knowledge of the Company, is any other party thereto, in breach or default thereunder,

nor has any event occurred that with notice or lapse of time or both would constitute a default thereunder.

(d) No

Action is pending or, to the Company’s Knowledge, threatened in writing against a Target Company that challenges the validity, enforceability,

ownership or right to use, sell, license or sublicense, or that otherwise relates to, any Intellectual Property currently owned by or

licensed to the Target Companies, nor, to the Knowledge of the Company, is there any reasonable basis for any such Action. No Target Company

has received any written notice or claim asserting or suggesting that any infringement, misappropriation, violation, dilution or unauthorized

use of the Intellectual Property of any other Person is or may be occurring or has or may have occurred, as a consequence of the business

activities of any Target Company, nor to the Knowledge of the Company is there a reasonable basis therefor. There are no Orders to which

any Target Company is a party or its otherwise bound that (i) restrict the rights of a Target Company to use, transfer, license or enforce

any Intellectual Property owned by a Target Company, (ii) restrict the conduct of the business of a Target Company in order to accommodate

a third Person’s Intellectual Property, or (iii) other than any applicable Outbound IP Licenses, grant any third Person any right

with respect to any Intellectual Property owned by a Target Company. To the Knowledge of the Company, no Target Company is currently infringing,

or has in the past infringed, misappropriated or violated any Intellectual Property of any other Person in any material respect in connection

with the ownership, use or license of any Intellectual Property owned or purported to be owned by a Target Company or, to the Knowledge

of the Company, otherwise in connection with the conduct of the respective businesses of the Target Companies. To the Company’s

Knowledge, no third party is currently, or in the past three (3) years has been, infringing upon, misappropriating or otherwise violating

any Intellectual Property owned, licensed by, licensed to, or otherwise used or held for use by any Target Company (“Company

IP”) in any material respect.

(e) All

officers, directors, employees and independent contractors of a Target Company (and each of their respective Affiliates) have assigned

to the Target Companies all Intellectual Property arising from the services performed for a Target Company by such Persons and, where

applicable, all such assignments of Company Registered IP have been recorded. No current or former officers, employees or independent

contractors of a Target Company have claimed any ownership interest in any Intellectual Property owned by a Target Company. To the Knowledge

of the Company, there has been no violation of a Target Company’s policies or practices related to protection of Company IP or any

confidentiality or nondisclosure Contract relating to the Intellectual Property owned by a Target Company. The Company has made available

to SPAC true and complete copies of all written Contracts referenced in subsections under which employees and independent contractors

assigned their Intellectual Property to a Target Company. To the Company’s Knowledge, none of the employees of any Target Company

is obligated under any Contract, or subject to any Order, that would materially interfere with the use of such employee’s best efforts

to promote the interests of the Target Companies, or that would materially conflict with the business of any Target Company as presently

conducted or contemplated to be conducted. Each Target Company has taken reasonable security measures in order to protect the secrecy,

confidentiality and value of the material Company IP.

(f) To

the Knowledge of the Company, no Person has obtained unauthorized access to third party information and data (including personally identifiable

information) in the possession of a Target Company, nor has there been any other material compromise of the security, confidentiality

or integrity of such information or data, and no written or, to the Knowledge of the Company, oral complaint relating to an improper use

or disclosure of, or a breach in the security of, any such information or data has been received by a Target Company. Each Target Company

has complied in all material respects with all applicable Laws and Contract requirements relating to privacy, personal data protection,

and the collection, processing and use of personal information and its own privacy policies and guidelines. The operation of the business

of the Target Companies has not and does not violate any right to privacy or publicity of any third person, or constitute unfair competition

or trade practices under applicable Law.

(g) The

consummation of any of the transactions contemplated by this Agreement will not result in the material breach, modification, cancellation,

termination, suspension of or acceleration of any payments with respect to, or release of source code because of (i) any Contract providing

for the license or other use of Intellectual Property owned by a Target Company, or (ii) any Company IP License. Following the Closing,

the Company shall be permitted to exercise, directly or indirectly through its Subsidiaries, all of the Target Companies’ rights

under such Contracts or Company IP Licenses to the same extent that the Target Companies would have been able to exercise had the transactions

contemplated by this Agreement not occurred, without the payment of any additional amounts or consideration other than ongoing fees, royalties

or payments which the Target Companies would otherwise be required to pay in the absence of such transaction.

5.14 Taxes

and Returns.

(a) Each

Target Company has or will have timely filed, or caused to be timely filed, all material Tax Returns required to be filed by it (taking

into account all available extensions), which Tax Returns are true, accurate, correct and complete in all material respects, and has paid,

collected or withheld, or caused to be paid, collected or withheld, all material Taxes required to be paid, collected or withheld, other

than such Taxes for which adequate reserves in the Company Financials have been established. Each Target Company has complied in all material

respects with all applicable Laws relating to Tax.

(b) There

is no Action currently pending or, to the Knowledge of the Company, threatened in writing against a Target Company by a Governmental Authority

in a jurisdiction where the Target Company does not file Tax Returns that it is subject to taxation by that jurisdiction.

Target Company is being audited by any Tax authority or has been notified in writing by any Tax authority that any such audit is contemplated

or pending. There are no claims, assessments, audits, examinations, investigations or other Actions pending against a Target Company in

respect of any Tax, and no Target Company has been notified in writing of any proposed Tax claims or assessments against it (other than,

in each case, claims or assessments for which adequate reserves in the Company Financials have been established).

(d) There

are no Liens with respect to any Taxes upon any Target Company’s assets, other than Permitted Liens.

(e) No

Target Company has any outstanding waivers or extensions of any applicable statute of limitations to assess any amount of material Taxes.

There are no outstanding requests by a Target Company for any extension of time within which to file any Tax Return or within which to

pay any Taxes shown to be due on any Tax Return.

(f) No

Target Company has made any change in accounting method (except as required by a change in Law) or entered into any closing agreement

with any taxing authority affecting or otherwise settled or compromised any material Tax Liability or refund.

(g) No

Target Company has participated in, or sold, distributed or otherwise promoted, any “reportable transaction,” as defined in

U.S. Treasury Regulation section 1.6011-4.

(h) No

Target Company has any Liability or potential Liability for the Taxes of another Person (other than another Target Company) that are not

adequately reflected in the Company Financials (i) under any applicable Tax Law, (ii) as a transferee or successor, or (iii) by contract,

indemnity or otherwise (excluding commercial agreements entered into in the ordinary course of business the primary purpose of which is

not the sharing of Taxes). No Target Company is a party to or bound by any Tax indemnity agreement, Tax sharing agreement or Tax allocation

agreement or similar agreement, arrangement or practice (excluding commercial agreements entered into in the ordinary course of business

the primary purpose of which is not the sharing of Taxes) with respect to Taxes (including advance pricing agreement, closing agreement

or other agreement relating to Taxes with any Governmental Authority) that will be binding on any Target Company with respect to any period

following the Closing Date.

(i) No

Target Company has requested, or is it the subject of or bound by any private letter ruling, technical advice memorandum, closing agreement

or similar ruling, memorandum or agreement with any Governmental Authority with respect to any Taxes, nor is any such request outstanding.

(j) At

all times since each Target Company’s date of formation, each such Target Company has been classified as either a disregarded entity

or a partnership (in each case, for U.S. federal income Tax purposes or, where applicable, state and/or local income Tax purposes). No

such Target Company has made an election to be treated as an association taxable as a corporation for U.S. federal income Tax purposes

or, where applicable, state and/or local income Tax purposes.

(k) To

the Knowledge of the Company, there are no facts or circumstances that would reasonably be expected to prevent the Mergers from qualifying

as an exchange described in Section 351 of the Code.

5.15 Real

Property. Schedule 5.15 contains a complete and accurate list of all premises currently leased or subleased or otherwise used

or occupied by a Target Company for the operation of the business of a Target Company, and of all current leases and lease guarantees,

including all amendments, terminations and modifications thereof or waivers thereto (collectively, the “Company Real Property

Leases”), as well as the current annual rent and term under each Company Real Property Lease. The Company has provided to

SPAC a true and complete copy of each of the Company Real Property Leases. The Company Real Property Leases are valid, binding and enforceable

in accordance with their terms and are in full force and effect, subject to the Enforceability Exceptions. No event has occurred which

(whether with or without notice, lapse of time or both or the happening or occurrence of any other event) would constitute a default on

the part of a Target Company or, to the Knowledge of the Company, any other party under any of the Company Real Property Leases, and no

Target Company has received notice of any such condition. No Target Company owns or has ever owned any real property or any interest in

real property (other than the leasehold interests in the Company Real Property Leases).

5.16 Personal

Property. Each item of Personal Property which is currently owned, used or leased by a Target Company with a book value or fair market

value of greater than Fifty Thousand Dollars ($50,000) is set forth on Schedule 5.16, along with, to the extent applicable, a list

of lease agreements, lease guarantees, security agreements and other agreements related thereto, including all amendments, terminations

and modifications thereof or waivers thereto (“Company Personal Property Leases”). Except as set forth on Schedule

5.16, all such items of Personal Property are in good operating condition and repair (reasonable wear and tear excepted consistent

with the age of such items) in all material respects, and are suitable for their intended use in the business of the Target Companies.

The operation of each Target Company’s business as it is now conducted or presently proposed to be conducted is not dependent upon

the right to use the Personal Property of Persons other than a Target Company, except for such Personal Property that is owned, leased

or licensed by or otherwise contracted to a Target Company. The Company has provided to SPAC a true and complete copy of each of the Company

Personal Property Leases. The Company Personal Property Leases are valid, binding and enforceable in accordance with their terms and are

in full force and effect. To the Knowledge of the Company, no event has occurred which (whether with or without notice, lapse of time

or both or the happening or occurrence of any other event) would constitute a default on the part of a Target Company or any other party

under any of the Company Personal Property Leases, and no Target Company has received notice of any such condition.

5.17 Title

to and Sufficiency of Assets. Each Target Company has good and marketable title to, or a valid leasehold interest in or right to use,

all of its assets, free and clear of all Liens other than (a) Permitted Liens, (b) the rights of lessors under leasehold interests, (c)

Liens specifically identified on the most recent balance sheet included in the Company Financials and (d) Liens set forth on Schedule

5.17. The assets (including Intellectual Property rights and contractual rights) of the Target Companies constitute all of the material

assets, rights and properties that are currently used in the operation of the businesses of the Target Companies as it is now conducted

or that are used or held by the Target Companies for use in the operation of the businesses of the Target Companies, and taken together,

are adequate and sufficient for the operation of the businesses of the Target Companies as currently conducted.

5.18 Employee

Matters

(a) Except

as set forth on Schedule 5.18(a), no Target Company is a party to any collective bargaining agreement or other Contract covering

any group of employees, labor organization or other representative of any of the employees of any Target Company, and the Company has

no Knowledge of any activities or proceedings of any labor union or other party to organize or represent such employees. There has not

occurred or, to the Knowledge of the Company, been threatened any strike, slow-down, picketing, work-stoppage, or other similar labor

activity with respect to any such employees. Schedule 5.18(a) sets forth all unresolved labor controversies (including unresolved

employee, consultant or independent contractor claims, grievances and/or disputes, whether raised internally with the Company or through

a representative, including any harassment, age or other discrimination, or retaliation claims, wage and hour claims, and any other claims

arising under local, state or federal labor and employment laws), if any, that are pending or, to the Knowledge of the Company, threatened

between any Target Company and Persons employed by or providing services as independent contractors to a Target Company. No current officer

or employee of a Target Company has provided any Target Company written or, to the Knowledge of the Company, oral notice of his or her

plan to terminate his or her employment with any Target Company.

(b) Except

as set forth on Schedule 5.18(b), each Target Company (i) is and for the last three (3) years has been in compliance in all material

respects with all applicable Laws respecting employment and employment practices, terms and conditions of employment, legally-required

trainings and notices, health and safety and wages and hours, and other Laws relating to discrimination, harassment, retaliation, disability,

labor relations, hours of work, payment of wages and overtime wages, pay equity, immigration, workers compensation, working conditions,

employee scheduling, occupational safety and health, family and medical leave, and employee terminations, and has not received written

notice that there is any pending Action involving unfair labor practices against a Target Company, (ii) is not liable for any material

past due arrears of wages or any material penalty for failure to comply with any of the foregoing, and (iii) is not liable for any

material payment to any Governmental Authority with respect to unemployment compensation benefits, social security or other benefits or

obligations for employees, independent contractors or consultants (other than routine payments to be made in the ordinary course of business

and consistent with past practice). There are no Actions pending or, to the Knowledge of the Company, threatened in writing against a

Target Company brought by or on behalf of any applicant for employment, any current or former employee, any Person alleging to be a current

or former employee, or any Governmental Authority, relating to any such Law or regulation, or alleging breach of any express or implied

contract of employment, wrongful termination of employment, or alleging any other discriminatory, wrongful or tortious conduct in connection

with the employment relationship.

5.18(c) hereto sets forth a complete and accurate list as of the date hereof of all employees of the Target Companies showing for

each as of such date (i) the employee’s name, job title or description, employer, location, salary level (including any bonus, commission,

deferred compensation or other remuneration payable (other than any such arrangements under which payments are at the discretion of the

Target Companies)), (ii) any bonus, commission or other remuneration other than salary paid during the fiscal year ending December 31,

2025, and (iii) any wages, salary, bonus, commission or other compensation due and owing to each employee during or for the fiscal year

ended December 31, 2025. Except as set forth on Schedule 5.18(c), (A) no employee is a party to a written employment Contract with

a Target Company and each is employed “at will”, and (B) the Target Companies have paid in full to all their employees all

wages, salaries, commission, bonuses and other compensation due to their employees, including overtime compensation, and no Target Company

has any obligation or Liability (whether or not contingent) with respect to severance payments to any such employees under the terms of

any written agreement, or commitment or any applicable Law, custom, trade or practice. Except as set forth on Schedule 5.18(c),

each Target Company employee has entered into the Company’s standard form of employee non-disclosure, inventions and restrictive

covenants agreement with a Target Company (whether pursuant to a separate agreement or incorporated as part of such employee’s overall

employment agreement), a copy of which has been made available to SPAC by the Company.

(d) Schedule

5.18(d) contains a list of all independent contractors (including consultants) currently engaged by any Target Company, along with

the position, the entity engaging such Person, date of retention and rate of remuneration, most recent increase (or decrease) in remuneration

and amount thereof, for each such Person. Except as set forth on Schedule 5.18(d), all of such independent contractors are a party

to a written Contract with a Target Company. Except as set forth on Schedule 5.18(d), each such independent contractor has entered

into customary covenants regarding confidentiality, non-competition and assignment of inventions and copyrights in such Person’s

agreement with a Target Company, a copy of which has been provided to SPAC by the Company. For the purposes of applicable Law, including

the Code, all independent contractors who are currently, or within the last three (3) years have been, engaged by a Target Company are

bona fide independent contractors and not employees of a Target Company. Each independent contractor is terminable on fewer than thirty

(30) days’ notice, without any obligation of any Target Company to pay severance or a termination fee.

(e) To

the Knowledge of the Company, since January 1, 2025, the Company has investigated all workplace harassment (including sexual harassment),

discrimination, retaliation, and workplace violence written claims, if any, related to current and/or former employees of the Company

or third parties who interacted with current and/or former employees of the Company. With respect to each such written claim with potential

merit, the Company has taken corrective action. Further, to the Knowledge of the Company, since January 1, 2025, no allegations of sexual

harassment have been made to the Company against any individual in his or her capacity as director or an executive officer of the Company.

5.19 Benefit

Plans.

(a) Set

forth on Schedule 5.19(a) is a true and complete list of each Benefit Plan of a Target Company (each, a “Company Benefit

Plan”). With respect to each Company Benefit Plan, there are no funded benefit obligations for which contributions have

not been made or properly accrued and there are no unfunded benefit obligations that have not been accounted for by reserves, or otherwise

properly footnoted in accordance with GAAP on the Company Financials. No Target Company is or has in the past been a member of a “controlled

group” for purposes of Section 414(b), (c), (m) or (o) of the Code, nor does any Target Company have any Liability with respect

to any collectively-bargained for plans, whether or not subject to the provisions of ERISA.

(b) Except

as set forth on Schedule 5.19(b), each Company Benefit Plan is and has been operated in compliance with all applicable Laws in

all material respects, including ERISA and the Code. Each Company Benefit Plan which is intended to be “qualified” within

the meaning of Section 401(a) of the Code (i) has been determined by the IRS to be so qualified (or is based on a prototype plan which

has received a favorable opinion letter) during the period from its adoption to the date of this Agreement and (ii) its related trust

has been determined to be exempt from taxation under Section 501(a) of the Code or the Target Companies have requested an initial favorable

IRS determination of qualification and/or exemption within the period permitted by applicable Law. No fact exists which could adversely

affect the qualified status of such Company Benefit Plans or the exempt status of such trusts.

respect to each Company Benefit Plan, the Company has provided to or made available to SPAC accurate and complete copies, if applicable,

of: (i) all Company Benefit Plan texts and agreements and related trust agreements or annuity Contracts, (ii) all summary plan descriptions

and material modifications thereto, (iii) the three (3) most recent Forms 5500, if applicable, and annual report, including all schedules

thereto, (iv) the most recent annual and periodic accounting of plan assets, (v) the three (3) most recent nondiscrimination testing reports,

(vi) the most recent determination letter received from the IRS, if any, (vii) the most recent actuarial valuation, and (viii) all material

written communications between a Target Company or any Company Benefit Plan and any Governmental Authority.

(d) Except

as set forth on Schedule 5.19(d), with respect to each Company Benefit Plan: (i) such Company Benefit Plan has been administered

and enforced in all material respects in accordance with its terms, (ii) no breach of fiduciary duty that could reasonably be expected

to result in Liability to any Target Company has occurred, (iii) no Action is pending or to the Company’s Knowledge, threatened

in writing (other than routine claims for benefits arising in the ordinary course of administration), (iv) no prohibited transaction,

as defined in Section 406 of ERISA or Section 4975 of the Code, has occurred that could reasonably be likely to result in Liability to

any Target Company, excluding transactions effected pursuant to a statutory or administration exemption; (v) no filing has been made with

respect to any Company Benefit Plan under any voluntary correction program; (vi) there has been no amendment to, written interpretation

or announcement (whether or not written) by any Target Company relating to, any change in participation or coverage under, any Company

Benefit Plan that would materially increase the expense of maintaining such Company Benefit Plan above the level of expense incurred with

respect to such Company Benefit Plan for the most recent full fiscal year included in the Company Financials; and (vii) all contributions

and premiums due through the Closing Date have been made in all material respects as required under all applicable Laws, including the

Code and ERISA or have been fully accrued in all material respects on the Company Financials.

(e) During

the six (6) year period preceding the Effective Time, no Target Company or any of their ERISA Affiliates has maintained, contributed to,

sponsored, had an obligation to contribute to or any Liability, whether absolute or contingent, with respect to (i) a “defined benefit

plan” (as defined in Section 414(j) of the Code), (ii) a “multiemployer plan” (as defined in Section 3(37) of ERISA)

or (iii) a “multiple employer plan” (as described in Section 413(c) of the Code). No Company Benefit Plan is subject to Title

IV of ERISA or Section 412 of the Code, and neither the Target Company nor any ERISA Affiliate has incurred any Liability or otherwise

could have any Liability, contingent or otherwise, under Title IV of ERISA and no condition presently exists that is expected to cause

such Liability to be incurred. No Company Benefit Plan will become a multiple employer plan with respect to any Target Company immediately

after the Closing Date. No Target Company currently maintains or has ever maintained, or is required currently or has ever been required

to contribute to or otherwise participate in, a multiple employer welfare arrangement or voluntary employees’ beneficiary association

as defined in Section 501(c)(9) of the Code.

(f) There

is no arrangement under any Company Benefit Plan with respect to any employee that would result in the payment of any amount that by operation

of Sections 280G or 162(m) of the Code would not be deductible by the Target Companies and no arrangement exists pursuant to which a Target

Company will be required to “gross up” or otherwise compensate any person because of the imposition of any excise tax on a

payment to such person.

(g) With

respect to each Company Benefit Plan which is a “welfare plan” (as described in Section 3(1) of ERISA): (i) no such plan provides

medical or death benefits with respect to current or former employees of a Target Company beyond their termination of employment (other

than coverage mandated by Law, which is paid solely by such employees); and (ii) there are no reserves, assets, surplus or prepaid premiums

under any such plan. Each Target Company has complied with the provisions of Section 601 et seq. of ERISA and Section 4980B, 4980D, 4980H,

6721 and 6722 of the Code.

(h) Except

as set forth on Schedule 5.19(h), the consummation of the transactions contemplated by this Agreement and the Ancillary Documents

will not: (i) entitle any individual to severance pay, unemployment compensation or other benefits or compensation, (ii) accelerate the

time of payment, funding or vesting, or increase the amount of any compensation due, or in respect of, any individual, or (iii) result

in or satisfy a condition to the payment of compensation that would, in combination with any other payment, result in an “excess

parachute payment” within the meaning of Section 280G of the Code. No Target Company has incurred any Liability for any Tax imposed

under Chapter 43 of the Code or civil liability under Section 502(i) or (l) of ERISA.

(i) Except

to the extent required by Section 4980B of the Code or similar state Law, no Target Company provides health or welfare benefits to any

former or retired employee or is obligated to provide such benefits to any active employee following such employee’s retirement

or other termination of employment or service.

(j) All

Company Benefit Plans can be terminated at any time as of or after the Closing Date without resulting in any Liability to the Surviving

Subsidiaries or Pubco, or their respective Affiliates for any additional contributions, penalties, premiums, fees, fines, excise taxes

or any other charges or liabilities.

(k) Each

Company Benefit Plan that is subject to Section 409A of the Code (each, a “Section 409A Plan”) as of the Closing

Date is indicated as such on Schedule 5.19(k). No equity-based awards have been issued or granted by the Company that are, or are

subject to, a Section 409A Plan. Except as set forth on Schedule 5.19(k), (i) each Section 409A Plan has been administered in compliance,

and is in documentary compliance, with the applicable provisions of Section 409A of the Code, the regulations thereunder and other official

guidance issued thereunder, (ii) no Target Company has any obligation to any employee or other service provider with respect to any Section

409A Plan that may be subject to any Tax under Section 409A of the Code, and (iii) no payment to be made under any Section 409A Plan is,

or to the Knowledge of the Company will be, subject to the penalties of Section 409A(a)(1) of the Code. There is no Contract or plan to

which any Target Company is a party or by which it is bound to compensate, reimburse or indemnify any employee, consultant or director

for any Taxes or interest imposed pursuant to Section 409A of the Code.

(l) Each

Foreign Pension Plan, in form and operation, materially complies with its terms and with the requirements of all applicable Laws and has

been maintained, where required, in good standing with applicable regulatory authorities. All contributions required to be made with respect

to a Foreign Pension Plan have been timely made, and no Foreign Pension Plan has any Liability which is not properly accrued on the Company

Financials. No Target Company has incurred any obligation in connection with the termination of, or withdrawal from, any Foreign Pension

Plan. The present value of the accrued benefit Liabilities (whether or not vested) under each Foreign Pension Plan, determined as of the

end of the Target Company’s most recently ended fiscal year on the basis of actuarial assumptions, each of which is reasonable,

did not exceed the current value of the assets of such Foreign Pension Plan allocable to such benefit Liabilities.

5.20 Environmental

Matters. Except as set forth on Schedule 5.20:

(a) Each

Target Company is and has been in compliance in all material respects with all applicable Environmental Laws, including obtaining, maintaining

in good standing, and complying in all material respects with all Permits required for its business and operations by Environmental Laws

(“Environmental Permits”), no Action is pending or threatened in writing to revoke, modify, or terminate any

such Environmental Permit, and, to the Company’s Knowledge, no facts, circumstances, or conditions currently exist that would adversely

affect such continued compliance in any material respect with Environmental Laws and Environmental Permits or require capital expenditures

to achieve or maintain such continued compliance with Environmental Laws and Environmental Permits.

(b) No

Target Company is the subject of any outstanding Order or Contract with any Governmental Authority or other Person in respect of any (i)

Environmental Laws, (ii) Remedial Action, or (iii) Release or threatened Release of a Hazardous Material. No Target Company has assumed,

contractually or by operation of Law, any Liabilities or obligations under any Environmental Laws.

Action has been made or is pending or threatened in writing against any Target Company or any assets of a Target Company alleging either

or both that a Target Company may be in material violation of any Environmental Law or Environmental Permit or may have any material Liability

under any Environmental Law.

(d) No

Target Company has manufactured, treated, stored, disposed of, arranged for or permitted the disposal of, generated, handled or Released

any Hazardous Material, or owned or operated any property or facility, in a manner that has given or would reasonably be expected to give

rise to any material Liability or obligation under applicable Environmental Laws. No fact, circumstance, or condition exists in respect

of any Target Company or any property currently or formerly owned, operated, or leased by any Target Company or any property to which

a Target Company arranged for the disposal or treatment of Hazardous Materials that would reasonably be expected to result in a Target

Company incurring any material Environmental Liabilities.

(e) There

is no investigation of the business, operations, or currently owned, operated, or leased property of a Target Company or, to the Company’s

Knowledge, previously owned, operated, or leased property of a Target Company pending or, to the Company’s Knowledge, threatened

that could lead to the imposition of any Liens under any Environmental Law or material Environmental Liabilities.

(f) To

the Knowledge of the Company, there is not located at any of the properties of a Target Company any (i) underground storage tanks, (ii)

asbestos-containing material, or (iii) equipment containing polychlorinated biphenyls.

(g) The

Company has provided to SPAC all environmentally related site assessments, audits, studies, reports, analysis and results of investigations

that have been performed in respect of the currently or previously owned, leased, or operated properties of any Target Company.

5.21 Transactions

with Related Persons. Except as set forth on Schedule 5.21, no Target Company nor any of its Affiliates, nor any officer, director,

manager, employee, trustee or beneficiary of a Target Company or any of its Affiliates, nor any immediate family member of any of the

foregoing (whether directly or indirectly through an Affiliate of such Person) (each of the foregoing, a “Related Person”)

is presently, or in the past three (3) years, has been, a party to any transaction with a Target Company, including any Contract or other

arrangement (a) providing for the furnishing of services by (other than as officers, directors or employees of the Target Company), (b)

providing for the rental of real property or Personal Property from or (c) otherwise requiring payments to (other than for services or

expenses as directors, officers or employees of the Target Company in the ordinary course of business consistent with past practice) any

Related Person or any Person in which any Related Person has an interest as an owner, officer, manager, director, trustee or partner or

in which any Related Person has any direct or indirect interest (other than the ownership of securities representing no more than two

percent (2%) of the outstanding voting power or economic interest of a publicly traded company). Except as set forth on Schedule 5.21,

no Target Company has outstanding any Contract or other arrangement or commitment with any Related Person, and no Related Person owns

any real property or Personal Property, or right, tangible or intangible (including Intellectual Property) which is used in the business

of any Target Company. The assets of the Target Companies do not include any receivable or other obligation from a Related Person, and

the liabilities of the Target Companies do not include any payable or other obligation or commitment to any Related Person.

5.22 Insurance.

(a) Schedule

5.22(a) lists all insurance policies (by policy number, insurer, coverage period, coverage amount, annual premium and type of policy)

held by a Target Company relating to a Target Company or its business, properties, assets, directors, officers and employees, copies of

which have been provided to SPAC. All premiums due and payable under all such insurance policies have been timely paid and the Target

Companies are otherwise in material compliance with the terms of such insurance policies. Each such insurance policy (i) is legal, valid,

binding, enforceable and in full force and effect and (ii) will continue to be legal, valid, binding, enforceable, and in full force and

effect on identical terms following the Closing. No Target Company has any self-insurance or co-insurance programs. In the past three

(3) years, no Target Company has received any written notice from, or on behalf of, any insurance carrier relating to or involving any

adverse change or any change other than in the ordinary course of business, in the conditions of insurance, any refusal to issue an insurance

policy or non-renewal of a policy.

(b) Schedule

5.22(b) identifies each individual insurance claim in excess of $50,000 made by a Target Company in the past three (3) years. Each

Target Company has reported to its insurers all claims and pending circumstances that would reasonably be expected to result in a claim,

except where such failure to report such a claim would not be reasonably likely to be material to the Target Companies. To the Knowledge

of the Company, no event has occurred, and no condition or circumstance exists, that would reasonably be expected to (with or without

notice or lapse of time) give rise to or serve as a basis for the denial of any such insurance claim. No Target Company has made any claim

against an insurance policy as to which the insurer is denying coverage.

5.23 Top

Customers and Suppliers. Schedule 5.23 lists, by dollar volume received or paid, as applicable, for each of (a) the twelve

(12) months ended on December 31, 2025 and (b) the period from January 1, 2026 through the most recent balance sheet date, the ten (10)

largest customers of the Target Companies (the “Top Customers”) and the ten (10) largest suppliers of goods

or services to the Target Companies (the “Top Suppliers”), along with the amounts of such dollar volumes. (i)

no Top Supplier or Top Customer within the last twelve (12) months has cancelled or otherwise terminated, or, to the Company’s Knowledge,

intends to cancel or otherwise terminate, any material relationships of such Person with a Target Company, (ii) no Top Supplier or Top

Customer has during the last twelve (12) months decreased materially or, to the Company’s Knowledge, threatened to stop, decrease

or limit materially, or intends to modify materially its material relationships with a Target Company or intends to stop, decrease or

limit materially its products or services to any Target Company or its usage or purchase of the products or services of any Target Company,

(iii) to the Company’s Knowledge, no Top Supplier or Top Customer intends to refuse to pay any amount due to any Target Company

or seek to exercise any remedy against any Target Company, (iv) no Target Company has within the past two (2) years been engaged in any

material dispute with any Top Supplier or Top Customer, and (v) to the Company’s Knowledge, the consummation of the transactions

contemplated in this Agreement and the Ancillary Documents will not adversely affect the relationship of any Target Company with any Top

Supplier or Top Customer.

5.24 Certain

Business Practices.

(a) No

Target Company, nor any of their respective officers, managers or directors or, to the Company’s Knowledge, any of their other Representatives

acting on their behalf, has (i) used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to

political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees, to foreign or domestic political

parties or campaigns or violated any provision of the U.S. Foreign Corrupt Practices Act of 1977 or (iii) made any other unlawful payment.

Since January 1, 2023, no Target Company, nor any of their respective officers, managers or directors or, to the Company’s Knowledge,

any of their other Representatives acting on their behalf, has directly or knowingly indirectly, given or agreed to give any unlawful

gift or similar benefit in any material amount to any customer, supplier, governmental employee or other Person who is or may be in a

position to help or hinder any Target Company or assist any Target Company in connection with any actual or proposed transaction.

(b) The

operations of each Target Company are and have been conducted at all times in compliance with money laundering Laws in all applicable

jurisdictions that govern the operations of the Target Company, the rules and regulations thereunder and any related or similar rules,

regulations or guidelines, issued, administered or enforced by any Governmental Authority that have jurisdiction over the Target Companies,

and no Action involving a Target Company with respect to any of the foregoing is pending or threatened in writing.

Target Company or any of their respective directors, managers or officers, or, to the Knowledge of the Company, any other Representative

acting on behalf of a Target Company is currently (i) identified on the specially designated nationals or other blocked person list or

otherwise currently subject to any U.S. sanctions administered by OFAC, the U.S. Department of State, or other applicable Governmental

Authority, (ii) organized, resident, or located in, or a national of a Cuba, Iran, Syria, Sudan, Myanmar or any other country sanctioned

by OFAC, or (iii) in the aggregate, fifty percent (50%) or greater owned, directly or indirectly, or otherwise controlled, by a person

identified in (i) or (ii); and no Target Company has in the last five (5) years directly or, knowingly, indirectly, used any funds, or

loaned, contributed or otherwise made available such funds to any Subsidiary, joint venture partner or other Person, in connection with

any sales or operations in Cuba, Iran, Syria, Sudan, Myanmar or any other country sanctioned by OFAC or for the purpose of financing the

activities of any Person currently subject to, or otherwise in violation of, any U.S. sanctions administered by OFAC or the U.S. Department

of State.

5.25 Privacy

and Data Security.

(a) The

Target Companies, and, to the Knowledge of the Company, all vendors, processors, or other third parties acting for or on behalf of a Target

Company in connection with the Processing of Personal Information or that otherwise have been authorized to have access to Personal Information

in the possession or control of the Target Companies, comply and at all times in the past three (3) years have complied, in all material

respects with all of the following: (i) Privacy Laws; (ii) the Company Privacy and Data Security Policies; and (iii) any Contract requirements

or terms of use concerning the Processing of Personal Information to which a Target Company is a party or otherwise bound as of the date

hereof (“Privacy Agreements”). To the Knowledge of the Company, the operation of the business of the Target

Companies has not and does not violate any right to privacy or publicity of any third person under applicable Law.

(b) The

execution, delivery, and performance of this Agreement and the consummation of the transactions contemplated hereby do not and will not:

(i) conflict with or result in a violation or breach of any Privacy Laws, Company Privacy and Data Security Policies (as currently existing

or as existing at any time during which any Personal Information was collected or Processed by or for the Target Companies, or Privacy

Agreements); or (ii) require the consent of or notice to any Person concerning such Person’s Personal Information.

Company has delivered or made available to SPAC true, complete, and correct copies of all Company Privacy and Data Security Policies.

(d) To

the Knowledge of the Company, no Person has obtained unauthorized access to Personal Information in the possession of a Target Company,

nor has there been any other material compromise of the security, confidentiality or integrity of such information or data, and no written

or, to the Knowledge of the Company, oral complaint relating to an improper use or disclosure of, or a breach in the security of, any

such information or data has been received by a Target Company (a “Security Incident”). The Target Companies

have not notified and, to the Knowledge of the Company, there have been no facts or circumstances that would require a Target Company

to notify, any Governmental Authority or other Person of any Security Incident.

(e) In

the past three (3) years, the Target Companies have not received any notice, request, claim, complaint, correspondence, or other communication

in writing from any Governmental Authority or other Person, and there has not been any audit, investigation, enforcement action (including

any fines or other sanctions), or other Action, (i) relating to any actual, alleged, or suspected Security Incident or violation of any

Privacy Agreements, or any Person’s individual privacy rights involving Personal Information in the possession or control of the

Target Companies, or held or Processed by any vendor, processor, or other third party for or on behalf of the Target Companies; (ii) prohibiting

or threatening to prohibit the transfer of Personal Information to any place; or (iii) permitting or mandating any Governmental Authority

to investigate, requisition information from, or enter the premises of, the Target Companies, and, to the Knowledge of the Company, there

are no facts or circumstances that would reasonably be expected to give rise to any of the foregoing.

(f) The

Company maintains a cyber insurance policy that is adequate and suitable for the nature and volume of Personal Information Processed by

or on behalf of the Target Companies and is sufficient for compliance with all applicable Laws and Contracts to which any of the Target

Companies is a party or by which it is bound. The Company has delivered or made available to SPAC a true, complete, and correct copy of

such cyber insurance policy.

(g) To

the extent any Target Company creates, receives, maintains, or transmits “protected health information” (as defined in 45

C.F.R. § 160.103) (“PHI”), each Target Company is, and has at all times during the past three (3)years

been, in compliance in all material respects with the Health Insurance Portability and Accountability Act of 1996, as amended and supplemented

by the Health Information Technology for Economic and Clinical Health Act of the American Recovery and Reinvestment Act of 2009, and the

rules and regulations promulgated thereunder (collectively, “HIPAA”), including the Standards for Privacy of

Individually Identifiable Health Information, the Security Standards for the Protection of Electronic Protected Health Information, and

the Notification in the Case of Breach of Unsecured Protected Health Information, each as set forth in 45 C.F.R. Parts 160 and 164 (collectively,

the “HIPAA Rules”). Each Target Company has entered into a “business associate agreement” (as defined

in 45 C.F.R. § 160.103) with each Person that is a “business associate” (as defined in 45 C.F.R. § 160.103) of such

Target Company, and each such agreement is in full force and effect and complies in all material respects with the requirements of the

HIPAA Rules. Each Target Company has implemented and maintains policies, procedures, and administrative, technical, and physical safeguards,

and training programs designed to ensure compliance with the HIPAA Rules.

(h) During

the past three (3) years, no Target Company has experienced any “breach” (as defined in 45 C.F.R. § 164.402) of “unsecured

protected health information” (as defined in 45 C.F.R. § 164.402) requiring notification under 45 C.F.R. Part 164, Subpart

D. No Target Company has received any written notice from the U.S. Department of Health and Human Services, Office for Civil Rights, or

any other Governmental Authority regarding any investigation, compliance review, or enforcement action with respect to the HIPAA Rules.

No Target Company is a party to or bound by any resolution agreement, corrective action plan, or consent order with any Governmental Authority

with respect to the HIPAA Rules.

5.26 Healthcare

Compliance.

(a) Each

Target Company, and each of its direct and indirect owners, officers, directors, managers, and employees (each, a “Company

Agent”) is, and has at all times been during the past three (3) years, in compliance in all material respects with Healthcare

Laws. During the past three (3)years, no Target Company nor any Company Agent has received written notice, correspondence, or other written

communication, or to the Company’s Knowledge, any oral communication of (A) any violation, alleged violation or potential violation

of, or liability under, any Healthcare Law, or to the effect that a Target Company, a Company Agent or any Person acting on behalf of

a Target Company, is under investigation or inquiry with respect to any violation or alleged violation of any Healthcare Law, or (B) any

actual, alleged, or potential obligation to undertake, or to bear all or any portion of the cost of, any remedial action with respect

to any violation of any Healthcare Laws.

(b) Schedule

5.26(b) lists all National Provider Identifiers and provider numbers for Third-Party Payor Programs in which any Target Company participates,

all of which are in full force and effect. Each Target Company is qualified to participate in each Third-Party Payor Program that it participates

in and is duly enrolled and certified in such Third-Party Payor Program as a supplier of health care items or administrative services

at every location at which a Target Company provides services.

Target Company is, and has at all times during the past three (3) years been, in compliance in all material respects with all applicable

conditions for coverage and participating provider and supplier requirements of the Third-Party Payor Programs and with the terms, conditions,

and provisions of the Third-Party Payor Agreements, including all record maintenance requirements. The Third-Party Payor Agreements are

each in full force and effect, and, to the Company’s Knowledge, no event or fact exists that would reasonably be expected to cause

any Third-Party Payor Agreement to be suspended, terminated, restricted or withdrawn. During the past three (3) years, no Third-Party

Payor Program (i) has indicated (in writing or otherwise) its intent to cancel or otherwise substantially modify its relationship with

the Company or any Subsidiary, or (ii) has advised the Company or any Subsidiary in writing of any material problem or dispute other than

payor adjustments, recoupments or discounts in the ordinary course of business and non-material routine or periodic inspections or reviews

by any payor.

(d) No

Target Company nor any owner, officer, director, partner, managing employee or Person with a direct or indirect “ownership or control

interest” (as that phrase is defined in 42 C.F.R. §1001.2) in any Target Company (i) is a party to, or bound by, any order,

individual integrity agreement, corporate integrity agreement, corporate compliance agreement, deferred prosecution agreement or other

formal or informal agreement with any Governmental Authority concerning compliance with Healthcare Laws, (ii) has reporting obligations

pursuant to any settlement agreement entered into with any Governmental Authority, (iii) has been the subject of any Third-Party Payor

Program investigation conducted by any Governmental Authority, (iv) has been a defendant in any qui tam/False Claims Act litigation, (v)

has been served with or received any search warrant, subpoena, civil investigation demand, contact letter, or personal contact by or from

any federal or state enforcement agency, or (vi) has received any complaints through any Company compliance “hotline” from

any employees, independent contractors, vendors, providers, patients, or any other Persons that the Company has violated, or is currently

in violation of, any Law.

(e) During

the past three (3) years, no Target Company has made any self-disclosure to any Governmental Authority for any actual or alleged violation

of Healthcare Laws, including any voluntary disclosure to the United States Department of Health and Human Services, Office of Inspector

General (“OIG”) pursuant to the OIG’s Self-Disclosure Protocol or to the Centers for Medicare and Medicaid

Services (“CMS”) Self-Referral Disclosure Protocol.

(f) No

Target Company nor, to the Company’s Knowledge, any Company Agent, including any Person with an “ownership interest”

(as that phrase is defined in 42 C.F.R. § 420.201) in any Target Company, has been convicted of, charged with or investigated for,

a criminal offense related to Medicare or any other Federal Health Care Program or been convicted of, charged with or investigated for,

a violation of any Law related to fraud, theft, embezzlement, breach of fiduciary duty, kickbacks, bribes, other financial misconduct,

obstruction of an investigation or controlled substances. No Target Company nor any Company Agent is or has been (or, to the Company’s

Knowledge, has been threatened in writing to be) during the past three (3)years (i) excluded from any Third-Party Payor Program or been

subject to sanctions pursuant to 42 U.S.C. § 1320a-7 or §1320a-8 and related regulations or been convicted of a crime described

at 42 U.S.C. § 1320a-7b, (ii) “suspended” or “debarred” from selling products to the U.S. government or its

agencies pursuant to the Federal Acquisition Regulation, relating to debarment and suspension applicable to federal government agencies

generally (48 C.F.R. Subpart 9.4), or other Laws, (iii) debarred, disqualified, suspended or excluded from participation in any Third-Party

Payor Program or is listed on the General Services Administration’s published list of excluded parties, nor is any such debarment,

disqualification, suspension or exclusion threatened or pending, or (iv) made a party to any other action by any Governmental Authority

that prohibits it from selling products or providing services to any governmental or other purchaser pursuant to any federal, state or

local laws or regulations. No Target Company nor any Company Agent has received any written notice that any action described in the foregoing

clauses (i) through (iv) is threatened.

(g) Each

Target Company has (i) timely and accurately filed all reports and billings required to be filed with respect to each patient or Third-Party

Payor, all of which were prepared in compliance in all material respects with all applicable Laws governing reimbursement and claims and

the payment policies of the applicable patient or Third-Party Payor, (ii) paid within all required timeframes, all known and undisputed

refunds, overpayments, discounts and adjustments due with respect to any such report or billing, and there is no pending or, to the Company’s

Knowledge, threatened, appeal, adjustment, challenge, audit (including notice of an intent to audit), inquiry or litigation by any patient

or Third-Party Payor with respect to any Target Company’s billing practices and reimbursement claims, and (iii) never been subject

to an adverse audit or other review by any Governmental Authority or Third-Party Payor, in each case, other than payor adjustments, recoupments

or discounts in the ordinary course of business and non-material routine or periodic inspections or reviews by any payor. All billings

submitted by each Target Company have reflected goods actually sold and services actually performed by the billing Person to eligible

patients in accordance with the applicable payment rates of the applicable Third-Party Payor, and each Target Company has sufficient documentation

required to support such billings. Any and all bills submitted to any Federal Health Care Program have been properly billed under each

Target Company’s applicable National Provider Identifier. Each Target Company collects all copayments, deductibles and other patient

financial responsibilities in compliance in all material respects with applicable Healthcare Laws. There is no pending or, to the Company’s

Knowledge, threatened, audit or investigation by any Third-Party Payor with respect to any Target Company’s billing practices, other

than routine review and discussion regarding reimbursement claims occurring in the ordinary course of business. To the extent that any

Target Company has identified any overpayments received by the applicable Target Company from any Federal Health Care Program, it has

notified the applicable Governmental Authority and returned such overpayments within sixty (60) days of identification.

(h) Each

Target Company and its respective Company Agents, and authorized representatives operating on behalf of any Target Company have at all

times during the past three (3) years operated on behalf of the Target Companies in compliance in all material respects with (i) the Federal

Health Care Program anti-kickback statute (42 U.S.C. § 1320a-7b, et seq.), (ii) the federal physician self-referral law (commonly

known as the Stark Law) (42 U.S.C. § 1395nn, et seq., and its implementing regulations, 42 C.F.R. Part 424, Subpart J), and (iii)

all other applicable Healthcare Laws with respect to direct and indirect compensation arrangements, ownership interests or other relationships

between such Person and any past, present or potential patient, physician, supplier, contractor, Third-Party Payor or other Person in

a position to refer, recommend or arrange for the referral of patients or other health care business to such Person or to whom such Person

refers, recommends or arranges for the referral of patients or other health care business.

(i) All

marketing or advertising, including websites and social media, of any Target Company, except with respect to patient testimonials and

other statements or promotions, is and has in all material respects been during the past three (3) years truthful, accurate, and in compliance

with all applicable Laws and not misleading or deceptive in any material respect. The Target Companies (i) maintain a compliance program

having the elements of an effective corporate compliance and ethics program identified in U.S.S.G. § 8B2.1 in all material respects,

(ii) are and have at all times been, in material compliance with their compliance program, (iii) promptly and duly investigate any reports

of alleged compliance violations, (iv) take and have taken corrective actions as determined to be warranted and (v) to the Company’s

Knowledge, have no current material compliance problems.

(j) Schedule

5.26(j) sets forth a true, correct, and complete list of all products (including in vitro diagnostic products, laboratory-developed

tests, test kits, reagents, instruments, devices, and software) that are manufactured, marketed, sold, distributed, developed, or held

for commercial distribution by any Target Company, or that any Target Company is developing on behalf of third parties, including biopharma

companies (collectively, “Company Products”). To the extent required by applicable Law, each Company Product

(i) has received all necessary clearances, approvals, or authorizations from the U.S. Food and Drug Administration (the “FDA”),

including, as applicable, pursuant to a premarket notification under Section 510(k) of the Federal Food, Drug, and Cosmetic Act (the “FDCA”)

(21 U.S.C. § 301, et seq.), a premarket approval application under Section 515 of the FDCA, a de novo classification request under

Section 513(f)(2) of the FDCA, or an emergency use authorization under Section 564 of the FDCA, or is otherwise lawfully marketed in the

United States, and each such clearance, approval, or authorization is in full force and effect and has not been withdrawn, suspended,

revoked, or modified, (ii) has been manufactured, tested, stored, labeled, promoted, marketed, distributed, and imported or exported in

compliance in all material respects with all applicable requirements of the FDCA and the regulations promulgated thereunder (including

current good manufacturing practice requirements under the Quality System Regulation set forth in 21 C.F.R. Part 820, and applicable requirements

of 21 C.F.R. Parts 801, 809, and 812), and (iii) is listed and each applicable manufacturing establishment is registered with the FDA

in accordance with 21 U.S.C. §§ 360 and 360e and the regulations promulgated thereunder. All Company Products developed by a

Target Company for or on behalf of any third-party biopharma company have been and are being developed in compliance in all material respects

with all applicable requirements of the FDCA and applicable FDA guidance documents.

(k) No

Target Company has received from the FDA or any other Governmental Authority any (i) warning letter, untitled letter, or other written

notice of violation or alleged violation of any applicable Law, including the FDCA, (ii) Form FDA-483 inspection observation that remains

unresolved, (iii) consent decree, debarment order, or similar enforcement action, (iv) clinical hold on any clinical investigation of

a Company Product, or (v) notice of a recall, withdrawal, market suspension, detention, seizure, or import alert with respect to any Company

Product. To the Company’s Knowledge, there are no facts or circumstances that would reasonably be expected to give rise to any of

the foregoing. No Company Product has been the subject of any voluntary or involuntary recall, market withdrawal, safety alert, post-sale

warning, or other notice or action relating to an alleged deficiency, defect, or regulatory noncompliance.

(l) Each

clinical investigation or study conducted by, on behalf of, or sponsored by any Target Company with respect to any Company Product has

been and is being conducted in compliance in all material respects with all applicable requirements of the FDCA and the regulations promulgated

thereunder (including 21 C.F.R. Parts 50, 54, 56, 58, and 812), the Federal Policy for the Protection of Human Subjects (the “Common

Rule”), and all applicable Healthcare Laws. Each such clinical investigation or study has been and is being conducted with

the approval of, and in compliance in all material respects with the requirements of, an institutional review board constituted and operating

in accordance with the applicable provisions of 21 C.F.R. Part 56. Each Target Company has filed all required notices of investigational

use with the FDA and has obtained all required informed consents for all human subjects participating in such investigations or studies.

Each Target Company has complied in all material respects with all applicable adverse event and medical device reporting requirements,

including under 21 C.F.R. Parts 803 and 812.

5.27 Investment

Company Act. No Target Company is an “investment company”, a Person directly or indirectly “controlled” by

or acting on behalf of an “investment company”, or required to register as an “investment company”, in each case

within the meaning of the Investment Company Act.

5.28 Finders

and Brokers. Except as set forth on Schedule 5.28, no Target Company has incurred or will incur any Liability for any brokerage,

finder’s or other fee or commission in connection with the transactions contemplated hereby.

5.29 Exclusivity

of Representations.

(a) Neither

SPAC nor any of its Representatives have made any representation or warranty as to any SPAC Party or this Agreement, except as expressly

set forth in this Agreement (including the related portions of SPAC Disclosure Schedules) or in any certificate delivered to the Company

pursuant hereto.

(b) SPAC

specifically disclaims that it is relying upon or has relied upon any other representations and warranties that may have been made by

any Person and acknowledges and agrees that Pubco, the Merger Subs and the Company have specifically disclaimed any such other representations

and warranties.

5.30 Information

Supplied. None of the information supplied or to be supplied by the Company expressly for inclusion or incorporation by reference:

(a) in any current report on Form 8-K, and any exhibits thereto or any other report, form, registration or other filing made with any

Governmental Authority or stock exchange with respect to the transactions contemplated by this Agreement or any Ancillary Documents; (b)

in the Registration Statement; or (c) in the mailings or other distributions to SPAC’s shareholders and/or prospective investors

with respect to the consummation of the transactions contemplated by this Agreement or in any amendment to any of documents identified

in (a) through (c), will, when filed, made available, mailed or distributed, as the case may be, contain any untrue statement of a material

fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of

the circumstances under which they are made, not misleading. None of the information supplied or to be supplied by the Company expressly

for inclusion or incorporation by reference in any of the Signing Press Release, the Signing Filing, the Closing Press Release and the

Closing Filing will, when filed or distributed, as applicable, contain any untrue statement of a material fact or omit to state any material

fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they

are made, not misleading. Notwithstanding the foregoing, the Company makes no representation, warranty or covenant with respect to any

information supplied by or on behalf of SPAC or its Affiliates.

Article

COVENANTS

6.1 Access

and Information.

(a) During

the period from the date of this Agreement and continuing until the earlier of the termination of this Agreement in accordance with Section

8.1 or the Closing (the “Interim Period”), subject to Section 6.15, the Company shall give, and shall

cause its Representatives to give, SPAC and its Representatives, at reasonable times during normal business hours and upon reasonable

intervals and notice, reasonable access to all offices and other facilities and to all employees, properties, Contracts, agreements, commitments,

books and records, financial and operating data and other information (including Tax Returns, internal working papers, client files, client

Contracts and director service agreements), of or pertaining to the Target Companies, as SPAC or its Representatives may reasonably request

regarding the Target Companies and their respective businesses, assets, Liabilities, financial condition, prospects, operations, management,

employees and other aspects (including unaudited quarterly financial statements, including a consolidated quarterly balance sheet and

income statement, a copy of each material report, schedule and other document filed with or received by a Governmental Authority pursuant

to the requirements of applicable securities Laws, and independent public accountants’ work papers (subject to the consent or any

other conditions required by such accountants, if any)) and cause each of the Company’s Representatives to reasonably cooperate

with SPAC and its Representatives in their investigation; provided, however, that SPAC and its Representatives shall conduct any

such activities in such a manner as not to unreasonably interfere with the business or operations of the Target Companies.

(b) During

the Interim Period, subject to Section 6.15, SPAC shall give, and shall cause its Representatives to give, the Company and its

Representatives, at reasonable times during normal business hours and upon reasonable intervals and notice, reasonable access to all offices

and other facilities and to all employees, properties, Contracts, agreements, commitments, books and records, financial and operating

data and other information (including Tax Returns, internal working papers, client files, client Contracts and director service agreements),

of or pertaining to SPAC or its Subsidiaries, as the Company or its Representatives may reasonably request regarding SPAC, its Subsidiaries

and their respective businesses, assets, Liabilities, financial condition, prospects, operations, management, employees and other aspects

(including unaudited quarterly financial statements, including a consolidated quarterly balance sheet and income statement, a copy of

each material report, schedule and other document filed with or received by a Governmental Authority pursuant to the requirements of applicable

securities Laws, and independent public accountants’ work papers (subject to the consent or any other conditions required by such

accountants, if any)) and cause each of SPAC’s Representatives to reasonably cooperate with the Company and its Representatives

in their investigation; provided, however, that the Company and its Representatives shall conduct any such activities in such a

manner as not to unreasonably interfere with the business or operations of SPAC or any of its Subsidiaries.

6.2 Conduct

of Business of the Company.

(a) Unless

SPAC shall otherwise consent in writing (such consent not to be unreasonably withheld, conditioned or delayed), during the Interim Period,

except as expressly contemplated by this Agreement or the Ancillary Documents or as set forth on Schedule 6.2, the Company shall,

and shall cause its Subsidiaries to, (i) conduct their respective businesses, in all material respects, in the ordinary course of business

consistent with past practice, (ii) comply with all Laws applicable to the Target Companies and their respective businesses, assets and

employees, and (iii) take all commercially reasonable measures necessary or appropriate to preserve intact, in all material respects,

their respective business organizations, to keep available the services of their respective managers, directors, officers, employees and

consultants, and to preserve the possession, control and condition of their respective material assets, all as consistent with past practice.

(b) Without

limiting the generality of Section 6.2(a) and except as contemplated by the terms of this Agreement or the Ancillary Documents,

during the Interim Period, without the prior written consent of SPAC (such consent not to be unreasonably withheld, conditioned or delayed),

the Company shall not, and shall cause its Subsidiaries to not:

(i) amend,

waive or otherwise change, in any respect, its Organizational Documents, except as required by applicable Law;

(ii) except

for with respect to the GMRF Agreement and in connection with the Secured Note Transaction Documents, authorize for issuance, issue, grant,

sell, pledge, dispose of or propose to issue, grant, sell, pledge or dispose of any of its equity securities or any options, warrants,

commitments, subscriptions or rights of any kind to acquire or sell any of its equity securities, or other securities, including any securities

convertible into or exchangeable for any of its shares or other equity securities or securities of any class and any other equity-based

awards, or engage in any hedging transaction with a third Person with respect to such securities;

(iii) split,

reverse split, combine, subdivide, exchange, recapitalize or reclassify any of its shares or other equity interests or issue any other

securities in respect thereof or pay or set aside any dividend or other distribution (whether in cash, equity or property or any combination

thereof) in respect of its equity interests, or directly or indirectly redeem, purchase or otherwise acquire or offer to acquire any of

its securities;

(iv) incur,

create, assume, prepay or otherwise become liable for any Indebtedness (directly, contingently or otherwise) in excess of $100,000 individually

or $200,000 in the aggregate, make a loan or advance to or investment in any third party (other than advancement of expenses to employees

in the ordinary course of business), or guarantee or endorse any Indebtedness, Liability or obligation of any Person in excess of $100,000

individually or $200,000 in the aggregate;

(v) increase

the wages, salaries or compensation of its employees other than in the ordinary course of business, consistent with past practice, and

in any event not in the aggregate by more than five percent (5%), fund or commit to fund any Company Benefit Plan, or make or commit to

make any bonus, retention, transaction or other payment (whether in cash, property or securities) to any employee or other service provider,

or materially increase other benefits of employees generally, or grant, accelerate the vesting, lapsing or restrictions or payment or

in any way amend, modify or supplement the terms of any equity or equity-based or phantom equity award, or forgive any loans or issue

any loans to any service provider (other than in connection with a qualified retirement plan), or, except as set forth on Schedule

6.2(b)(v), hire any new employee or engage any new independent contractor (who is a natural person) with target annual cash compensation

in excess of $250,000, or enter into, establish, materially amend or terminate any Company Benefit Plan (except for the Post-Closing Equity

Plan) with, for or in respect of any current or former consultant, officer, manager director or employee, in each case other than as required

by applicable Law, pursuant to the terms of any Company Benefit Plans or in the ordinary course of business consistent with past practice;

(vi) make

or rescind any material election relating to Taxes, settle any claim, action, suit, litigation, proceeding, arbitration, investigation,

audit or controversy relating to Taxes, file any amended Tax Return or claim for refund, or make any material change in its accounting

or Tax policies or procedures, in each case except as required by applicable Law or in compliance with GAAP;

(vii) transfer

or license to any Person or otherwise extend, materially amend or modify, permit to lapse or fail to preserve any material Company Registered

IP, Company Licensed IP or other Company IP (excluding non-exclusive licenses of Company IP to Target Company customers in the ordinary

course of business consistent with past practice), or disclose to any Person who has not entered into a confidentiality agreement any

Trade Secrets;

(viii) terminate,

or waive or assign any material right under, any Company Material Contract or enter into any Contract that would be a Company Material

Contract, in any case outside of the ordinary course of business consistent with past practice;

(ix) fail

to maintain its books, accounts and records in all material respects in the ordinary course of business consistent with past practice;

(x) fail

to use commercially reasonable efforts to maintain or renew any Permits necessary for the conduct of the Company Business;

(xi) establish any Subsidiary or enter into any new line of business;

(xii) fail to use commercially reasonable efforts to keep in force

insurance policies or replacement or revised policies providing insurance coverage with respect to its assets, operations and activities

in such amount and scope of coverage as are currently in effect;

(xiii) revalue any of its material assets or make any change in accounting

methods, principles or practices, except to the extent required to comply with GAAP and after consulting with the Company’s outside

auditors;

(xiv) waive, release, assign, settle or compromise any claim, action or proceeding (including any suit, action, claim, proceeding

or investigation relating to this Agreement or the transactions contemplated hereby), other than waivers, releases, assignments, settlements

or compromises that involve only the payment of monetary damages (and not the imposition of equitable relief on, or the admission of wrongdoing

by, a Target Company or its Affiliates) not in excess of $100,000 (individually or in the aggregate), or otherwise pay, discharge or satisfy

any Actions, Liabilities or obligations, unless such amount has been reserved in the Company Financials;

(xv) close or materially reduce

its activities, or effect any layoff or other personnel reduction or change, at any of its facilities;

(xvi) acquire, including

by merger, consolidation, acquisition of equity interests or assets, or any other form of business combination, any corporation, partnership,

limited liability company, other business organization or any division thereof, or any material amount of assets outside the ordinary

course of business consistent with past practice;

(xvii) make

capital expenditures in excess of $500,000 (individually for any project (or set of related projects) or $1,000,000 in the aggregate),

except for those expenditures set forth on Schedule 6.2(b)(xvii);

(xviii) adopt

a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization;

(xix) voluntarily

incur any Liability or obligation (whether absolute, accrued, contingent or otherwise) in excess of $250,000 individually or $1,000,000

in the aggregate other than pursuant to the terms of a Company Material Contract or Company Benefit Plan;

(xx) sell,

lease, license, transfer, exchange or swap, mortgage or otherwise pledge or encumber (including securitizations), or otherwise dispose

of any material portion of its properties, assets or rights;

(xxi) enter

into any agreement, understanding or arrangement with respect to the voting of equity securities of the Company;

(xxii) take

any action that would reasonably be expected to significantly delay or impair the obtaining of any Consents of any Governmental Authority

to be obtained in connection with this Agreement;

(xxiii) accelerate

the collection of any trade receivables or delay the payment of trade payables or any other liabilities other than in the ordinary course

of business consistent with past practice;

(xxiv) enter

into, amend, waive or terminate (other than terminations in accordance with their terms) any transaction with any Related Person (other

than compensation and benefits and advancement of expenses, in each case, provided in the ordinary course of business consistent with

past practice); or

(xxv) authorize

or agree to do any of the foregoing actions.

6.3 Conduct

of Business of SPAC.

(a) Unless

the Company shall otherwise consent in writing (such consent not to be unreasonably withheld, conditioned or delayed), during the Interim

Period, except as expressly contemplated by this Agreement or the Ancillary Documents or as set forth on Schedule 6.3, SPAC shall,

and shall cause its Subsidiaries to, (i) conduct their respective businesses, in all material respects, in the ordinary course of business

consistent with past practice, (ii) comply with all Laws applicable to SPAC and its Subsidiaries and their respective businesses, assets

and employees, and (iii) take all commercially reasonable measures necessary or appropriate to preserve intact, in all material respects,

their respective business organizations, to keep available the services of their respective managers, directors, officers, employees and

consultants, and to preserve the possession, control and condition of their respective material assets, all as consistent with past practice.

Notwithstanding anything to the contrary in this Section 6.3, nothing in this Agreement shall prohibit or restrict SPAC from: (i)

extending, in accordance with SPAC’s Organizational Documents and the IPO Prospectus, the deadline by which it must complete its

Business Combination (an “Extension”); (ii) incurring costs and expenses in connection with the Extension; (iii)

approving any other matters required in connection with the Extension and (iv) redeeming the Class A Ordinary Shares held by its Public

Shareholders as those Public Shareholders request in connection with the Extension pursuant to SPAC Organizational Documents; and no consent

of any other Party shall be required in connection therewith.

(b) Without

limiting the generality of Section 6.3(a) and except as contemplated by the terms of this Agreement or the Ancillary Documents

(including the Conversion or any Extension) or as set forth on Schedule 6.3, during the Interim Period, without the prior written

consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed), SPAC shall not, and shall cause its Subsidiaries

to not:

(i) amend,

waive or otherwise change, in any respect, its Organizational Documents except as required by applicable Law;

(ii) authorize

for issuance, issue, grant, sell, pledge, dispose of or propose to issue, grant, sell, pledge or dispose of any of its equity securities

or any options, warrants, restricted stock units, commitments, subscriptions or rights of any kind to acquire or sell any of its equity

securities, or other securities, including any securities convertible into or exchangeable for any of its equity securities or other security

interests of any class and any other equity-based awards, or engage in any hedging transaction with a third Person with respect to such

securities;

(iii) split,

reverse split, combine, subdivide, exchange, recapitalize or reclassify any of its shares or other equity interests or issue any other

securities in respect thereof or pay or set aside any dividend or other distribution (whether in cash, equity or property or any combination

thereof) in respect of its shares or other equity interests, or directly or indirectly redeem, purchase or otherwise acquire or offer

to acquire any of its securities;

(iv) incur,

create, assume, prepay or otherwise become liable for any Indebtedness (directly, contingently or otherwise) in excess of $500,000 in

the aggregate, make a loan or advance to or investment in any third party, or guarantee or endorse any Indebtedness, Liability or obligation

of any Person (provided, that this Section 6.3(b)(iv) shall not prevent SPAC from borrowing funds necessary to finance its ordinary

course administrative costs and expenses and Expenses incurred in connection with the consummation of the Conversion, Mergers and the

other transactions contemplated by this Agreement (including any Transaction Financing) and the costs and expenses necessary for an Extension);

(v) make

or rescind any material election relating to Taxes, settle any claim, action, suit, litigation, proceeding, arbitration, investigation,

audit or controversy relating to Taxes, file any amended Tax Return or claim for refund, or make any material change in its accounting

or Tax policies or procedures, in each case except as required by applicable Law or in compliance with GAAP;

(vi) amend,

waive or otherwise change the Trust Agreement in any manner adverse to SPAC;

(vii) terminate,

waive or assign any material right under any SPAC Material Contract;

(viii) fail

to maintain its books, accounts and records in all material respects in the ordinary course of business consistent with past practice;

(ix) establish

any Subsidiary or enter into any new line of business;

(x) fail

to use commercially reasonable efforts to keep in force insurance policies or replacement or revised policies providing insurance coverage

with respect to its assets, operations and activities in such amount and scope of coverage substantially similar to that which is currently

in effect;

(xi) revalue

any of its material assets or make any material change in accounting methods, principles or practices, except to the extent required to

comply with GAAP and after consulting SPAC’s outside auditors;

(xii) waive,

release, assign, settle or compromise any claim, action or proceeding (including any Action relating to this Agreement or the transactions

contemplated hereby), other than waivers, releases, assignments, settlements or compromises that involve only the payment of monetary

damages (and not the imposition of equitable relief on, or the admission of wrongdoing by, SPAC or its Subsidiary) not in excess of $100,000

(individually or in the aggregate), or otherwise pay, discharge or satisfy any Actions, Liabilities or obligations, unless such amount

has been reserved in SPAC Financials;

(xiii) acquire,

including by merger, consolidation, acquisition of equity interests or assets, or any other form of business combination, any corporation,

partnership, limited liability company, other business organization or any division thereof, or any material amount of assets outside

the ordinary course of business;

(xiv) make

capital expenditures in excess of $100,000 individually for any project (or set of related projects) or $250,000 in the aggregate (excluding

for the avoidance of doubt, incurring any Expenses);

(xv) adopt

a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization

(other than with respect to the Conversion and the Mergers);

(xvi) sell,

lease, license, transfer, exchange or swap, mortgage or otherwise pledge or encumber (including securitizations), or otherwise dispose

of any material portion of its properties, assets or rights;

(xvii) enter

into any agreement, understanding or arrangement with respect to the voting of SPAC Securities;

(xviii) take

any action that would reasonably be expected to significantly delay or impair the obtaining of any Consents of any Governmental Authority

to be obtained in connection with this Agreement; or

(xix) authorize

or agree to do any of the foregoing actions.

6.4 Additional

Financial Information.

(a) The

Company shall deliver the audited consolidated financial statements of the Company as of and for each of the six (6) months ended December

31, 2024 and the twelve (12) months ended December 31, 2025, consisting of the audited consolidated balance sheet of the Company as of

December 31, 2024 and December 31, 2025, and the related audited consolidated income statement, changes in members’ equity and statement

of cash flows for the applicable periods then ended, and the related notes thereto, audited by a PCAOB qualified auditor in accordance

with PCAOB auditing standards (the “Audited Financials” and together with the Unaudited Financial Statements,

the “Company Financials”) to the Purchaser as soon as practicable after the date of this Agreement but no later

than ten (10) Business Days from the date of this Agreement (the “Audit Delivery Date”). The Audited Financials

(i) shall be prepared in accordance with GAAP, (ii) shall fairly present, in all material respects, the financial position, results of

operations, members’ deficit and cash flows of the Company, (iii) shall be (A) certified as audited in accordance with GAAP and

the standards of the PCAOB by a PCAOB qualified auditor upon the filing of the initial Registration Statement/Proxy, (B) shall contain

an unqualified report of the Company’s auditors, and (C) shall be substantially identical in all material respects to the Unaudited

Financial Statements from the same period except that such Audited Financials shall include completed going concern, lease accounting,

unit base compensation, and related party transactions sections, and (iv) shall comply in all material respects with the applicable accounting

requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the respective dates

of delivery (including Regulation S-X or Regulation S-K, as applicable).

(b) During

the Interim Period, within thirty (30) calendar days following the end of each three-month quarterly period and each fiscal year, the

Company shall deliver to SPAC an unaudited consolidated income statement and an unaudited consolidated balance sheet of the Target Companies

for the period from December 31, 2025 through the end of such calendar month, quarterly period or fiscal year and the applicable comparative

period in the preceding fiscal year, in each case accompanied by a certificate of the Chief Financial Officer of the Company to the effect

that all such financial statements fairly present the consolidated financial position and results of operations of the Target Companies

as of the date or for the periods indicated, in accordance with GAAP, subject to year-end audit adjustments and excluding footnotes (collectively,

the “Interim Financial Information”). From the date hereof through the Closing Date, the Company will also promptly

deliver to SPAC copies of any audited consolidated financial statements of the Target Companies that the Target Companies’ certified

public accountants may issue.

6.5 SPAC

Public Filings. During the Interim Period, SPAC will keep current and timely file all of its public filings with the SEC and otherwise

comply in all material respects with applicable securities Laws and shall use reasonable efforts prior to the Closing to maintain the

listing of SPAC Public Units, SPAC Class A Ordinary Shares, and SPAC Public Warrants on NYSE; provided, that the Parties acknowledge

and agree that from and after the Closing, the Parties intend to list on NYSE only the Pubco Common Stock and the Pubco Public Warrants.

6.6 No

Solicitation; Change in Recommendation.

(a) For

purposes of this Agreement:

(i)

an “Acquisition Proposal” means any inquiry, proposal or offer, or any indication of interest in making an offer

or proposal, from any Person or group at any time relating to an Alternative Transaction,

(ii) an

“Alternative Transaction” means (A) with respect to the Company and its Affiliates, a transaction (other than

the transactions contemplated by this Agreement) concerning the sale or acquisition by a Person (or group of Persons) of (x) all or any

material part of the business or assets of the Target Companies (other than in the ordinary course of business consistent with past practice)

or (y) any of the shares or other equity interests or profits of the Target Companies, in any case, whether such transaction takes the

form of a sale of shares or other equity interests, assets, merger, consolidation, issuance of debt securities, management Contract, joint

venture or partnership, or otherwise and (B) with respect to SPAC and its Affiliates, a transaction (other than the transactions contemplated

by this Agreement) concerning a Business Combination involving SPAC.

(iii) an

“Intervening Event” means, with respect to the Company, a material event, fact, development, circumstance or

occurrence (but specifically excluding any Acquisition Proposal or Alternative Transaction) that was not known by, and was not reasonably

foreseeable to, the board of directors of SPAC as of the date of this Agreement (or the consequences or magnitude of which were not known

by, or reasonably foreseeable to, the relevant board of directors as of the date of this Agreement), and that becomes known to such board

of directors after the date of this Agreement and prior to the time the Required SPAC Shareholder Approval is obtained, and does not relate

to, and excludes, (A) the transactions contemplated hereby or this Agreement (or any actions taken pursuant to this Agreement) including

clearance of the transactions by any Governmental Authority or under any other applicable Laws and any action in connection therewith

taken pursuant to or required to be taken pursuant to Section 6.9; (B) any change in the price or trading volume of SPAC Class

A Ordinary Shares, and (C) any change described in subsections (i) through (v) of the definition of “Material Adverse Effect”;

provided, however, that any such change described in this clause (C) described in subsections (i) through (v) of the definition of “Material

Adverse Effect” may be taken into account in determining whether an Intervening Event has occurred to the extent that it disproportionately

affects the relevant Party, taken as a whole, relative to other participants in the industries or geographical areas in which such Party

operates.

(b) During

the Interim Period, in order to induce the other Parties to continue to commit to expend management time and financial resources in furtherance

of the transactions contemplated hereby, each Party shall not, and shall cause its Representatives to not, without the prior written consent

of the Company and SPAC, directly or indirectly, (i) solicit, assist, initiate or facilitate the making, submission or announcement of,

or intentionally encourage, any Acquisition Proposal, (ii) furnish any non-public information regarding such Party or its Affiliates or

their respective businesses, operations, assets, Liabilities, financial condition, prospects or employees to any Person or group (other

than a Party to this Agreement or their respective Representatives) in connection with or in response to an Acquisition Proposal, (iii) engage

or participate in discussions or negotiations with any Person or group with respect to, or that could reasonably be expected to lead to,

an Acquisition Proposal, (iv) approve, endorse or recommend, or publicly propose to approve, endorse or recommend, any Acquisition Proposal,

or otherwise change, withdraw, withhold, qualify or modify, or publicly propose to change, withdraw, withhold, qualify or modify, the

SPAC Board Recommendation (in the case of SPAC and Merger Sub) (a “Change in Recommendation”), (v) negotiate

or enter into any letter of intent, agreement in principle, acquisition agreement or other similar agreement related to any Acquisition

Proposal, (vi) release any third Person from, or waive any provision of, any confidentiality agreement to which such Party is a party

or (vii) agree or resolve to do any of the foregoing.

Party shall notify the others as promptly as practicable (and in any event within 48 hours) in writing of the receipt by such Party or

any of its Representatives of (i) any bona fide inquiries, proposals or offers, requests for information or requests for discussions or

negotiations regarding or constituting any Acquisition Proposal or any bona fide inquiries, proposals or offers, requests for information

or requests for discussions or negotiations that would reasonably be expected to result in an Acquisition Proposal, and (ii) any request

for non-public information relating to such Party or its Affiliates in connection with any Acquisition Proposal, specifying in each case,

the material terms and conditions thereof (including a copy thereof if in writing or a written summary thereof if oral), as applicable,

and the identity of the party making such inquiry, proposal, offer or request for information. Each Party shall keep the others promptly

informed of the status of any such inquiries, proposals, offers or requests for information. During the Interim Period, each Party shall,

and shall cause its Representatives to, immediately cease and cause to be terminated any solicitations, discussions or negotiations with

any Person with respect to any Acquisition Proposal and shall, and shall direct its Representatives to, cease and terminate any such solicitations,

discussions or negotiations.

(d) Notwithstanding

anything in this Section 6.6 or otherwise in this Agreement to the contrary, if, at any time prior to (but not after) obtaining

the Required SPAC Shareholder Approval, the board of directors of SPAC determines in good faith, in response to an Intervening Event,

after consultation with its outside legal counsel, that the failure to make a Change in Recommendation would be a breach of its fiduciary

duties under applicable Law, SPAC’s board of directors may make a Change in Recommendation; provided that SPAC will not be

entitled to make, or agree or resolve to make, a Change in Recommendation unless (i) SPAC delivers to the Company a written notice (a

“Change in Recommendation Notice”) advising the Company that its board of directors proposes to take such action

and containing the material facts underlying its board of directors’ determination that an Intervening Event has occurred, and (ii)

at or after 5:00 p.m., New York City time, on the fifth (5th) Business Day immediately following the day on which the Change in Recommendation

Notice is delivered (such period from the time the Change in Recommendation Notice is delivered until 5:00 p.m. New York City time on

the fifth (5th) Business Day immediately following the day on which the Change in Recommendation Notice is delivered (it being understood

that any material development with respect to an Intervening Event shall require a new notice but with an additional three (3) Business

Day period from the date of such notice), the “Change in Recommendation Notice Period”), the board of directors

of SPAC reaffirms in good faith (after consultation with its outside legal counsel and taking into account any adjustments in the terms

and conditions of this Agreement offered by the Company as described in the following sentence) that the failure to make a Change in Recommendation

would be a breach of its fiduciary duties under applicable Law. If requested by the Company, SPAC will use its reasonable best efforts

to cause its Representatives to, during the Change in Recommendation Notice Period, engage in good faith negotiations with the Company

and its Representatives to make such adjustments in the terms and conditions of this Agreement so as to obviate the need for a Change

in Recommendation.

(e) Notwithstanding

anything to the contrary contained in this Agreement, during a Change in Recommendation Notice Period, the obligations of SPAC and/or

SPAC Board to give notice for or to convene a meeting, to make a recommendation, or, except as required by applicable Law, to make filings

with the SEC with respect to the proposals contemplated herein shall be tolled to the extent reasonably necessary until such time as SPAC

has filed an update to the Registration Statement with the SEC (which SPAC shall file as promptly as practicable after the Change in Recommendation

by SPAC Board), and in the event a filing and/or notice for a meeting was made prior to the Change in Recommendation Notice Period, SPAC

shall be permitted to adjourn such meeting and to amend such filing as necessary in order to provide sufficient time for the shareholders

to consider any revised recommendation. To the fullest extent permitted by applicable Law, SPAC’s obligations to establish a record

date for, duly call, give notice of, convene and hold SPAC Extraordinary General Meeting shall not be affected by any Change in Recommendation

by SPAC Board.

(f) Notwithstanding

anything to the contrary herein, nothing in this Section 6.6 shall limit SPAC’s and its Representatives’ ability to

(A) have discussions with third parties and provide such third parties confidential information in connection with a Transaction Financing

and (B) negotiate or enter into a letter of intent, agreement in principle, term sheet or definitive agreement relating to any Transaction

Financing to be consummated at Closing.

6.7 No

Trading. The Company acknowledges and agrees that it is aware, and that the Company’s Affiliates are aware (and each of their

respective Representatives is aware or, upon receipt of any material nonpublic information of SPAC, will be advised) of the restrictions

imposed by U.S. federal securities laws and the rules and regulations of the SEC and NYSE promulgated thereunder or otherwise (the “Federal

Securities Laws”) and other applicable foreign and domestic Laws on a Person possessing material nonpublic information about

a publicly traded company. The Company hereby agrees that, while it is in possession of such material nonpublic information, it shall

not purchase or sell any securities of SPAC (other than to engage in the Mergers in accordance with Article I), communicate such

information to any third party, take any other action with respect to SPAC in violation of such Laws, or cause or encourage any third

party to do any of the foregoing.

6.8 Notification

of Certain Matters. During the Interim Period, each Party shall give prompt notice to the other Parties if such Party or its Affiliates:

(a) fails to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it or its Affiliates hereunder

in any material respect; (b) receives any notice or other communication in writing from any third party (including any Governmental Authority)

alleging (i) that the Consent of such third party is or may be required in connection with the transactions contemplated by this Agreement

or (ii) any non-compliance with any Law by such Party or its Affiliates; (c) receives any notice or other communication from any Governmental

Authority in connection with the transactions contemplated by this Agreement; (d) discovers any fact or circumstance that, or becomes

aware of the occurrence or non-occurrence of any event the occurrence or non-occurrence of which, would reasonably be expected to cause

or result in any of the conditions to the Closing set forth in Article VII not being satisfied or the satisfaction of those conditions

being materially delayed; or (e) becomes aware of the commencement or threat, in writing, of any Action against such Party or any

of its Affiliates, or any of their respective properties or assets, or, to the Knowledge of such Party, any officer, director, partner,

member or manager, in his, her or its capacity as such, of such Party or of its Affiliates with respect to the consummation of the transactions

contemplated by this Agreement. No such notice shall constitute an acknowledgement or admission by the Party providing the notice regarding

whether or not any of the conditions to the Closing have been satisfied or in determining whether or not any of the representations, warranties

or covenants contained in this Agreement have been breached.

6.9 Efforts.

(a) Subject

to the terms and conditions of this Agreement, each Party shall use its commercially reasonable efforts, and shall cooperate fully with

the other Parties, to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary, proper

or advisable under applicable Laws and regulations to consummate the transactions contemplated by this Agreement (including the receipt

of all applicable Consents of Governmental Authorities) and to comply as promptly as practicable with all requirements of Governmental

Authorities applicable to the transactions contemplated by this Agreement.

(b) In

furtherance and not in limitation of Section 6.9(a), to the extent required under any Laws that are designed to prohibit, restrict

or regulate actions having the purpose or effect of monopolization or restraint of trade (“Antitrust Laws”),

each Party hereto agrees to make any required filing or application under Antitrust Laws, as applicable, at such Party’s sole cost

and expense, with respect to the Transactions as promptly as practicable, to supply as promptly as reasonably practicable any additional

information and documentary material that may be reasonably requested pursuant to Antitrust Laws and to take all other actions reasonably

necessary, proper or advisable to cause the expiration or termination of the applicable waiting periods under Antitrust Laws as soon as

practicable, including by requesting early termination of the waiting period provided for under the Antitrust Laws. Each Party shall,

in connection with its efforts to obtain all requisite approvals and authorizations for the transactions contemplated by this Agreement

under any Antitrust Law, use its commercially reasonable efforts to: (i) cooperate in all respects with each other Party or its Affiliates

in connection with any filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated

by a private Person, (ii) keep the other Parties reasonably informed of any communication received by such Party or its Representatives

from, or given by such Party or its Representatives to, any Governmental Authority and of any communication received or given in connection

with any proceeding by a private Person, in each case regarding any of the transactions contemplated by this Agreement, (iii) permit a

Representative of the other Parties and their respective outside counsel to review any communication given by it to, and consult with

each other in advance of any meeting or conference with, any Governmental Authority or, in connection with any proceeding by a private

Person, with any other Person, and to the extent permitted by such Governmental Authority or other Person, give a Representative or Representatives

of the other Parties the opportunity to attend and participate in such meetings and conferences, (iv) in the event a Party’s Representative

is prohibited from participating in or attending any meetings or conferences, the other Parties shall keep such Party promptly and reasonably

apprised with respect thereto, and (v) use commercially reasonable efforts to cooperate in the filing of any memoranda, white papers,

filings, correspondence or other written communications explaining or defending the transactions contemplated hereby, articulating any

regulatory or competitive argument, and/or responding to requests or objections made by any Governmental Authority.

soon as reasonably practicable following the date of this Agreement, the Parties shall reasonably cooperate with each other and use (and

shall cause their respective Affiliates to use) their respective commercially reasonable efforts to prepare and file with Governmental

Authorities requests for approval that are required in connection with the transactions contemplated by this Agreement and shall use all

commercially reasonable efforts to have such Governmental Authorities approve the transactions contemplated by this Agreement as may be

required. Each Party shall give prompt written notice to the other Parties if such Party or any of its Representatives receives any notice

from such Governmental Authorities in connection with the transactions contemplated by this Agreement, and shall promptly furnish the

other Parties with a copy of such Governmental Authority notice. If any Governmental Authority requires that a hearing or meeting be held

in connection with its approval of the transactions contemplated hereby, whether prior to the Closing or after the Closing, each of Party

shall arrange for Representatives of such Party to be present for such hearing or meeting. If any objections are asserted with respect

to the transactions contemplated by this Agreement under any applicable Law or if any Action is instituted (or threatened to be instituted)

by any applicable Governmental Authority or any private Person challenging any of the transactions contemplated by this Agreement or any

Ancillary Document as violative of any applicable Law or which would otherwise prevent, materially impede or materially delay the consummation

of the transactions contemplated hereby or thereby, the Parties shall use their commercially reasonable efforts to resolve any such objections

or Actions so as to timely permit consummation of the transactions contemplated by this Agreement and the Ancillary Documents, including

in order to resolve such objections or Actions which, in any case if not resolved, could reasonably be expected to prevent, materially

impede or materially delay the consummation of the transactions contemplated hereby or thereby. In the event any Action is instituted

(or threatened to be instituted) by a Governmental Authority or private Person challenging the transactions contemplated by this Agreement,

or any Ancillary Document, the Parties shall, and shall cause their respective Representatives to, reasonably cooperate with each other

and use their respective commercially reasonable efforts to contest and resist any such Action and to have vacated, lifted, reversed or

overturned any Order, whether temporary, preliminary or permanent, that is in effect and that prohibits, prevents or restricts consummation

of the transactions contemplated by this Agreement or the Ancillary Documents.

(d) Prior

to the Closing, each Party shall use its commercially reasonable efforts to obtain any Consents of Governmental Authorities or other third

Persons as may be necessary for the consummation by such Party or its Affiliates of the transactions contemplated by this Agreement or

required as a result of the execution or performance of, or consummation of the transactions contemplated by, this Agreement by such Party

or its Affiliates, and the other Parties shall provide reasonable cooperation in connection with such efforts.

(e) At

the request of SPAC, the Company shall make the members of its management reasonably available to participate in management presentations,

“road shows,” rating agency presentations, meetings with financing sources and similar events in connection with obtaining

the approval of SPAC shareholders, any “share recycling” efforts by SPAC and/or the obtaining of any debt or equity financing

(including Transaction Financing) or the obtaining of ratings or Governmental Authority and other third party approvals.

6.10 Tax

Matters.

(a) Each

of the Parties shall use its reasonable best efforts to cause the Mergers to qualify as an exchange described in Section 351 of the Code.

None of the Parties shall (and each of the Parties shall cause their respective Subsidiaries not to) take any action, or fail to take

any action, that could reasonably be expected to cause the Mergers to fail to qualify as an exchange described in Section 351 of the Code.

The Parties intend to report and, except to the extent otherwise required by Law, shall report, for federal income tax purposes, the Mergers

as an exchange described in Section 351 of the Code.

(b) Any

and all transfer, documentary, sales, use, stamp, registration and other similar Taxes, and all conveyance fees, recording charges and

other fees and charges (including any penalties and interest) incurred in connection with the Mergers will be paid by the responsible

Party when due, and the responsible Party will, at its own expense, file all necessary Tax Returns and other documentation with respect

to all such Taxes, fees and charges.

6.11 Further

Assurances. The Parties hereto shall further cooperate with each other and use their respective commercially reasonable efforts to

take or cause to be taken all actions, and do or cause to be done all things, necessary, proper or advisable on their part under this

Agreement and applicable Laws to consummate the transactions contemplated by this Agreement as soon as reasonably practicable, including

preparing and filing as soon as practicable all documentation to effect all necessary notices, reports and other filings.

6.12 The

Registration Statement.

(a) As

promptly as practicable after the date hereof, SPAC, Pubco and the Company shall prepare, and file with the SEC a registration statement

on Form S-4 (as amended or supplemented from time to time, and including the Proxy Statement contained therein, the “Registration

Statement”) in connection with the registration under the Securities Act of (x) the Pubco Common Stock to be issued under

this Agreement to the holders of SPAC Common Stock and to the Sellers pursuant to the Mergers and (y) the Pubco Public Warrants, which

Registration Statement will also contain a proxy statement (as amended, the “Proxy Statement”) for the purpose

of soliciting proxies from SPAC shareholders for the matters to be acted upon at SPAC Extraordinary General Meeting and providing the

Public Shareholders an opportunity in accordance with SPAC’s Organizational Documents to have their SPAC Class A Ordinary Shares

redeemed (the “Redemption”). The Proxy Statement shall include proxy materials for the purpose of soliciting

proxies from SPAC shareholders to vote, at an extraordinary general meeting of SPAC shareholders to be called and held for such purpose

(the “SPAC Extraordinary General Meeting”), in favor of resolutions approving (i) the adoption and approval

of this Agreement, the Ancillary Documents and the transactions contemplated hereby or referred to herein, including the Mergers (and,

to the extent required, the issuance of any shares in connection with Transaction Financing, if any), by the holders of SPAC Ordinary

Shares in accordance with SPAC’s Organizational Documents, the Act, the DGCL and the rules and regulations of the SEC and NYSE,

(ii) the adoption and approval of the Conversion by the holders of SPAC Ordinary Shares in accordance with SPAC’s Organizational

Documents, the Act and the DGCL, (iii) the adoption and approval of the Amended Pubco Charter (as hereinafter defined), (iv) adoption

and approval of a new equity incentive plan for Pubco in a form satisfactory to SPAC and Company (the “Incentive Plan”

or “Post-Closing Equity Plan”), and which will provide for awards for a number of shares of Pubco Common Stock

equal to fifteen percent (15%) of the aggregate number of shares of Pubco Common Stock issued and outstanding immediately after the Closing

(after giving effect to the Redemption), as further set forth in the Incentive Plan, (v) the appointment of the members of the Post-Closing

Pubco Board in accordance with Section 6.17 hereof, (vi) the approval of an amendment to the Insider Letter, effective upon the Closing

(the “Insider Letter Amendment Approval”), (vii) such other matters (or, to the extent applicable, excluding

such approval matters) as the Company and SPAC shall hereafter mutually determine to be necessary or appropriate in order to effect the

Mergers and the other transactions contemplated by this Agreement (the approvals described in foregoing clauses (i) through (vii), collectively,

the “SPAC Shareholder Approval Matters”), and (viii) the adjournment of SPAC Extraordinary General Meeting to

a later date or dates, if necessary or desirable in the reasonable determination of SPAC. If on the date for which SPAC Extraordinary

General Meeting is scheduled, SPAC has not received proxies representing a sufficient number of shares to obtain the Required SPAC Shareholder

Approval, whether or not a quorum is present, SPAC may (or will, at the direction of the Company) make one or more successive postponements

or adjournments of SPAC Extraordinary General Meeting provided that (A) SPAC shall not be required to adjourn or postpone the SPAC Extraordinary

General Meeting more than three times at the direction of the Company and (B) the adjourned or postponed SPAC Extraordinary General Meeting

is held at least ten (10) Business Days prior to the Outside Date.

(b) In

connection with the Registration Statement, SPAC, Pubco and the Company will file with the SEC financial and other information about the

transactions contemplated by this Agreement in accordance with applicable Law and applicable proxy solicitation and registration statement

rules set forth in SPAC’s Organizational Documents, the Act, the DGCL and the rules and regulations of the SEC and NYSE. The Company

shall promptly provide SPAC and Pubco with such information concerning the Target Companies and their stockholders, officers, directors,

employees, assets, Liabilities, condition (financial or otherwise), business and operations that may be required or appropriate for inclusion

in the Registration Statement, or in any amendments or supplements thereto, which information provided by the Company shall be true and

correct and not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements

made, in light of the circumstances under which they were made, not materially misleading.

and Pubco covenant and agree that the Proxy Statement (including the letter to shareholders, notice of meeting and form of proxy included

therewith), will not, at the time that the Proxy Statement or any amendment or supplement thereto is first mailed to the Buyer’s

stockholders and at the time of the SPAC Extraordinary General Meeting, contain any untrue statement of a material fact or omit to state

any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances

under which they were made, not misleading. Notwithstanding the foregoing, SPAC and Pubco make no covenant, representation or warranty

with respect to statements made in the Proxy Statement (and the letter to shareholders, notice of meeting and form of proxy included therewith)

(i) based on information furnished in writing by the Company specifically for inclusion therein, or (ii) that otherwise reflect information

about the Company or the planned business of SPAC following the Closing.

(d) SPAC,

Pubco and the Company shall take any and all reasonable and necessary actions required to satisfy the requirements of the SPAC Organizational

Documents, the Securities Act, the Exchange Act and other applicable Laws in connection with the Registration Statement, SPAC Extraordinary

General Meeting and the Redemption. Each of SPAC, Pubco and the Company shall, and shall cause each of its Subsidiaries to, make their

respective directors, officers and employees, upon reasonable advance notice, available to the Company, SPAC, Pubco and their respective

Representatives in connection with the drafting of the public filings with respect to the transactions contemplated by this Agreement,

including the Registration Statement, and responding in a timely manner to comments from the SEC. Each Party shall promptly correct any

information provided by it for use in the Registration Statement (and other related materials) if and to the extent that such information

is determined to have become false or misleading in any material respect or as otherwise required by applicable Laws. SPAC, Pubco and

the Company shall amend or supplement the Registration Statement and cause the Registration Statement, as so amended or supplemented,

to be filed with the SEC and to be disseminated to SPAC shareholders and the Sellers, in each case as and to the extent required by applicable

Laws and subject to the terms and conditions of this Agreement and SPAC’s Organizational Documents.

(e) Each

of Pubco, SPAC and the Company shall promptly respond to any SEC comments on the Registration Statement and shall otherwise use their

commercially reasonable efforts to cause the Registration Statement to “clear” comments from the SEC and become effective.

(f) As

soon as practicable following the Registration Statement “clearing” comments from the SEC and being declared effective by

the SEC (the “SEC Approval Date”), SPAC and Pubco shall distribute the Registration Statement to SPAC’s

shareholders and the Sellers, and, pursuant thereto, shall call SPAC Extraordinary General Meeting in accordance with SPAC’s Organizational

Documents and the Act for a date no later than thirty (30) days following the effectiveness of the Registration Statement or as otherwise

agreed upon by SPAC and the Company.

(g) SPAC

and Pubco shall comply with all applicable Laws, any applicable rules and regulations of NYSE, SPAC’s Organizational Documents and

this Agreement in the preparation, filing and distribution of the Registration Statement, any solicitation of proxies thereunder, the

calling and holding of SPAC Extraordinary General Meeting and the Redemption.

6.13 Company

Member Meeting. Promptly after the Registration Statement has become effective and been distributed by Pubco, the Company will call

a meeting of its members in order to obtain the Required Company Member Approval (the “Company Special Meeting”)

or obtain such approval by written consent (the “Required Company Member Written Consent”), and, if applicable,

the Company shall use its reasonable best efforts to solicit from the holders of the Company Interests proxies in favor of the Required

Company Member Approval prior to such Company Special Meeting, and to take all other actions necessary or advisable to secure the Required

Company Member Approval, including enforcing the Seller Support Agreements.

6.14 Public

Announcements.

(a) The

Parties agree that during the Interim Period no public release, statement, filing, announcement or other public communication concerning

this Agreement or the Ancillary Documents or the transactions contemplated hereby or thereby, including the existence or status thereof,

shall be issued by any Party or any of its Affiliates without the prior written consent of SPAC and the Company (which consent shall not

be unreasonably withheld, conditioned or delayed), except as such release or announcement may be required by applicable Law or the rules

or regulations of any securities exchange, in which case the applicable Party shall use commercially reasonably efforts to allow SPAC,

Pubco and the Company, reasonable time to comment on, and arrange for any required filing with respect to, such release or announcement

in advance of such issuance.

(b) SPAC

and the Company shall mutually agree upon and, as promptly as practicable after the execution of this Agreement (but in any event within

four (4) Business Days thereafter), issue a press release announcing the execution of this Agreement (the “Signing Press Release”).

Promptly after the issuance of the Signing Press Release, SPAC shall file a current report on Form 8-K (the “Signing Filing”)

with the Signing Press Release and a description of this Agreement as required by Federal Securities Laws, which the Company shall review,

comment upon and approve (which approval shall not be unreasonably withheld, conditioned or delayed) prior to filing (with the Company

reviewing, commenting upon and approving such Signing Filing in any event no later than the third (3rd) Business Day after

the execution of this Agreement). The Parties shall mutually agree upon and, as promptly as practicable after the Closing (but in any

event within four (4) Business Days thereafter), issue a press release announcing the consummation of the transactions contemplated by

this Agreement (the “Closing Press Release”). Promptly after the issuance of the Closing Press Release, Pubco

shall file a current report on Form 8-K (the “Closing Filing”) with the Closing Press Release and a description

of the Closing as required by Federal Securities Laws. In connection with the preparation of the Signing Press Release, the Signing Filing,

the Closing Filing, the Closing Press Release, or any other report, statement, filing notice or application made by or on behalf of a

Party to any Governmental Authority or other third party in connection with the transactions contemplated hereby, each Party shall, upon

request by any other Party, furnish the Parties with all information concerning themselves, their respective directors, officers and equity

holders, and such other matters as may be reasonably necessary or advisable in connection with the transactions contemplated hereby, or

any other report, statement, filing, notice or application made by or on behalf of a Party to any third party and/or any Governmental

Authority in connection with the transactions contemplated hereby.

6.15 Confidential

Information.

(a) The

Company hereby agrees that during the Interim Period and, in the event that this Agreement is terminated in accordance with Article

VIII, for a period of two (2) years after such termination, it shall, and shall cause its Affiliates and Representatives to: (i) treat

and hold in strict confidence any SPAC Confidential Information, and will not use for any purpose (except in connection with the consummation

of the transactions contemplated by this Agreement or the Ancillary Documents, performing their obligations hereunder or thereunder, enforcing

their rights hereunder or thereunder, or in furtherance of their authorized duties on behalf of SPAC or its Subsidiaries), nor directly

or indirectly disclose, distribute, publish, disseminate or otherwise make available to any third party any of SPAC Confidential Information

without SPAC’s prior written consent; and (ii) in the event that the Company or any of its Affiliates or Representatives, during

the Interim Period or, in the event that this Agreement is terminated in accordance with Article VIII, for a period of two (2)

years after such termination, becomes legally compelled to disclose any SPAC Confidential Information, (A) provide SPAC to the extent

legally permitted with prompt written notice of such requirement so that SPAC or an Affiliate thereof may seek, at SPAC’s cost,

a protective Order or other remedy or waive compliance with this Section 6.15(a), and (B) in the event that such protective Order

or other remedy is not obtained, or SPAC waives compliance with this Section 6.15(a), furnish only that portion of such SPAC Confidential

Information which is legally required to be provided as advised in writing by outside counsel and to exercise its commercially reasonable

efforts to obtain assurances that confidential treatment will be accorded such SPAC Confidential Information. In the event that this Agreement

is terminated and the transactions contemplated hereby are not consummated, the Company shall, and shall cause its Affiliates and Representatives

to, promptly deliver to SPAC or destroy (at SPAC’s election) any and all copies (in whatever form or medium) of SPAC Confidential

Information and destroy all notes, memoranda, summaries, analyses, compilations and other writings related thereto or based thereon; provided,

however, that the Company and its Affiliates and Representatives shall be entitled to keep any records required by applicable Law or bona

fide record retention policies; and provided, further, that any SPAC Confidential Information that is not returned or destroyed shall

remain subject to the confidentiality obligations set forth in this Agreement.

(b) SPAC

hereby agrees that during the Interim Period and, in the event that this Agreement is terminated in accordance with Article VIII,

for a period of two (2) years after such termination, it shall, and shall cause its Representatives to: (i) treat and hold in strict confidence

any Company Confidential Information, and will not use for any purpose (except in connection with the consummation of the transactions

contemplated by this Agreement or the Ancillary Documents, performing its obligations hereunder or thereunder or enforcing its rights

hereunder or thereunder), nor directly or indirectly disclose, distribute, publish, disseminate or otherwise make available to any third

party any of the Company Confidential Information without the Company’s prior written consent; and (ii) in the event that SPAC or

any of its Representatives, during the Interim Period or, in the event that this Agreement is terminated in accordance with Article

VIII, for a period of two (2) years after such termination, becomes legally compelled to disclose any Company Confidential Information,

(A) provide the Company to the extent legally permitted with prompt written notice of such requirement so that the Company may seek, at

the Company’s sole expense, a protective Order or other remedy or waive compliance with this Section 6.15(b) and (B) in the

event that such protective Order or other remedy is not obtained, or the Company waives compliance with this Section 6.15(b), furnish

only that portion of such Company Confidential Information which is legally required to be provided as advised in writing by outside counsel

and to exercise its commercially reasonable efforts to obtain assurances that confidential treatment will be accorded such Company Confidential

Information. In the event that this Agreement is terminated and the transactions contemplated hereby are not consummated, SPAC shall,

and shall cause its Representatives to, promptly deliver to the Company or destroy (at SPAC’s election) any and all copies (in whatever

form or medium) of Company Confidential Information and destroy all notes, memoranda, summaries, analyses, compilations and other writings

related thereto or based thereon; provided, however, that SPAC and its Representatives shall be entitled to keep any records required

by applicable Law or bona fide record retention policies; and provided, further, that any Company Confidential Information that is not

returned or destroyed shall remain subject to the confidentiality obligations set forth in this Agreement. Notwithstanding the foregoing,

SPAC and its Representatives shall be permitted to disclose any and all Company Confidential Information to the extent required by the

Federal Securities Laws.

6.16 Documents

and Information. After the Closing Date, Pubco shall, and shall cause its Subsidiaries (including the Company) to, until the seventh

(7th) anniversary of the Closing Date, retain all books, records and other documents pertaining to the business of SPAC and

the Company in existence on the Closing Date.

6.17 Post-Closing

Board of Directors and Executive Officers.

(a) The

Parties shall take all necessary action, including causing the directors of the Pubco to resign, so that effective as of the Closing,

Pubco’s board of directors (the “Post-Closing Pubco Board”) will consist of seven (7) individuals. Immediately

after the Closing, the Parties shall take all necessary action to designate and appoint to the Post-Closing Pubco Board those persons

designated by the Company prior to the Closing (the “Company Directors”), at least four (4) of whom shall be

required to qualify as an independent director under NYSE rules and one (1) of whom shall be the chief executive officer of the Company.

At or prior to the Closing, Pubco will provide each member of the Post-Closing Pubco Board with a customary director indemnification agreement,

in form and substance reasonably acceptable to such Company Director.

(b) The

Parties shall take all action necessary, including causing the executive officers of Pubco to resign, so that the individuals serving

as the chief executive officer and chief financial officer, respectively, of Pubco immediately after the Closing will be the same individuals

(in the same office) as that of the Company immediately prior to the Closing (unless, at its sole discretion, the Company desires to appoint

another qualified person to either such role, in which case, such other person(s) identified by the Company shall serve in such role or

roles).

6.18 Indemnification

of Directors and Officers; Tail Insurance.

(a) The

Parties agree that all rights to exculpation, indemnification and advancement of expenses existing in favor of the current or former directors,

managers and officers of each Target Company, SPAC and each Person who served as a director, officer, manager, member, trustee or fiduciary

of another corporation, partnership, joint venture, trust, pension or other employee benefit plan or enterprise at the request of SPAC

or the Company (the “D&O Indemnified Persons”) as provided in their respective Organizational Documents

or under any indemnification, employment or other similar agreements between any D&O Indemnified Person and SPAC, Pubco, any Merger

Sub or the Company, in each case as in effect on the date of this Agreement, shall survive the Closing and continue in full force and

effect in accordance with their respective terms to the extent permitted by applicable Law. For a period of six (6) years after the Effective

Time, Pubco shall cause the Organizational Documents of Pubco and the Surviving Subsidiaries to contain provisions no less favorable with

respect to exculpation and indemnification of and advancement of expenses to D&O Indemnified Persons than are set forth as of the

date of this Agreement in the Organizational Documents of SPAC to the extent permitted by applicable Law. The provisions of this Section

6.18 shall survive the Closing and are intended to be for the benefit of, and shall be enforceable by, each of the D&O Indemnified

Persons and their respective heirs and representatives.

(b) For

the benefit of SPAC’s directors and officers, the Pubco shall, prior to the Effective Time, obtain and fully pay the premium for

a “tail” insurance policy that provides coverage for up to a six-year period from and after the Effective Time for events

occurring prior to the Effective Time (the “SPAC D&O Tail Insurance”) that is substantially equivalent to

and in any event not less favorable in the aggregate than SPAC’s existing policy or, if substantially equivalent insurance coverage

is unavailable, the best available coverage.

the benefit of the Company’s managers and officers, the Company shall, prior to the Effective Time, obtain and fully pay the premium

for a “tail” insurance policy that provides coverage for up to a six-year period from and after the Effective Time for events

occurring prior to the Effective Time (the “Company D&O Tail Insurance”) that is substantially equivalent

to and in any event not less favorable in the aggregate than the Company’s existing policy or, if substantially equivalent insurance

coverage is unavailable, the best available coverage.

(d) Pubco

and the Surviving Subsidiaries shall maintain SPAC D&O Tail Insurance and the Company D&O Tail Insurance, in full force and effect,

and continue to honor the obligations thereunder, and Pubco and the Surviving Subsidiaries shall timely pay or caused to be paid all premiums

with respect to SPAC D&O Tail Insurance and the Company D&O Tail Insurance.

6.19 Trust

Account Proceeds. The Parties agree that after the Closing, the funds in the Trust Account, after taking into account payments for

the Redemption, and any proceeds from any Transaction Financing shall first be used to pay (a) SPAC’s accrued and unpaid Expenses,

(b) SPAC’s deferred Expenses (including cash amounts payable to the IPO Underwriter and any legal fees) of the IPO, (c) any loans

owed by SPAC to the Sponsor for any Expenses (including deferred Expenses) or other administrative costs and expenses incurred by or on

behalf of SPAC or Extension Expenses, and (d) any other unpaid Expenses of the Company as of the Closing. Such Expenses, as well as any

Expenses that are required to be paid by delivery of the Pubco Securities, will be paid at the Closing. Any remaining cash will be used

for working capital and general corporate purposes of Pubco and the Surviving Subsidiaries. For the avoidance of doubt, no amount should

be paid from the Trust Account, Transaction Financing proceeds or other cash sources available to Pubco or its Subsidiaries at Closing

in respect of any financing, placement agent, bookrunner, capital markets advisory or post-closing financing services provided to the

Company or to Pubco unless such payment is expressly set forth on the closing funds-flow schedule and approved by the Company and Pubco;

provided, that the foregoing approval requirement shall not apply to (i) any costs, fees or expenses payable pursuant to

agreements entered into prior to the date of this Agreement, or (ii) any costs, fees or expenses incurred in connection with any Transaction

Financing to the extent such costs, fees or expenses are otherwise permitted or required to be paid under the terms of this Agreement

or any Financing Agreement.

6.20 Transaction

Financing.

(a) During

the Interim Period, (i) SPAC shall use its best efforts to obtain up to $20,000,000 in Transaction Financing, and (ii) the Company shall

use its best efforts to obtain up to $10,000,000 in Transaction Financing. SPAC or the Company, as applicable, may enter into financing

agreements (“Financing Agreements”) for one or more Transaction Financings on such terms and structuring, and

using such strategy, placement agents and approach as SPAC and the Company shall reasonably agree (with the other Party’s agreement

thereto not to be unreasonably withheld, conditioned or delayed). SPAC or the Company, as applicable, may also enter into agreements and

consummate other backstop, non-redemption or similar agreements to effect a Transaction Financing, as defined herein.

(b) SPAC,

the Company and Pubco shall, and shall cause their respective Representatives to, cooperate with each other and their respective Representatives

in connection with the Transaction Financing and Financing Agreements, and each of SPAC, the Company and Pubco will use their respective

reasonable best efforts to cause such Transaction Financing to occur (including having the Company’s senior management and, as applicable,

SPAC’s management participate in any investor meetings and roadshows as reasonably requested by the other Party).

6.21 Qualification

to do Business. The Company hereby agrees that it shall, as promptly as practicable after the date of this Agreement but no later

than the Closing Date, obtain foreign qualifications to do business in each jurisdiction in which it reasonably determines it is required

to do so.

Article

VII

CLOSING CONDITIONS

7.1 Conditions

to Each Party’s Obligations. The obligations of each Party to consummate the Mergers and the other transactions described herein

shall be subject to the satisfaction or written waiver (where permissible) by the Company and SPAC of the following conditions:

(a) Required

SPAC Shareholder Approval. The SPAC Shareholder Approval Matters that are submitted to the vote of the shareholders of SPAC at SPAC

Extraordinary General Meeting in accordance with the Proxy Statement shall have been approved by the requisite vote of the shareholders

of SPAC at SPAC Extraordinary General Meeting in accordance with SPAC’s Organizational Documents, applicable Law and the Proxy Statement

(the “Required SPAC Shareholder Approval”).

(b) Required

Company Member Approval. (i) The Company Special Meeting shall have been held in accordance with the DLLCA and the Company Operating

Agreement, and at such meeting, the requisite vote of the holders of Company Interests (including any separate class or series vote that

is required, whether pursuant to the Company Operating Agreement, any stockholder agreement or otherwise) shall have authorized, approved

and consented to, the execution, delivery and performance of this Agreement and each of the Ancillary Documents to which the Company is

or is required to be a party or bound, and the consummation of the transactions contemplated hereby and thereby, including the Company

Merger or (ii) the Company shall have obtained the Required Company Member Written Consent in accordance with the DLLCA and the Company

Operating Agreement (the “Required Company Member Approval”).

Laws. Any waiting period (and any extension thereof) applicable to the consummation of this Agreement under any Antitrust Laws shall

have expired or been terminated.

(d) Requisite

Regulatory Approvals. All Consents required to be obtained from or made with any Governmental Authority in order to consummate the

transactions contemplated by this Agreement shall have been obtained or made.

(e) Requisite

Consents. The Consents required to be obtained from or made with any third Person (other than a Governmental Authority) in order to

consummate the transactions contemplated by this Agreement that are set forth on Schedule 7.1(e) shall have each been obtained

or made.

(f) No

Adverse Law or Order. No Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Law (whether temporary,

preliminary or permanent) or Order that is then in effect and which has the effect of making the transactions or agreements contemplated

by this Agreement illegal or which otherwise prevents or prohibits consummation of the transactions contemplated by this Agreement.

(g) Appointment

to the Board. The members of the Post-Closing Pubco Board shall have been elected or appointed as of the Closing consistent with the

requirements of Section 6.17.

(h) Registration

Statement. The Registration Statement shall have been declared effective by the SEC and shall remain effective as of the Closing,

and no stop order or similar order shall be in effect with respect to the Registration Statement.

(i) SPAC

Conversion. The Conversion shall have been consummated in accordance with Section 1.7.

(j) Pubco

Charter Amendment. Prior to the Closing, Pubco shall have amended and restated its certificate of incorporation in a form satisfactory

to SPAC and the Company (the “Amended Pubco Charter”).

(k) NYSE

Listing. The shares of Pubco Common Stock and the Pubco Public Warrants shall have been

approved for listing on NYSE upon the Closing.

(l) Incentive

Plan. Pubco shall have adopted, effective on or prior to Closing, the Incentive Plan.

7.2 Conditions

to Obligations of the Company . In addition to the conditions specified in Section 7.1, the obligations of the Company to consummate

the Mergers and the other transactions contemplated by this Agreement are subject to the satisfaction or written waiver (by the Company)

of the following conditions:

(a) Representations

and Warranties. (i) SPAC Fundamental Representations shall be true and correct in all material respects on and as of the date of this

Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation

and warranty is expressly made as of an earlier date, in which case such representation and warranty shall be true and correct in all

material respects as of such earlier date), (ii) the representations and warranties set forth in the first sentence of Section 3.5(a)

shall be true and correct in all respects (except for de minimis inaccuracies) on and as of the date of this Agreement and as of

the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is expressly

made as of an earlier date, in which case such representation and warranty shall be true and correct in all respects (except for de

minimis inaccuracies) as of such earlier date), (iii) the other representations and warranties of SPAC in Article III (other

than SPAC Fundamental Representations and the representations and warranties set forth in the first sentence of Section 3.5(a))

and the representations and warranties of the other SPAC Parties shall be true and correct (without giving effect to any limitations as

to “materiality” or any similar limitation set forth herein) in all respects on and as of the date of this Agreement and as

of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is expressly

made as of an earlier date, in which case such representation and warranty shall be true and correct in all respects as of such earlier

date), except where the failure of such representations and warranties to be true and correct, individually and in the aggregate has not

had a SPAC Material Adverse Effect.

(b) Agreements

and Covenants. The SPAC Parties shall have performed in all material respects all of their respective obligations and complied in

all material respects with all of their respective agreements and covenants under this Agreement to be performed or complied with by them

on or prior to the Closing Date.

Ancillary Documents. The Insider Letter Amendment, the Amended Registration Rights Agreement and the Sponsor Letter shall be in full

force and effect as of the Closing.

(d) Closing

Deliveries.

(i) Officer

Certificate. SPAC shall have delivered to the Company a certificate, dated the Closing Date, signed by an executive officer of

SPAC in such capacity, certifying as to the satisfaction of the conditions specified in Sections 7.2(a) and 7.2(b).

(ii) Secretary

Certificate. SPAC shall have delivered to the Company a certificate from its secretary or other executive officer certifying as

to, and attaching, (A) copies of each of the SPAC Parties’ Organizational Documents as in effect as of the Closing Date prior to

the Effective Time (after giving effect to the Conversion), (B) the resolutions of the board of directors of each of the SPAC Parties

authorizing and approving the execution, delivery and performance of this Agreement and each of the Ancillary Documents to which it is

a party or by which it is bound, the adoption of the Company Surviving Subsidiary Organizational Documents, and the consummation of the

transactions contemplated hereby and thereby, (C) evidence that the Required SPAC Shareholder Approval has been obtained and (D) the incumbency

of officers of each SPAC Party authorized to execute this Agreement or any Ancillary Document to which a SPAC Party is or is required

to be a party or otherwise bound.

(iii) Good

Standing. SPAC shall have delivered to the Company a good standing certificate (or similar documents applicable for such jurisdictions)

for each SPAC Party certified as of a date no earlier than thirty (30) days prior to the Closing Date from the proper Governmental Authority

of such SPAC Parties’ jurisdiction of organization and from each other jurisdiction in which such SPAC Party is qualified to do

business as a foreign entity as of the Closing, in each case to the extent that good standing certificates or similar documents are generally

available in such jurisdictions.

(iv) Resignations.

Subject to the requirements of Section 5.18, the Company shall have received written resignations, effective as of the Closing,

of each of the directors and officers of SPAC as requested by the Company prior to the Closing.

(e) SPAC

Minimum Cash Condition. The sum of (i) the aggregate cash proceeds available for release from the Trust Account (after giving effect

to the completion and payment of the Redemption), plus (ii) the net proceeds of any Transaction Financings conducted by SPAC, shall

equal or exceed $15,000,000 (the “SPAC Minimum Cash Condition”).

7.3 Conditions

to Obligations of SPAC. In addition to the conditions specified in Section 7.1, the obligations of SPAC to consummate the Mergers

and the other transactions contemplated by this Agreement are subject to the satisfaction or written waiver (by SPAC) of the following

conditions:

(a) Representations

and Warranties. (i) the Target Company Fundamental Representations shall be true and correct (without giving effect to any limitation

as to “materiality” set forth therein) in all material respects on and as of the date of this Agreement and as of the Closing

Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is expressly made as

of an earlier date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier

date), (ii) the representations and warranties set forth in the first sentence of Section 5.3(a) shall be true and correct in all

respects on and as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date, and (iii) the

representations and warranties of the Target Companies, as applicable, set forth in Article V (other than the Target Company Fundamental

Representations and the representations and warranties set forth in the first sentence of Section 5.3(a) and the representations

and warranties of the Company (other than the representations and warranties of the Company) shall be true and correct (without giving

effect to any limitation as to “materiality” or “Material Adverse Effect” or any similar limitation set forth

herein) in all respects on and as of the date of this Agreement and on and as of the Closing Date, as though made on and as of the Closing

Date (except to the extent that any such representation and warranty is expressly made as of an earlier date, in which case such representation

and warranty shall be true and correct in all respects as of such earlier date), except where the failure of such representations and

warranties to be true and correct, individually and in the aggregate has not had a Material Adverse Effect.

(b) Agreements

and Covenants. The Company shall have performed in all material respects all of its obligations and complied in all material respects

with all of its agreements and covenants under this Agreement to be performed or complied with by it on or prior to the Closing Date.

Material Adverse Effect. No Material Adverse Effect shall have occurred with respect to the Target Companies since the date of this

Agreement.

(d) Certain

Ancillary Documents. Each Non-Competition Agreement, each Lock-Up Agreement, the Insider Letter Amendment, the Seller Support Agreement

and the Amended Registration Rights Agreement shall be in full force and effect as of the Closing.

(e) Closing

Deliveries.

(i) Officer

Certificate. SPAC shall have received a certificate from the Company, dated as the Closing Date, signed by an executive officer

of the Company in such capacity, certifying as to the satisfaction of the conditions specified in Sections 7.3(a), 7.3(b)

and 7.3(c)

(ii) Secretary

Certificate. The Company shall have delivered to SPAC a certificate from its secretary or other executive officer certifying as

to, and attaching, (A) copies of the Company’s Organizational Documents as in effect as of the Closing Date prior to the Effective

Time, (B) the requisite resolutions of the Company and the Sellers authorizing and approving the execution, delivery and performance of

this Agreement and each Ancillary Document to which the Company is or is required to be a party or bound, and the consummation of the

Mergers and the other transactions contemplated hereby and thereby, and recommending the approval and adoption of the same by the holders

of Company Interests at a duly called meeting of members, (C) evidence that the Required Company Member Approval has been obtained, and

(D) the incumbency of officers authorized to execute this Agreement or any Ancillary Document to which the Company is or is required to

be a party or otherwise bound.

(iii) Good

Standing. The Company shall have delivered to SPAC good standing certificates (or similar documents applicable for such jurisdictions)

for each Target Company certified as of a date no earlier than thirty (30) days prior to the Closing Date from the proper Governmental

Authority of the Target Company’s jurisdiction of organization and from each other jurisdiction in which the Target Company is qualified

to do business as a foreign corporation or other entity as of the Closing, in each case to the extent that good standing certificates

or similar documents are generally available in such jurisdictions.

(iv) Resignations.

Subject to the requirements of Section 5.18, SPAC shall have received written resignations, effective as of the Closing, of each

of the directors and officers of the Company as requested by SPAC prior to the Closing.

(v) Employment

Agreement. SPAC and Pubco shall have received employment agreements, in each case effective as of the Closing, in form and

substance acceptable to SPAC, between each of Jeffrey M. Busch, Faith Zaslavavsky and Ronald Tam and Pubco or a Target Company, as noted

on Schedule 7.3(e)(v), and each such employment agreement duly executed by the parties thereto.

(f) Company

Minimum Cash Condition. The sum of the net proceeds of any Transaction Financings conducted by the Company, shall equal or

exceed $7,500,000 (the “Company Minimum Cash Condition”).

(g) Indebtedness

Pay-Off. All Indebtedness of the Company shall have been repaid, forgiven, discharged, or otherwise satisfied in full on or

prior to the Closing Date, or arrangements for the repayment, forgiveness, discharge, or satisfaction thereof shall have been made, in

form and substance reasonably satisfactory to SPAC, such that no Indebtedness of the Company shall remain outstanding immediately following

the Closing.

(h) Intellectual

Property Assignment Agreements. Each employee of the Company who is engaged in the development of Intellectual Property for

the Company shall have executed and delivered to SPAC a customary intellectual property assignment agreement (including any invention

assignment, proprietary information, confidentiality, or similar agreement), in form and substance reasonably satisfactory to both SPAC

and the Company, assigning to the Company all right, title, and interest in and to any Intellectual Property conceived, created, developed,

or reduced to practice by such employee in connection with such employee’s employment with the Company.

7.4 Frustration

of Conditions. Notwithstanding anything contained herein to the contrary, no Party may rely on the failure of any condition set forth

in this Article VII to be satisfied if such failure was caused by the failure of such Party or its Affiliates (or with respect

to the Company, any Target Company or Seller) to comply with or perform any of its covenants or obligations set forth in this Agreement.

Article

VIII

TERMINATION AND EXPENSES

8.1 Termination.

This Agreement may be terminated and the transactions contemplated hereby may be abandoned at any time prior to the Closing as follows:

(a) by

mutual written consent of SPAC and the Company;

(b) by

written notice by either SPAC or the Company to the other if any of the conditions to the Closing set forth in Article VII have

not been satisfied or waived by September 30, 2026 (as may be extended pursuant to this Section 8.1(b), the “Outside Date”);

provided, however, that the Outside Date shall be automatically extended for one thirty (30) day period, and thereafter the Outside

Date may be further extended by the mutual written consent of SPAC and the Company for successive thirty (30) day periods, in the event

that, as of such date, the SEC shall not have declared the Registration Statement effective or the SEC’s review of the Registration

Statement shall not have been completed and all comments of the SEC staff thereon shall not have been resolved to the reasonable satisfaction

of SPAC and the Company; provided, further, that the right to terminate this Agreement under this Section 8.1(b) shall not

be available to a Party if the breach or violation by such Party or its Affiliates of any representation, warranty, covenant or obligation

under this Agreement was the cause of, or resulted in, the failure of the Closing to occur on or before the Outside Date;

written notice by either SPAC or the Company to the other if a Governmental Authority of competent jurisdiction shall have issued an Order

or taken any other action permanently restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement,

and such Order or other action has become final and non-appealable; provided, however, that the right to terminate this Agreement

pursuant to this Section 8.1(c) shall not be available to a Party if the failure by such Party or its Affiliates to comply with

any provision of this Agreement has been a substantial cause of, or substantially resulted in, such action by such Governmental Authority;

(d) by

written notice by the Company to SPAC, if (i) there has been a material breach by SPAC of any of its representations, warranties, covenants

or agreements contained in this Agreement or if any representation or warranty of SPAC shall have become materially untrue or materially

inaccurate, in any case, which would result in a failure of a condition set forth in Section 7.2(a) or Section 7.2(b) to

be satisfied (treating the Closing Date for such purposes as the date of this Agreement or, if later, the date of such breach), and (ii)

the material breach or material inaccuracy is incapable of being cured or is not cured within the earlier of (A) thirty (30) days after

written notice of such material breach or material inaccuracy is provided to SPAC or (B) the Outside Date; provided, that the Company

shall not have the right to terminate this Agreement pursuant to this Section 8.1(d) if at such time the Company is in material

uncured breach of this Agreement;

(e) by

written notice by SPAC to the Company, if (i) there has been a material breach by the Company of any of its representations, warranties,

covenants or agreements contained in this Agreement, or if any representation or warranty of such Parties shall have become untrue or

inaccurate, in any case, which would result in a failure of a condition set forth in Section 7.3(a) or Section 7.3(b) to

be satisfied (treating the Closing Date for such purposes as the date of this Agreement or, if later, the date of such breach), and (ii)

the breach or inaccuracy is incapable of being cured or is not cured within the earlier of (A) thirty (30) days after written notice of

such breach or inaccuracy is provided by SPAC or (B) the Outside Date; provided, that SPAC shall not have the right to terminate this

Agreement pursuant to this Section 8.1(e) if at such time SPAC is in material uncured breach of this Agreement;

(f) by

written notice by SPAC to the Company, if there shall have been a Material Adverse Effect on the Target Companies taken as a whole following

the date of this Agreement which is uncured and continuing;

(g) by

written notice by either SPAC or the Company to the other, if SPAC Extraordinary General Meeting is held (including any adjournment or

postponement thereof) and has concluded, SPAC’s shareholders have duly voted, and the Required SPAC Shareholder Approval was not

obtained; or

(h) by

written notice by SPAC to the Company if the Company has not delivered the Audited Financials to SPAC on or before the Audit Delivery

Date.

8.2 Effect

of Termination. This Agreement may only be terminated in the circumstances described in Section 8.1 and pursuant to a written

notice delivered by the applicable Party to the other applicable Parties, which sets forth the basis for such termination, including the

provision of Section 8.1 under which such termination is made. In the event of the valid termination of this Agreement pursuant

to Section 8.1, this Agreement shall forthwith become void, and there shall be no Liability on the part of any Party or any of

their respective Representatives, and all rights and obligations of each Party shall cease, except: (i) Sections 6.14, 6.15,

8.3, 9.1, Article X and this Section 8.2 shall survive the termination of this Agreement, and (ii) nothing

herein shall relieve any Party from Liability for any willful breach of any representation, warranty, covenant or obligation under this

Agreement or any Fraud Claim against such Party, in either case, prior to termination of this Agreement (in each case of clauses (i) and

(ii) above, subject to Section 9.1). Without limiting the foregoing, and except as provided in Sections 8.3 and this Section

8.2 (but subject to Section 9.1) and subject to the right to seek injunctions, specific performance or other equitable relief

in accordance with Section 10.6, the Parties’ sole right prior to the Closing with respect to any breach of any representation,

warranty, covenant or other agreement contained in this Agreement by another Party or with respect to the transactions contemplated by

this Agreement shall be the right, if applicable, to terminate this Agreement pursuant to Section 8.1.

8.3 Fees

and Expenses. Subject to Section 9.1, all Expenses incurred in connection with this Agreement and the transactions contemplated

hereby shall be paid by the Party incurring such expenses, subject to Section 6.19; provided that (i) if the Closing occurs

all Expenses incurred by SPAC will be paid or reimbursed by Pubco from the Trust Account, the Transaction Financing, or other cash sources

available to Pubco or its Subsidiaries at the Closing, (ii) all fees, costs and expenses (including filing fees) paid or payable by any

Party or any of its Affiliates as a result of or in connection with or arising under any applicable Antitrust Laws, including fees and

expenses relating to any pre-merger notification required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended shall

be shared equally between the Parties, (iii) all fees, costs and expenses (including filing fees and printer costs) paid or payable by

any Party or any of its Affiliates as a result of or in connection with or arising from filing the Registration Statement with the SEC

shall be shared equally between the Parties, (iv) all fees, costs and expenses (including filing fees) paid or payable by any Party or

any of its Affiliates as a result of or in connection with or arising from submitting to NYSE a listing application for the shares of

Pubco Common Stock (including any filing fees arising therefrom) shall be shared equally between the Parties, (v) if the Company Minimum

Cash Condition is not satisfied (or irrevocably committed) at or prior to the Closing, then the Company shall reimburse SPAC and/or the

Sponsor for their reasonable, documented out-of-pocket third-party costs and expenses incurred in connection with the transactions contemplated

hereby (including legal, financial advisory, consulting and accounting fees and expenses), up to an aggregate cap of $1,500,000, and (vi)

if the SPAC Minimum Cash Condition is not satisfied (or irrevocably committed) at or prior to the Closing, then SPAC shall reimburse the

Company for its reasonable, documented out-of-pocket third-party costs and expenses incurred in connection with the transactions contemplated

hereby (including legal, financial advisory, consulting and accounting fees and expenses), up to an aggregate cap of $1,500,000. With

respect to any loans owed by SPAC to the Sponsor for any Expenses (including deferred Expenses) or other administrative costs and expenses

incurred by or on behalf of SPAC or Extension Expenses, which loans are to be paid out of the funds in the Trust Account: (i) to the extent

such loans have been made prior to the date hereof, such loans are listed on Schedule 8.3 hereto, including the loan amount and

use of proceeds and (ii) to the extent such loans are made during the Interim Period, SPAC shall in each instance provide reasonable advance

notice thereof to the Company, including the loan amount and use of proceeds.

8.4 Survival.

The representations and warranties of the Parties contained in this Agreement or in any certificate or instrument delivered by or on behalf

of the Parties or their respective Representatives pursuant to this Agreement shall not survive the Closing, and from and after the Closing,

the Parties and their respective Representatives shall not have any further obligations, nor shall any claim be asserted or action be

brought against the Parties or their respective Representatives with respect thereto. The covenants and agreements made by the Parties

and their respective Representatives in this Agreement or in any certificate or instrument delivered pursuant to this Agreement, including

any rights arising out of any breach of such covenants or agreements, shall not survive the Closing, except for those covenants and agreements

contained herein and therein that by their terms apply or are to be performed in whole or in part after the Closing (which such covenants

shall survive the Closing and continue until fully performed in accordance with their terms).

Article

WAIVERS AND RELEASES

9.1 Waiver

of Claims Against Trust. Reference is made to the IPO Prospectus. The Company hereby represents and warrants that it has read the

IPO Prospectus and understands that SPAC has established the Trust Account containing the proceeds of the IPO and the overallotment shares

acquired by SPAC’s underwriters and from certain private placements occurring simultaneously with the IPO (including interest accrued

from time to time thereon) for the benefit of SPAC’s public shareholders (including overallotment shares acquired by SPAC’s

underwriters) (the “Public Shareholders”) and that, except as otherwise described in the IPO Prospectus, SPAC

may disburse monies from the Trust Account only: (a) to the Public Shareholders in the event they elect to redeem their SPAC shares in

connection with the consummation of SPAC’s initial business combination (as such term is used in the Prospectus) (the “Business

Combination”) or in connection with an extension of its deadline to consummate a Business Combination, (b) to the Public

Shareholders if SPAC fails to consummate a Business Combination within twenty-four (24) months after the closing of the IPO, subject to

extension by an amendment to SPAC’s organizational documents, (c) with respect to any interest earned on the amounts held in the

Trust Account, amounts necessary to pay for any franchise or income taxes or (d) to SPAC after or concurrently with the consummation of

a Business Combination. For and in consideration of SPAC entering into this Agreement and for other good and valuable consideration, the

receipt and sufficiency of which is hereby acknowledged, the Company hereby agrees on behalf of itself and its Affiliates that, notwithstanding

anything to the contrary in this Agreement, none of the Company nor any of its Affiliates do now or shall at any time hereafter have any

right, title, interest or claim of any kind in or to any monies in the Trust Account or distributions therefrom, or make any claim against

the Trust Account (including any distributions therefrom), regardless of whether such claim arises as a result of, in connection with

or relating in any way to, this Agreement or any proposed or actual business relationship between SPAC or any of its Representatives,

on the one hand, and the Company or any of its Representatives, on the other hand, or any other matter, and regardless of whether such

claim arises based on contract, tort, equity or any other theory of legal liability (any and all such claims are collectively referred

to herein as, the “Released Claims”). The Company, on behalf of itself and its Affiliates, hereby irrevocably

waives any Released Claims that any such Party or any of its Affiliates may have against the Trust Account (including any distributions

therefrom) now or in the future as a result of, or arising out of, any negotiations, contracts or agreements with SPAC or its Representatives

and will not seek recourse against the Trust Account (including any distributions therefrom) for any reason whatsoever (including for

an alleged breach of this Agreement or any other agreement with SPAC or its Affiliates). The Company agrees and acknowledges that such

irrevocable waiver is material to this Agreement and specifically relied upon by SPAC and its Affiliates to induce SPAC to enter into

this Agreement, and the Company further intends and understands such waiver to be valid, binding and enforceable against such Party and

each of its Affiliates under applicable Law. To the extent that the Company or any of its respective Affiliates commences any Action based

upon, in connection with, relating to or arising out of any matter relating to SPAC or its Representatives, which proceeding seeks, in

whole or in part, monetary relief against SPAC or its Representatives, the Company hereby acknowledges and agrees that its and its Affiliates’

sole remedy shall be against funds held outside of the Trust Account and that such claim shall not permit such Party or any of its Affiliates

(or any Person claiming on any of their behalves or in lieu of them) to have any claim against the Trust Account (including any distributions

therefrom) or any amounts contained therein. In the event that the Company or any of its respective Affiliates commences Action based

upon, in connection with, relating to or arising out of any matter relating to SPAC or its Representatives which proceeding seeks, in

whole or in part, relief against the Trust Account (including any distributions therefrom) or the Public Shareholders, whether in the

form of money damages or injunctive relief, SPAC and its Representatives, as applicable, shall be entitled to recover from the Company

and its Affiliates, as applicable, the associated legal fees and costs in connection with any such Action, in the event SPAC or its Representatives,

as applicable, prevails in such Action. This Section 9.1 shall survive termination of this Agreement for any reason and continue

indefinitely.

Article

MISCELLANEOUS

10.1 Notices.

All notices, consents, waivers and other communications hereunder shall be in writing and shall be deemed to have been duly given when

delivered (i) in person, (ii) by electronic means (including email), with affirmative confirmation of receipt, (iii) one Business Day

after being sent, if sent by reputable, nationally recognized overnight courier service or (iv) three (3) Business Days after being mailed,

if sent by registered or certified mail, pre-paid and return receipt requested, in each case to the applicable Party at the following

addresses (or at such other address for a Party as shall be specified by like notice):

If to SPAC at or prior to the Closing, to:

Copley

Acquisition Corp

Suite 4005-4006, 40/F, One Exchange Square

8 Connaught Place, Central, Hong Kong

Attn: [***]

Email:

[***]

with a copy (which will not constitute notice) to:

Winston Taylor LLP

800 Capitol St., Suite 2400

Houston, Texas 77002-2925

Attn: [***]

Telephone No.: [***]

Email: [***]

If to the Company or the Company Surviving Subsidiary, to:

Ignite Proteomics, LLC

15000 West 6th Avenue, Suite 400

Golen, Colorado 80401

Attn: [***]

Telephone No.: [***]

Email: [***]

with a copy (which will not constitute notice) to:

Meister Seelig & Schuster PLLC

125 Park Ave, 7th Floor

New York, New York 10017

Attn: [***]

Telephone No.: [***]

Email: [***]

If to Pubco after the Closing, to:

Ignite Proteomics Holdings, Inc.

15000 West 6th Avenue, Suite 400

Golen, Colorado 80401

Attn: [***]

Telephone No.: [***]

Email: [***]

with a copy (which will not constitute notice) to:

Meister Seelig & Schuster PLLC

125 Park Ave, 7th Floor

New York, New York 10017

Attn: [***]

Telephone No.: [***]

Email: [***]

10.2 Binding

Effect; Assignment. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the Parties

hereto and their respective successors and permitted assigns. This Agreement shall not be assigned by operation of Law or otherwise without

the prior written consent of SPAC, Pubco and the Company, and any assignment without such consent shall be null and void; provided

that no such assignment shall relieve the assigning Party of its obligations hereunder.

10.3 Third

Parties. Except for the rights of the D&O Indemnified Persons set forth in Section 6.18, which the Parties acknowledge

and agree are express third party beneficiaries of this Agreement, nothing contained in this Agreement or in any instrument or document

executed by any party in connection with the transactions contemplated hereby shall create any rights in, or be deemed to have been executed

for the benefit of, any Person that is not a Party hereto or thereto or a successor or permitted assign of such a Party.

10.4 Governing

Law; Jurisdiction. This Agreement shall be governed by, construed and enforced in accordance with the Laws of the State of Delaware

without regard to the conflict of laws principles thereof. All Actions arising out of or relating to this Agreement shall be heard and

determined exclusively in any state court located in Wilmington, Delaware or federal court located in the State of Delaware (or in any

appellate court thereof) (the “Specified Courts”). Each Party hereto hereby (a) submits to the exclusive

jurisdiction of any Specified Court for the purpose of any Action arising out of or relating to this Agreement brought by any Party hereto

and (b) irrevocably waives, and agrees not to assert by way of motion, defense or otherwise, in any such Action, any claim that it

is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution,

that the Action is brought in an inconvenient forum, that the venue of the Action is improper, or that this Agreement or the transactions

contemplated hereby may not be enforced in or by any Specified Court. Each Party agrees that a final judgment in any Action shall be conclusive

and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. Each Party irrevocably consents

to the service of the summons and complaint and any other process in any other Action relating to the transactions contemplated by this

Agreement, on behalf of itself, or its property, by personal delivery of copies of such process to such Party at the applicable address

set forth in Section 10.1. Nothing in this Section 10.4 shall affect the right of any Party to serve legal process in any other manner

permitted by Law.

10.5 WAIVER

OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL

BY JURY WITH RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS

CONTEMPLATED HEREBY. EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE,

THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND

THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS

IN THIS SECTION 10.5.

10.6 Specific

Performance. Each Party acknowledges that the rights of each Party to consummate the transactions contemplated hereby are unique,

recognizes and affirms that in the event of a breach of this Agreement by any Party, money damages may be inadequate and the non-breaching

Parties may have not adequate remedy at law, and agree that irreparable damage would occur in the event that any of the provisions of

this Agreement were not performed by an applicable Party in accordance with their specific terms or were otherwise breached. Accordingly,

each Party shall be entitled to seek an injunction or restraining order to prevent breaches of this Agreement and to seek to enforce specifically

the terms and provisions hereof, without the requirement to post any bond or other security or to prove that money damages would be inadequate,

this being in addition to any other right or remedy to which such Party may be entitled under this Agreement, at law or in equity.

10.7 Severability.

In case any provision in this Agreement shall be held invalid, illegal or unenforceable in a jurisdiction, such provision shall be modified

or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal and enforceable, and the validity,

legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby nor shall the validity,

legality or enforceability of such provision be affected thereby in any other jurisdiction. Upon such determination that any term or other

provision is invalid, illegal or incapable of being enforced, the Parties will substitute for any invalid, illegal or unenforceable provision

a suitable and equitable provision that carries out, so far as may be valid, legal and enforceable, the intent and purpose of such invalid,

illegal or unenforceable provision.

10.8 Amendment.

This Agreement may be amended, supplemented or modified only by execution of a written instrument signed by SPAC, the Company and Pubco.

10.9 Waiver.

SPAC on behalf of itself and its Affiliates and the Company on behalf of itself and its Affiliates, may in its sole discretion (i) extend

the time for the performance of any obligation or other act of any other non-Affiliated Party hereto, (ii) waive any inaccuracy in

the representations and warranties by such other non-Affiliated Party contained herein or in any document delivered pursuant hereto and

(iii) waive compliance by such other non-Affiliated Party with any covenant or condition contained herein. Any such extension or waiver

shall be valid only if set forth in an instrument in writing signed by the Party or Parties to be bound thereby (including by the SPAC

Representative or the Seller Representative in lieu of such Party to the extent provided in this Agreement). Notwithstanding the foregoing,

no failure or delay by a Party in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise

thereof preclude any other or further exercise of any other right hereunder. Notwithstanding the foregoing, any waiver of any provision

of this Agreement after the Closing shall also require the prior written consent of the SPAC Representative and the Seller Representative.

10.10 Entire

Agreement. This Agreement and the documents or instruments referred to herein, including any exhibits and schedules attached hereto,

which exhibits and schedules are incorporated herein by reference, together with the Ancillary Documents, embody the entire agreement

and understanding of the Parties hereto in respect of the subject matter contained herein. There are no restrictions, promises, representations,

warranties, covenants or undertakings, other than those expressly set forth or referred to herein or the documents or instruments referred

to herein, which collectively supersede all prior agreements and the understandings among the Parties with respect to the subject matter

contained herein.

10.11 Interpretation.

The table of contents and the Article and Section headings contained in this Agreement are solely for the purpose of reference, are not

part of the agreement of the Parties and shall not in any way affect the meaning or interpretation of this Agreement. In this Agreement,

unless the context otherwise requires: (a) any pronoun used in this Agreement shall include the corresponding masculine, feminine or neuter

forms, and words in the singular, including any defined terms, include the plural and vice versa; (b) reference to any Person includes

such Person’s successors and assigns but, if applicable, only if such successors and assigns are permitted by this Agreement, and

reference to a Person in a particular capacity excludes such Person in any other capacity; (c) any accounting term used and not otherwise

defined in this Agreement or any Ancillary Document has the meaning assigned to such term in accordance with GAAP; (d) “including”

(and with correlative meaning “include”) means including without limiting the generality of any description preceding or succeeding

such term and shall be deemed in each case to be followed by the words “without limitation”; (e) the words “herein,”

“hereto,” and “hereby” and other words of similar import in this Agreement shall be deemed in each case to refer

to this Agreement as a whole and not to any particular Section or other subdivision of this Agreement; (f) the word “if” and

other words of similar import when used herein shall be deemed in each case to be followed by the phrase “and only if”; (g)

the term “or” means “and/or”; (h) any reference to the term “ordinary course” or “ordinary course

of business” shall be deemed in each case to be followed by the words “consistent with past practice”; (i) any agreement,

instrument, insurance policy, Law or Order defined or referred to herein or in any agreement or instrument that is referred to herein

means such agreement, instrument, insurance policy, Law or Order as from time to time amended, modified or supplemented, including (in

the case of agreements or instruments) by waiver or consent and (in the case of statutes, regulations, rules or orders) by succession

of comparable successor statutes, regulations, rules or orders and references to all attachments thereto and instruments incorporated

therein; (j) except as otherwise indicated, all references in this Agreement to the words “Section,” “Article”,

“Schedule” and “Exhibit” are intended to refer to Sections, Articles, Schedules and Exhibits to this Agreement;

and (k) the term “Dollars” or “$” means United States dollars. Any reference in this Agreement to a Person’s

directors shall include any member of such Person’s governing body and any reference in this Agreement to a Person’s officers

shall include any Person filling a substantially similar position for such Person. Any reference in this Agreement or any Ancillary Document

to a Person’s shareholders or stockholders shall include any applicable owners of the equity interests of such Person, in whatever

form, including with respect to SPAC its shareholders (prior to the Conversion) under the Companies Act or its stockholders under the

DGCL or its Organizational Documents. The Parties have participated jointly in the negotiation and drafting of this Agreement. Consequently,

in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the

Parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any

provision of this Agreement. To the extent that any Contract, document, certificate or instrument is represented and warranted to by the

Company to be given, delivered, provided or made available by the Company, in order for such Contract, document, certificate or instrument

to have been deemed to have been given, delivered, provided and made available to SPAC or its Representatives, such Contract, document,

certificate or instrument shall have been posted to the electronic data site maintained on behalf of the Company and made available to

SPAC and its Representatives and SPAC and its Representatives have been given access to the electronic folders containing such information.

10.12 Counterparts.

This Agreement and each Ancillary Document may be executed and delivered (including by facsimile, pdf or other electronic transmission)

in one or more counterparts, and by the different Parties hereto in separate counterparts, each of which when executed shall be deemed

to be an original but all of which taken together shall constitute one and the same agreement.

10.13 SPAC

Representative.

(a) SPAC,

on behalf of itself and its Subsidiaries, successors and assigns, by execution and delivery of this Agreement, hereby irrevocably appoints

Chibo Tang, in his capacity as SPAC Representative, as each such Person’s agent, attorney-in-fact and representative, with full

power of substitution to act in the name, place and stead of such Person, to act on behalf of such Person from and after the Closing in

connection with: (i) terminating, amending or waiving on behalf of such Person any provision of this Agreement or any Ancillary Documents

to which SPAC Representative is a party or otherwise has rights in such capacity (together with this Agreement, the “SPAC

Representative Documents”); (ii) signing on behalf of such Person any releases or other documents with respect to any dispute

or remedy arising under any SPAC Representative Documents; (iii) employing and obtaining the advice of legal counsel, accountants and

other professional advisors as SPAC Representative, in its reasonable discretion, deems necessary or advisable in the performance of its

duties as SPAC Representative and to rely on their advice and counsel; (iv) incurring and paying reasonable out-of-pocket costs and expenses,

including fees of brokers, attorneys and accountants incurred pursuant to the transactions contemplated hereby, and any other out-of-pocket

fees and expenses allocable or in any way relating to such transaction; and (v) otherwise enforcing the rights and obligations of any

such Persons under any SPAC Representative Documents, including giving and receiving all notices and communications hereunder or thereunder

on behalf of such Person; provided, that the Parties acknowledge that SPAC Representative is specifically authorized and directed to act

on behalf of, and for the benefit of, the holders of SPAC Securities (other than the Sellers immediately prior to the Effective Time and

their respective successors and assigns). All decisions and actions by SPAC Representative, including any agreement between SPAC Representative

and the Seller Representative, shall be binding upon SPAC and its Subsidiaries, successors and assigns, and neither they nor any other

Party shall have the right to object, dissent, protest or otherwise contest the same. The provisions of this Section 10.13 are

irrevocable and coupled with an interest. The SPAC Representative hereby accepts its appointment and authorization as SPAC Representative

under this Agreement.

(b) The

SPAC Representative shall not be liable for any act done or omitted under any SPAC Representative Document as SPAC Representative while

acting in good faith and without willful misconduct or gross negligence, and any act done or omitted pursuant to the advice of counsel

shall be conclusive evidence of such good faith. SPAC shall indemnify, defend and hold harmless SPAC Representative from and against any

and all Losses incurred without gross negligence, bad faith or willful misconduct on the part of SPAC Representative (in its capacity

as such) and arising out of or in connection with the acceptance or administration of SPAC Representative’s duties under any SPAC

Representative Document, including the reasonable fees and expenses of any legal counsel retained by SPAC Representative. In no event

shall SPAC Representative in such capacity be liable under or in connection with any SPAC Representative Document for any indirect, punitive,

special or consequential damages. The SPAC Representative shall be fully protected in relying upon any written notice, demand, certificate

or document that it in good faith believes to be genuine, including facsimiles or copies thereof, and no Person shall have any Liability

for relying on SPAC Representative in the foregoing manner. In connection with the performance of its rights and obligations hereunder,

SPAC Representative shall have the right at any time and from time to time to select and engage, at the cost and expense of SPAC, attorneys,

accountants, investment bankers, advisors, consultants and clerical personnel and obtain such other professional and expert assistance,

maintain such records and incur other out-of-pocket expenses, as SPAC Representative may deem necessary or appropriate from time to time.

All of the indemnities, immunities, releases and powers granted to SPAC Representative under this Section 10.13 shall survive the

Closing and continue indefinitely.

Person serving as SPAC Representative may resign upon ten (10) days’ prior written notice to Pubco, SPAC and the Seller Representative,

provided, that SPAC Representative appoints in writing a replacement SPAC Representative. Each successor SPAC Representative shall have

all of the power, authority, rights and privileges conferred by this Agreement upon the original SPAC Representative, and the term “SPAC

Representative” as used herein shall be deemed to include any such successor SPAC Representatives.

10.14 Seller

Representative.

(a) Each

Seller, by approval of the Transactions and this Agreement, on behalf of itself and its successors and assigns, irrevocably constitutes

and appoints Jeffrey M. Busch, in his capacity as the Seller Representative, as the true and lawful agent and attorney-in-fact of such

Persons with full powers of substitution to act in the name, place and stead thereof with respect to the performance on behalf of such

Person under the terms and provisions of this Agreement and the Ancillary Documents to which the Seller Representative is a party or otherwise

has rights in such capacity (together with this Agreement, the “Seller Representative Documents”), as the same

may be from time to time amended, and to do or refrain from doing all such further acts and things, and to execute all such documents

on behalf of such Person, if any, as the Seller Representative will deem necessary or appropriate in connection with any of the transactions

contemplated under the Seller Representative Documents, including: (i) terminating, amending or waiving on behalf of such Person any provision

of any Seller Representative Document (provided, that any such action, if material to the rights and obligations of the Sellers in the

reasonable judgment of the Seller Representative, will be taken in the same manner with respect to all Sellers unless otherwise agreed

by each Seller who is subject to any disparate treatment of a potentially material and adverse nature); (ii) signing on behalf of such

Person any releases or other documents with respect to any dispute or remedy arising under any Seller Representative Document; (iii) employing

and obtaining the advice of legal counsel, accountants and other professional advisors as the Seller Representative, in its reasonable

discretion, deems necessary or advisable in the performance of its duties as the Seller Representative and to rely on their advice and

counsel; (iv) incurring and paying reasonable costs and expenses, including fees of brokers, attorneys and accountants incurred pursuant

to the transactions contemplated hereby, and any other reasonable fees and expenses allocable or in any way relating to such transaction,

whether incurred prior or subsequent to Closing; (v) receiving all or any portion of the consideration provided to the Sellers under this

Agreement and to distribute the same to the Sellers in accordance with their Percentage Share; and (vi) otherwise enforcing the rights

and obligations of any such Persons under any Seller Representative Document, including giving and receiving all notices and communications

hereunder or thereunder on behalf of such Person. All decisions and actions by the Seller Representative, including any agreement between

the Seller Representative and SPAC Representative, shall be binding upon each Seller and their respective successors and assigns, and

neither they nor any other Party shall have the right to object, dissent, protest or otherwise contest the same. The provisions of this

Section 10.14 are irrevocable and coupled with an interest. The Seller Representative hereby accepts its appointment and authorization

as the Seller Representative under this Agreement.

(b) Any

other Person, including SPAC Representative, Pubco, SPAC and the Company may conclusively and absolutely rely, without inquiry, upon any

actions of the Seller Representative as the acts of the Sellers under any Seller Representative Documents. The SPAC Representative, Pubco,

SPAC and the Company shall be entitled to rely conclusively on the instructions and decisions of the Seller Representative as to (i) the

settlement of any disputes with respect to Section 1.8, (ii) any payment instructions provided by the Seller Representative or

(iii) any other actions required or permitted to be taken by the Seller Representative hereunder, and no Seller shall have any cause of

action against SPAC Representative, SPAC, the Company for any action taken by any of them in reliance upon the instructions or decisions

of the Seller Representative. None of SPAC Representative, Pubco, SPAC, or the Company shall have any Liability to any Seller for any

allocation or distribution among the Sellers by the Seller Representative of payments made to or at the direction of the Seller Representative.

All notices or other communications required to be made or delivered to a Seller under any Seller Representative Document shall be made

to the Seller Representative for the benefit of such Seller, and any notices so made shall discharge in full all notice requirements of

the other parties hereto or thereto to such Seller with respect thereto. All notices or other communications required to be made or delivered

by a Seller shall be made by the Seller Representative (except for a notice under Section 10.1 of the replacement of the Seller

Representative).

Seller Representative will act for the Sellers on all of the matters set forth in this Agreement in the manner the Seller Representative

believes to be in the best interest of the Sellers, but the Seller Representative will not be responsible to the Sellers for any Losses

that any Seller may suffer by reason of the performance by the Seller Representative of the Seller Representative’s duties under

this Agreement, other than Losses arising from the bad faith, gross negligence or willful misconduct by the Seller Representative in the

performance of its duties under this Agreement. From and after the Closing, the Sellers shall jointly and severally indemnify, defend

and hold the Seller Representative harmless from and against any and all Losses reasonably incurred without gross negligence, bad faith

or willful misconduct on the part of the Seller Representative (in its capacity as such) and arising out of or in connection with the

acceptance or administration of the Seller Representative’s duties under any Seller Representative Document, including the reasonable

fees and expenses of any legal counsel retained by the Seller Representative. In no event shall the Seller Representative in such capacity

be liable hereunder or in connection herewith for any indirect, punitive, special or consequential damages. The Seller Representative

shall not be liable for any act done or omitted under any Seller Representative Document as the Seller Representative while acting in

good faith and without willful misconduct or gross negligence, and any act done or omitted pursuant to the advice of counsel shall be

conclusive evidence of such good faith. The Seller Representative shall be fully protected in relying upon any written notice, demand,

certificate or document that it in good faith believes to be genuine, including facsimiles or copies thereof, and no Person shall have

any Liability for relying on the Seller Representative in the foregoing manner. In connection with the performance of its rights and obligations

hereunder, the Seller Representative shall have the right at any time and from time to time to select and engage, at the reasonable cost

and expense of the Sellers, attorneys, accountants, investment bankers, advisors, consultants and clerical personnel and obtain such other

professional and expert assistance, maintain such records and incur other reasonable out-of-pocket expenses, as the Seller Representative

may reasonably deem necessary or appropriate from time to time. All of the indemnities, immunities, releases and powers granted to the

Seller Representative under this Section 10.14 shall survive the Closing and continue indefinitely.

(d) If

the Seller Representative shall die, become disabled, dissolve, resign or otherwise be unable or unwilling to fulfill its responsibilities

as representative and agent of Sellers, then the Sellers shall, within ten (10) days after such death, disability, dissolution, resignation

or other event, appoint a successor Seller Representative (by vote or written consent of the Sellers holding in the aggregate a pro rata

share in excess of fifty percent (50%)), and promptly thereafter (but in any event within two (2) Business Days after such appointment)

notify SPAC Representative, Pubco and SPAC in writing of the identity of such successor. Any such successor so appointed shall become

the “Seller Representative” for purposes of this Agreement.

10.15 Legal

Representation. The Parties agree that, (a) notwithstanding the fact that Winston may have, prior to Closing, jointly represented

SPAC and/or the Sponsor in connection with this Agreement, the Ancillary Documents and the transactions contemplated hereby and thereby,

and has also represented SPAC and/or its Affiliates in connection with matters other than the transaction that is the subject of this

Agreement, Winston will be permitted in the future, after Closing, to represent one or more of the Sponsor or its respective Affiliates

in connection with matters in which such Persons are adverse to Pubco, SPAC or any of their respective Affiliates, including any disputes

arising out of, or related to, this Agreement. The Company, who is or has the right to be represented by independent counsel in connection

with the transactions contemplated by this Agreement, hereby agrees, in advance, to waive (and to cause their Affiliates to waive) any

actual or potential conflict of interest that may hereafter arise in connection with Winston’s future representation of one or more

of the Sponsor or its Affiliates in which the interests of such Person are adverse to the interests of Pubco, SPAC, the Company or any

of their respective Affiliates, including any matters that arise out of this Agreement or that are substantially related to this Agreement

or to any prior representation by Winston of SPAC or any of its Affiliates. The Parties acknowledge and agree that, for the purposes of

the attorney-client privilege, the Sponsor shall be deemed a client of Winston with respect to the negotiation, execution and performance

of this Agreement and the Ancillary Documents. All such communications shall remain privileged after the Closing and the privilege and

the expectation of client confidence relating thereto shall belong solely to the Sponsor, shall be controlled by the Sponsor and shall

not pass to or be claimed by Pubco or the Surviving Subsidiaries; provided, further, that nothing contained herein shall be deemed

to be a waiver by SPAC or any of its Affiliates (including, after the Effective Time, Pubco, the Surviving Subsidiaries, and their respective

Affiliates) of any applicable privileges or protections that can or may be asserted to prevent disclosure of any such communications to

any third party; and (b) notwithstanding the fact that Meister Seelig & Schuster PLLC (“MSS”) may have, prior to Closing,

jointly represented the Company and Sellers in connection with this Agreement, the Ancillary Documents and the transactions contemplated

hereby and thereby, and has also represented the Company and Sellers and/or their respective Affiliates in connection with matters other

than the transaction that is the subject of this Agreement, MSS will be permitted in the future, after Closing, to represent one or more

of the Company, Sellers or Pubco or their respective Affiliates in connection with matters in which such Persons are adverse to SPAC or

any of its Affiliates, including any disputes arising out of, or related to, this Agreement. SPAC, who is or has the right to be represented

by independent counsel in connection with the transactions contemplated by this Agreement, hereby agrees, in advance, to waive (and to

cause their Affiliates to waive) any actual or potential conflict of interest that may hereafter arise in connection with MSS’s

future representation of one or more of Pubco, the Company or Sellers or their respective Affiliates in which the interests of such Person

are adverse to the interests of SPAC or any of its Affiliates, including any matters that arise out of this Agreement or that are substantially

related to this Agreement or to any prior representation by MSS of the Company or Sellers or any of their respective Affiliates. The Parties

acknowledge and agree that, for the purposes of the attorney-client privilege, the Company and Sellers shall be deemed a client of MSS

with respect to the negotiation, execution and performance of this Agreement and the Ancillary Documents. All such communications shall

remain privileged after the Closing and the privilege and the expectation of client confidence relating thereto shall belong solely to

the Company and Sellers, as applicable, shall be controlled by the Company and Sellers, as applicable, and shall not pass to or be claimed

by SPAC or Pubco; provided, further, that nothing contained herein shall be deemed to be a waiver by SPAC or any of its Affiliates (including,

after the Effective Time, Pubco, the Surviving Subsidiaries, Sellers and their respective Affiliates) of any applicable privileges or

protections that can or may be asserted to prevent disclosure of any such communications to any third party.

Article

DEFINITIONS

11.1 Certain

Definitions. For purposes of this Agreement, the following capitalized terms have the following meanings:

“Accounting Principles”

means in accordance with GAAP as in effect at the date of the financial statement to which it refers or if there is no such financial

statement, then as of the Closing Date, using and applying the same accounting principles, practices, procedures, policies and methods

(with consistent classifications, judgments, elections, inclusions, exclusions and valuation and estimation methodologies) used and applied

by the Target Companies in the preparation of the Company Financials.

“Action”

means any notice of noncompliance or violation, or any claim, demand, charge, action, suit, litigation, audit, settlement, complaint,

stipulation, assessment or arbitration, or any request (including any request for information), inquiry, hearing, proceeding or investigation,

by or before any Governmental Authority.

“Affiliate”

means, with respect to any Person, any other Person directly or indirectly Controlling, Controlled by, or under common Control with such

Person. For the avoidance of doubt, Sponsor shall be deemed to be an Affiliate of SPAC prior to the Closing.

“Ancillary Documents”

means each agreement, instrument or document attached hereto as an Exhibit, and the other agreements, certificates and instruments to

be executed or delivered by any of the Parties hereto in connection with or pursuant to this Agreement.

“Benefit Plans”

of any Person means any and all deferred compensation, executive compensation, incentive compensation, phantom equity, option, stock appreciation

right, restricted stock, restricted stock unit, equity purchase or other equity-based compensation plan, employment or consulting, severance,

change in control, retention or termination pay, employee or consultant loan program, vacation, sick, or other bonus, deferred compensation

plan or practice, hospitalization or other medical, life, death, disability or other insurance, fringe benefit, Section 125 cafeteria

plan, welfare, supplemental unemployment benefits, profit sharing, pension, or retirement plan, program, agreement, commitment or arrangement,

Foreign Pension Plan, and each other employee benefit plan, program, agreement or arrangement, including each “employee benefit

plan” as such term is defined under Section 3(3) of ERISA (including any similar plan subject to laws of a jurisdiction outside

of the United States), maintained or contributed to or required to be contributed to by a Person for the benefit of any employee or former

employee of such Person, or with respect to which such Person has any Liability, whether direct or indirect, actual or contingent, whether

formal or informal, and whether legally binding or not.

“Business Day”

means any day other than a Saturday, Sunday or a legal holiday on which commercial banking institutions in New York, New York are authorized

to close for business, excluding as a result of “stay at home”, “shelter-in-place”, “non-essential employee”

or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority

so long as the electronic funds transfer systems, including for wire transfers, of commercially banking institutions in New York, New

York are generally open for use by customers on such day.

“Cayman Conversion

Documents” means the documents required to be filed with the Cayman Registrar in order to give effect to the Conversion

pursuant to SPAC Organizational Documents and the Act.

“Code”

means the Internal Revenue Code of 1986, as amended, and any successor statute thereto, as amended. Reference to a specific section of

the Code shall include such section and any valid treasury regulation promulgated thereunder.

“Company Confidential

Information” means all confidential or proprietary documents and information concerning the Target Companies or any of their

respective Representatives, furnished in connection with this Agreement or the transactions contemplated hereby; provided, however,

that Company Confidential Information shall not include any information which, (i) at the time of disclosure by SPAC or its Representatives,

is generally available publicly and was not disclosed in breach of this Agreement or (ii) at the time of the disclosure by the Company

or its Representatives to SPAC or its Representatives was previously known by such receiving party without violation of Law or any confidentiality

obligation by the Person receiving such Company Confidential Information.

“Company Convertible

Securities” means, collectively, any options, warrants or rights to subscribe for or purchase any equity securities of the

Company or securities convertible into or exchangeable for, or that otherwise confer on the holder any right to acquire any equity securities

of the Company (but excluding any Company Interests).

“Company Interests”

means the issued and outstanding membership interests of the Company.

“Company Operating

Agreement” means that certain Limited Liability Company Agreement of the Company, dated May 29, 2024.

“Company Privacy

and Data Security Policies” means all of the Target Companies’ past or present, internal or public-facing policies, notices,

and statements concerning the privacy, security, or Processing of Personal Information, including written information security policies.

“Consent”

means any consent, approval, waiver, authorization or Permit of, or notice to or declaration or filing with any Governmental Authority

or any other Person.

“Contracts”

means all contracts, agreements, binding arrangements, bonds, notes, indentures, mortgages, debt instruments, purchase order, licenses

(and all other contracts, agreements or binding arrangements concerning Intellectual Property), franchises, leases and other instruments

or obligations of any kind, written or oral (including any amendments and other modifications thereto).

“Control”

of a Person means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies

of such Person, whether through the ownership of voting securities, by contract, or otherwise. “Controlled”, “Controlling”

and “under common Control with” have correlative meanings. Without limiting the foregoing a Person (the “Controlled

Person”) shall be deemed Controlled by (a) any other Person (i) owning beneficially, as meant in Rule 13d-3 under the Exchange

Act, securities entitling such Person to cast ten percent (10%) or more of the votes for election of directors or equivalent governing

authority of the Controlled Person or (ii) entitled to be allocated or receive ten percent (10%) or more of the profits, losses, or distributions

of the Controlled Person; (b) an officer, director, general partner, partner (other than a limited partner), manager, or member (other

than a member having no management authority that is not a Person described in clause (a) above) of the Controlled Person; or (c) a spouse,

parent, lineal descendant, sibling, aunt, uncle, niece, nephew, mother-in-law, father-in-law, sister-in-law, or brother-in-law of an Affiliate

of the Controlled Person or a trust for the benefit of an Affiliate of the Controlled Person or of which an Affiliate of the Controlled

Person is a trustee.

“Copyrights”

means any works of authorship, including but not limited to mask works, textual works, visual, pictorial, or graphical works, or compilations

of data or other information and all copyrights therein, including all renewals and extensions, copyright registrations and applications

for registration and renewal, and non-registered copyrights.

“Delaware Conversion

Documents” means the documents required to be filed with the Delaware Secretary of State to give effect to the Conversion

pursuant to the DGCL.

“Environmental Law”

means any Law in any way relating to (a) the protection of human health and safety, (b) the protection, preservation or restoration of

the environment and natural resources (including air, water vapor, surface water, groundwater, drinking water supply, surface land, subsurface

land, plant and animal life or any other natural resource), or (c) the exposure to, or the use, storage, recycling, treatment, generation,

transportation, processing, handling, labeling, production, release or disposal of Hazardous Materials, including the Comprehensive Environmental

Response, Compensation and Liability Act, 42 USC. Section 9601 et. seq., the Resource Conservation and Recovery Act, 42 USC. Section 6901

et. seq., the Toxic Substances Control Act, 15 USC. Section 2601 et. seq., the Federal Water Pollution Control Act, 33 USC. Section 1151

et seq., the Clean Air Act, 42 USC. Section 7401 et seq., the Federal Insecticide, Fungicide and Rodenticide Act, 7 USC. Section 111 et.

seq., Occupational Safety and Health Act, 29 USC. Section 651 et. seq. (to the extent it relates to exposure to Hazardous Substances),

the Asbestos Hazard Emergency Response Act, 15 USC. Section 2601 et. seq., the Safe Drinking Water Act, 42 USC. Section 300f et. seq.,

the Oil Pollution Act of 1990 and analogous state acts.

“Environmental Liabilities”

means, in respect of any Person, all Liabilities, obligations, responsibilities, Remedial Actions, Losses, damages, costs, and expenses

(including all reasonable fees, disbursements, and expenses of counsel, experts, and consultants and costs of investigation and feasibility

studies), fines, penalties, sanctions, and interest incurred as a result of any claim or demand by any other Person or in response to

any violation of Environmental Law, whether known or unknown, accrued or contingent, whether based in contract, tort, implied or express

warranty, strict liability, criminal or civil statute, to the extent based upon, related to, or arising under or pursuant to any Environmental

Law, Environmental Permit, Order, or Contract with any Governmental Authority or other Person, that relates to any environmental, health

or safety condition, violation of Environmental Law, or a Release or threatened Release of Hazardous Materials.

“ERISA”

means the U.S. Employee Retirement Income Security Act of 1974, as amended.

“ERISA Affiliate”

means each person (as defined in Section 3(9) of ERISA) which together with any Target Company or any of its Subsidiaries would be deemed

to be a “single employer” within the meaning of Section 414(b), (c), (m) or (o) of the Code.

“Exchange Act”

means the U.S. Securities Exchange Act of 1934, as amended.

“Expenses”

shall mean all fees, costs and expenses, including all out-of-pocket expenses (including all such fees, costs and expenses with respect

to counsel, accountants, investment bankers, financial advisors, financing sources, experts and consultants to a Party hereto or any of

its Affiliates, exchange listings, SEC filings, compliance with the Hart Scott Rodino Antitrust Improvements Act of 1976 and obtaining

the D&O Tail Insurance), incurred by a Party or on its behalf in connection with or related to the authorization, preparation, negotiation,

execution or performance of this Agreement or any Ancillary Document related hereto and all other matters related to the consummation

of the transactions contemplated hereby and thereby. With respect to SPAC, Expenses shall include (i) any and all fees, costs and expenses

incurred by or on behalf of SPAC or the Sponsor, prior to or after the date hereof, in connection with SPAC’s efforts to identify

and evaluate potential business combination targets, (ii) any and all deferred expenses (including fees or commissions payable to the

underwriters and any legal fees) of the IPO upon consummation of a Business Combination, and (iii) any costs and expenses necessary for

an Extension (the expenses described in clause (iii), “Extension Expenses”). With respect to the Company, Expenses

shall include the Sponsor Payment.

“Federal Health

Care Program” has the meaning set forth in 42 U.S.C. §1320a-7b(f).

“Foreign Pension

Plan” means any plan, fund (including, without limitation, any superannuation fund) or other similar program (other than

social security or social insurance) established or maintained outside of the United States by any Target Company or any one or more of

its Affiliates primarily for the benefit of employees of a Target Company or one or more of its Affiliates residing outside the United

States, which plan, fund or other program provides, or results in, retirement income, a deferral of income in contemplation of retirement

or payments to be made upon termination of employment, and which is not subject to ERISA or the Code.

“Founder

Registration Rights Agreement” means the Registration Rights Agreement, dated as of April 30, 2025, by and among SPAC,

Sponsor and the other “Holders” named therein.

“Fraud Claim”

means any claim based in whole or in part upon fraud.

“GAAP”

means generally accepted accounting principles as in effect in the United States of America.

“Governmental Authority”

means any federal, state, local, foreign or other governmental, quasi-governmental or administrative body, instrumentality, department

or agency or any court, tribunal, administrative hearing body, arbitration panel, commission, or other similar dispute-resolving panel

or body.

“GMRF Agreement”

means that certain Assignment and Assumption of License and Consent of licensor, dated as of March 5, 2026, by and among IMAC Holdings,

Inc., a Delaware corporation, the Company, and George Mason Research Foundation, Inc.

“Hazardous Material”

means any waste, gas, liquid or other substance or material that is defined, listed or designated as a “hazardous substance”,

“pollutant”, “contaminant”, “hazardous waste”, “regulated substance”, “hazardous

chemical”, or “toxic chemical” (or by any similar term) under any Environmental Law, or any other material regulated,

or that could result in the imposition of Liability or responsibility, under any Environmental Law, including petroleum and its by-products,

asbestos, polychlorinated biphenyls, radon, mold, and urea formaldehyde insulation.

“Healthcare Laws”

means all Laws and Orders relating to health care providers and suppliers’ and health care facilities’ participation in Federal

Health Care Programs; any and all applicable policy guidance and manuals pertaining to or issued by Third-Party Payors concerning participation

in, and billing, coverage and reimbursement requirements for, Third-Party Payors; institutional and professional licensure required for

the provision of health care services, the practice of medicine and any other learned professional (including via telehealth or telemedicine);

institutional and professional licensure; pharmacology and the securing, administering and dispensing of drugs, devices, or controlled

substances; medical documentation and physician orders; medical record retention; unprofessional conduct, corporate practice of medicine

prohibitions or restrictions, fee-splitting, referrals, patient brokering, kickbacks; alternative payment arrangements and risk-bearing

organization requirements; billing and submission of false or fraudulent claims and submission of risk adjustment data (as defined in

42 C.F.R. § 422.310(a)); claims processing and submission, billing, coding, and reimbursement; quality, safety, medical necessity,

medical privacy and security, patient confidentiality and informed consent; the hiring of employees or acquisition of services or supplies

from Persons excluded from participation in Federal Health Care Programs; the provision of telemedicine services, and remote or electronic

prescribing; standards of care, quality assurance, risk management, utilization review, peer review, mandated reporting of incidents,

occurrences, diseases and events; advertising or marketing of health care services; and any other applicable Laws and Orders, including

the following: (a) Laws relating to participation in or claims submitted to Medicare, Medicaid, CHIP, TRICARE (10 U.S.C. § 1071,

et seq.), and any other Third-Party Payor Programs, (b) the civil False Claims Act (31 U.S.C. § 3729, et seq.), the Civil Monetary

Penalties Law (42 U.S.C. § 1320a-7a), the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)), the Exclusion Law (42 U.S.C.

§ 1320a-7), federal and state anti-kickback statutes (including 42 U.S.C. § 1320a-7b), federal and state referral laws (including

42 U.S.C. §1395nn), criminal false claims statutes (e.g. 18 U.S.C. §§ 287 and 1001), the False Statements Relating to Health

Care Matters Act (18 U.S.C. § 1035), the Health Care Fraud Act (18 U.S.C. § 1347), the Program Fraud Civil Remedies Act of 1986

(31 U.S.C. §3801, et seq.), the Laws regarding Exclusion and Civil Monetary Penalties (42 U.S.C. §§ 1320a-7, 1320a-7a and

1320a-7b), the Beneficiary Inducement Statute (42 U.S.C. §1320a-7a(a)(5)), (c) the Patient Protection and Affordable Care Act (Pub.

L. No. 111-148) and the Health Care and Education Reconciliation Act of 2010 (Pub. L. No. 111-152) and the regulations promulgated thereunder,

(d) Laws governing the licensure, permitting, certification, accreditation, registration or regulation of healthcare providers, professionals,

facilities, services, or equipment, (e) any Laws for business corporations or professional corporations or associations that provide medical

services or practice medicine and other health care professions, including prohibitions on the corporate practice of medicine and anticompetitive

practices, (f) the Clinical Laboratory Improvement Act (42 U.S.C. § 263a, et seq.), (g) the Medicare Prescription Drug, Improvement

and Modernization Act of 2003 (P.L. 108-173, 117 Stat. 2066), (h) the Food, Drug and Cosmetic Act of 1938 (21 U.S.C. § 301, et seq.),

(i) the Prescription Drug Marketing Act of 1987 (P.L. 100-293, 102 Stat. 95), the Public Health Service Act (42 U.S.C. § 210 et seq.);

the Controlled Substances Act (21 U.S.C. § 801, et seq.) and the regulations promulgated pursuant to such statutes.

“Indebtedness”

of any Person means, without duplication, (a) all indebtedness of such Person for borrowed money (including the outstanding principal

and accrued but unpaid interest), (b) all obligations for the deferred purchase price of property or services (other than trade payables

incurred in the ordinary course of business), (c) any other indebtedness of such Person that is evidenced by a note, bond, debenture,

credit agreement or similar instrument, (d) all obligations of such Person under leases that should be classified as capital leases in

accordance with GAAP, (e) all obligations of such Person for the reimbursement of any obligor on any line or letter of credit, banker’s

acceptance, guarantee or similar credit transaction, in each case, that has been drawn or claimed against, (f) all obligations of such

Person in respect of acceptances issued or created, (g) all interest rate and currency swaps, caps, collars and similar agreements or

hedging devices under which payments are obligated to be made by such Person, whether periodically or upon the happening of a contingency,

(h) all obligations secured by an Lien on any property of such Person, (i) any premiums, prepayment fees or other penalties, fees, costs

or expenses associated with payment of any Indebtedness of such Person and (j) all obligation described in clauses (a) through (i) above

of any other Person which is directly or indirectly guaranteed by such Person or which such Person has agreed (contingently or otherwise)

to purchase or otherwise acquire or in respect of which it has otherwise assured a creditor against loss.

“Insider

Letter Agreement” means that certain letter agreement, dated as of April 30, 2025, by and among SPAC,

its officers and directors and the Sponsor.

“Internet Assets”

means any and all domain name registrations, web sites and web addresses and related rights, items and documentation related thereto,

and applications for registration therefor.

“IPO”

means the initial public offering of SPAC Public Units (and any successor equity thereto) pursuant to the IPO Prospectus.

“IPO Prospectus”

means the final prospectus of SPAC, dated as of April 30, 2025, and filed with the SEC on May 1, 2025 (File No. 333-283972).

“IPO Underwriter”

means Clear Street LLC.

“IRS”

means the U.S. Internal Revenue Service (or any successor Governmental Authority).

“Knowledge”

means, with respect to (i) the Company, the actual knowledge of the executive officers, managers or directors of any Target Company, after

reasonable inquiry consistent with their respective job duties and functions or (ii) any other Party, (A) if an entity, the actual knowledge

of its directors and executive officers, after reasonable inquiry consistent with their respective job duties and functions, or (B) if

a natural person, the actual knowledge of such Party after reasonable inquiry consistent with their respective job duties and functions.

“Law”

means any federal, state, local, municipal, foreign or other law, statute, legislation, principle of common law, ordinance, code, edict,

decree, proclamation, treaty, convention, rule, regulation, directive, requirement, writ, injunction, settlement, Order or Consent that

is or has been issued, enacted, adopted, passed, approved, promulgated, made, implemented or otherwise put into effect by or under the

authority of any Governmental Authority.

“Liabilities”

means any and all liabilities, Indebtedness, Actions or obligations of any nature (whether absolute, accrued, contingent or otherwise,

whether known or unknown, whether direct or indirect, whether matured or unmatured, whether due or to become due and whether or not required

to be recorded or reflected on a balance sheet under GAAP or other applicable accounting standards), including Tax liabilities due or

to become due.

“Lien”

means any mortgage, pledge, security interest, attachment, right of first refusal, option, proxy, voting trust, encumbrance, lien or charge

of any kind (including any conditional sale or other title retention agreement or lease in the nature thereof), restriction (whether on

voting, sale, transfer, disposition or otherwise), any subordination arrangement in favor of another Person, or any filing or agreement

to file a financing statement as debtor under the Uniform Commercial Code or any similar Law.

“Loss”

means any and all losses, obligations, penalties, amounts paid in settlement, damages (including consequential damages), costs and expenses

(including reasonable expenses of investigation, court costs and attorneys’ fees and expenses), diminution in value, Taxes, Liens

and interest, in each case arising out of or related to any Action, Order or other Liability.

“Material Adverse

Effect” means, with respect to any specified Person, any fact, event, occurrence, change or effect that has had, or would

reasonably be expected to have, individually or in the aggregate, a material adverse effect upon (a) the business, assets, Liabilities,

results of operations, prospects or condition (financial or otherwise) of such Person and its Subsidiaries, taken as a whole, or (b) the

ability of such Person or any of its Subsidiaries on a timely basis to consummate the transactions contemplated by this Agreement or the

Ancillary Documents to which it is a party or bound or to perform its obligations hereunder or thereunder; provided, however, that

for purposes of clause (a) above, any changes or effects directly or indirectly attributable to, resulting from, relating to or arising

out of the following (by themselves or when aggregated with any other, changes or effects) shall not be deemed to be, constitute, or be

taken into account when determining whether there has or may, would or could have occurred a Material Adverse Effect: (i) general changes

in the financial or securities markets or general economic or political conditions in the country or region in which such Person or any

of its Subsidiaries do business; (ii) changes, conditions or effects that generally affect the industries in which such Person or any

of its Subsidiaries principally operate; (iii) changes in GAAP or other applicable accounting principles or mandatory changes in the regulatory

accounting requirements applicable to any industry in which such Person and its Subsidiaries principally operate; (iv) conditions caused

by acts of God, terrorism, war (whether or not declared), earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wild fires,

weather conditions, natural or man-made disasters, emergencies, calamities, epidemics, pandemics, disease outbreaks, other acts of God

or other force majeure events in the United States or other political conditions or natural disasters; (v) any failure in and of itself

by such Person and its Subsidiaries to meet any internal or published budgets, projections, forecasts or predictions of financial performance

for any period (provided that the underlying cause of any such failure may be considered in determining whether a Material Adverse Effect

has occurred or would reasonably be expected to occur to the extent not excluded by another exception herein) and (vi), with respect to

SPAC, the consummation and effects of the Redemption (or any redemption in connection with the Extension); provided further, however,

that any event, occurrence, fact, condition, or change referred to in clauses (i) - (iv) immediately above shall be taken into account

in determining whether a Material Adverse Effect has occurred or could reasonably be expected to occur to the extent that such event,

occurrence, fact, condition, or change has a disproportionate effect on such Person or any of its Subsidiaries compared to other participants

in the industries in which such Person or any of its Subsidiaries primarily conducts its businesses.

“Medicaid”

means, collectively, the health care assistance program established by Title XIX of the Social Security Act (and any statutes succeeding

thereto), and all applicable Laws pertaining to such program, including (a) all federal statutes affecting such program, (b) all state

statutes and plans for medical assistance enacted in connection with such program and federal rules and regulations promulgated in connection

with such program and (c) all applicable provisions of all rules, regulations, manuals, orders and administrative guidance, reimbursement,

and requirements of all Governmental Authorities promulgated in connection with such program, in each case as the same may be amended,

restated, supplemented or otherwise modified from time to time.

“Medicare”

means, collectively, the health insurance program for the aged and disabled established by Title XVIII of the Social Security Act and

any statutes succeeding thereto, and all applicable Laws, rules, regulations, manuals, orders or requirements pertaining to such program

including (a) all federal statutes (whether set forth in Title XVIII of the Social Security Act or elsewhere) affecting such program and

(b) all applicable provisions of all rules, regulations, manuals, orders, administrative guidance, reimbursement and requirements of all

Governmental Authorities promulgated in connection with such program, in each case, as the same may be amended, restated, supplemented

or otherwise modified from time to time.

“NYSE”

means New York Stock Exchange.

“Order”

means any order, decree, ruling, judgment, injunction, writ, determination, binding decision, verdict, judicial award or other action

that is or has been made, entered, rendered, or otherwise put into effect by or under the authority of any Governmental Authority.

“Organizational

Documents” means, with respect to any Person that is an entity, its certificate of incorporation or formation, bylaws, operating

agreement, memorandum and articles of association or similar organizational documents, in each case, as amended.

“Patents”

means any patents, patent applications and the inventions, designs and improvements described and claimed therein, patentable inventions,

and other patent rights (including any divisionals, provisionals, continuations, continuations-in-part, substitutions, reexamined patents

or reissues thereof, whether or not patents are issued on any such applications and whether or not any such applications are amended,

modified, divided, continued, abandoned, withdrawn, or refiled).

“Percentage Merger

Consideration” means a number of shares of Pubco Common Stock equal to (a) 15,000,000, multiplied by (b) the percentage

set forth opposite such Seller’s name on Schedule 1.8.

“Percentage Share”

means with respect to each Seller, the percentage set forth opposite such Seller’s name on Schedule 1.8.

“Permits”

means all federal, state, local or foreign or other third-party permits, grants, easements, filings, accreditations, consents, approvals,

authorizations, exemptions, licenses, franchises, concessions, ratifications, permissions, clearances, confirmations, endorsements, waivers,

certifications, designations, ratings, registrations, certificates, enrollments, national provider identifiers (NPIs), qualifications

or orders of any Governmental Authority or any other Person.

“Permitted Liens”

means (a) Liens for Taxes or assessments and similar governmental charges or levies, which either are (i) not delinquent or (ii) being

contested in good faith and by appropriate proceedings, and adequate reserves have been established with respect thereto, (b) other Liens

imposed by operation of Law arising in the ordinary course of business for amounts which are not due and payable and as would not in the

aggregate materially adversely affect the value of, or materially adversely interfere with the use of, the property subject thereto, (c)

Liens incurred or deposits made in the ordinary course of business in connection with social security, (d) Liens on goods in transit incurred

pursuant to documentary letters of credit or operational expenses, in each case arising in the ordinary course of business, or (e) Liens

arising under this Agreement or any Ancillary Document.

“Person”

means an individual, corporation, partnership (including a general partnership, limited partnership or limited liability partnership),

limited liability company, exempted company, association, trust or other entity or organization, including a government, domestic or foreign,

or political subdivision thereof, or an agency or instrumentality thereof.

“Personal Information”

means any information that either directly or indirectly identifies or, alone or in combination with any other information, could reasonably

be used to identify, locate, or contact a natural Person, or that relates or links to, or is reasonably linkable to an identified or identifiable

individual, including name, street address, telephone number, email address, identification number issued by a Governmental Authority,

credit card number, bank information, customer or account number, online identifier, device identifier, IP address, browsing history,

search history, or other website, application, or online activity or usage data, location data, biometric data, medical or health information,

or any other information that is considered “personally identifiable information,” “personal information,” or

“personal data” under applicable Law, and all data associated with any of the foregoing that are or could reasonably be used

to develop a profile or record of the activities of a natural Person across multiple websites or online services, to predict or infer

the preferences, interests, or other characteristics of a natural Person, or to target advertisements or other content or products or

services to a natural Person.

“Personal Property”

means any machinery, equipment, tools, vehicles, furniture, leasehold improvements, office equipment, plant, parts and other tangible

personal property.

“Privacy Laws”

means all applicable Laws, Orders, and binding guidance issued by any Governmental Authority concerning the privacy, security, or Processing

of Personal Information (including Laws of jurisdictions where Personal Information was collected), including, as applicable, data breach

notification Laws, consumer protection Laws, Laws concerning requirements for website and mobile application privacy policies and practices,

Social Security number protection Laws, data security Laws, and Laws concerning email, text message, or telephone communications. Without

limiting the foregoing, Privacy Laws include: the Federal Trade Commission Act, the Telephone Consumer Protection Act, the Telemarketing

and Consumer Fraud and Abuse Prevention Act, the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, the Children’s

Online Privacy Protection Act, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, the

Computer Fraud and Abuse Act, the Electronic Communications Privacy Act, the Fair Credit Reporting Act, the Fair and Accurate Credit Transaction

Act, the Health Insurance Portability and Accountability Act of 1996, as amended and supplemented by the Health Information Technology

for Economic and Clinical Health Act of the American Recovery and Reinvestment Act of 2009, the Gramm-Leach-Bliley Act, the Family Educational

Rights and Privacy Act, the GDPR, and all other similar international, federal, state, provincial, and local Laws.

“Private Program”

means those private, non-Federal Health Care Programs, health care plans or health care reimbursement, including private insurance, health

maintenance organizations, accountable care organizations, clinically integrated networks, employer-sponsored programs, under which healthcare

providers and suppliers, and any healthcare facilities, centers, and units, directly or indirectly, receive payment for the provision

of services or goods to beneficiaries of the applicable program.

“Processing”

means any operation performed on Personal Information or that relevant Privacy Laws include in the definition of processing, processes,

or process, including the collection, creation, receipt, access, use, handling, recording, compilation, analysis, organizing, monitoring,

maintenance, retention, storage, holding, transmission, transfer, protection, disclosure, amendment, distribution, erasure, destruction,

or disposal of Personal Information.

“Pubco Common Stock”

means the shares of Pubco Common Stock, par value $0.0001 per share, along with any equity securities paid as dividends or distributions

after the Closing with respect to such shares or into which such shares are exchanged or converted after the Closing.

“Pubco Common Stock

Equivalents” means at the election of the Company (a) a prefunded warrant to purchase Pubco Common Stock, or (b) shares

of preferred stock designated by Pubco that is convertible on a one-for-one basis into shares of Pubco Common Stock, in each case in form

and substance reasonably accepted to the Company and Pubco and containing customary provisions for each such type of securities, and including,

without limitation, a customary beneficial ownership limitation provision.

“Pubco Private Warrants”

means one whole warrant entitling the holder thereof to purchase one (1) share of Pubco Common Stock at a price of $11.50 per share.

“Pubco Public Warrants”

means one whole warrant entitling the holder thereof to purchase one (1) share of Pubco Common Stock at a price of $11.50 per share.

“Pubco Securities”

means the Pubco Common Stock and the Pubco Warrants, collectively.

“Pubco Warrants”

means Pubco Private Warrants and Pubco Public Warrants, collectively.

“Release”

means any release, spill, emission, leaking, pumping, injection, deposit, disposal, discharge, dispersal, or leaching into the indoor

or outdoor environment, or into or out of any property.

“Remedial Action”

means all actions to (i) clean up, remove, treat, or in any other way address any Hazardous Material, (ii) prevent the Release of any

Hazardous Material so it does not endanger or threaten to endanger public health or welfare or the indoor or outdoor environment, (iii)

perform pre-remedial studies and investigations or post-remedial monitoring and care, or (iv) correct a condition of noncompliance with

Environmental Laws.

“Representatives”

means, as to any Person, such Person’s Affiliates and the respective managers, directors, officers, employees, independent contractors,

consultants, advisors (including financial advisors, counsel and accountants), agents and other legal representatives of such Person or

its Affiliates.

“SEC”

means the U.S. Securities and Exchange Commission (or any successor Governmental Authority).

“Secured Note Transaction

Documents” means (i) that certain Note Purchase Agreement, (ii) those certain Senior Secured Promissory Notes, (iii) that

certain Security and Pledge Agreement and (iv) that certain Pledge Agreement, in each case dated June 3, 2026, by and among the Company,

Aditxt, Inc., a Delaware corporation, and the investor(s) named therein.

“Securities Act”

means the Securities Act of 1933, as amended.

“Software”

means any computer software programs, including all source code, object code, and documentation related thereto and all software modules,

libraries, repositories, tools and databases.

“SOX”

means the U.S. Sarbanes-Oxley Act of 2002, as amended.

“SPAC Class A Ordinary

Shares” means the Class A ordinary shares, par value $0.0001 per share, of SPAC prior to consummation of the Conversion.

“SPAC Class B Ordinary

Shares” means the Class B ordinary shares, par value $0.0001 per share, of SPAC prior to consummation of the Conversion.

“SPAC Common Stock”

means the shares of common stock, par value $0.0001 per share, of SPAC following the consummation of the Conversion.

“SPAC Confidential

Information” means all confidential or proprietary documents and information concerning SPAC or any of its Representatives;

provided, however, that SPAC Confidential Information shall not include any information which, (i) at the time of disclosure by

the Company or any of its Representatives, is generally available publicly and was not disclosed in breach of this Agreement or (ii) at

the time of the disclosure by SPAC or its Representatives to the Company or any of its Representatives, was previously known by such receiving

party without violation of Law or any confidentiality obligation by the Person receiving such SPAC Confidential Information. For the avoidance

of doubt, from and after the Closing, SPAC Confidential Information will include the confidential or proprietary information of the Target

Companies.

“SPAC Fundamental

Representations” means the representations and warranties specified in Section 3.1 (Organization and Standing), Section

3.2 (Authorization; Binding Agreement); Section 3.4 (Non-Contravention); Section 3.5(a) (other than the first sentence

of Section 3.5(a)) (Capitalization); Section 3.5(b) (Capitalization); and Section 3.16 (Finders and Brokers).

“SPAC Ordinary Shares”

means SPAC Class A Ordinary Shares and SPAC Class B Ordinary Shares, collectively.

“SPAC

Organizational Documents” means, the Amended and Restated Memorandum and Articles of Association of SPAC,

as in force and effective under the Act.

“SPAC Preference

Shares” means preference shares, par value $0.0001 per share, of SPAC prior to the Conversion.

“SPAC Private Warrants”

means one (1) whole warrant that was issued to the Sponsor in a private placement that closed simultaneously with the IPO, with each whole

warrant entitling the holder thereof to purchase one (1) SPAC Class A Ordinary Share at a purchase price of $11.50 per share.

“SPAC Public Units”

means the units issued in the IPO (including overallotment units acquired by SPAC’s underwriter) consisting of one SPAC Class A

Ordinary Share and one-half (1/2) of one SPAC Public Warrant.

“SPAC Public Warrants”

means one whole warrant that was included in as part of each SPAC Public Unit, entitling the holder thereof to purchase one (1) SPAC Class

A Ordinary Share at a purchase price of $11.50 per share.

“SPAC Securities”

means SPAC Public Units, SPAC Ordinary Shares, SPAC Preference Shares and SPAC Warrants, collectively.

“SPAC Warrants”

means SPAC Private Warrants and SPAC Public Warrants, collectively.

“Sponsor”

means Copley Acquisition Sponsors, LLC, a Delaware limited liability company.

“Subsidiary”

means, with respect to any Person, any corporation, partnership, association or other business entity of which (i) if a corporation, a

majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election

of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of

the other Subsidiaries of that Person or a combination thereof, or (ii) if a partnership, association or other business entity, a majority

of the partnership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by any Person

or one or more Subsidiaries of that Person or a combination thereof. For purposes hereof, a Person or Persons will be deemed to have a

majority ownership interest in a partnership, association or other business entity if such Person or Persons will be allocated a majority

of partnership, association or other business entity gains or losses or will be or control the managing director, managing member, general

partner or other managing Person of such partnership, association or other business entity. A Subsidiary of a Person will also include

any variable interest entity which is consolidated with such Person under applicable accounting rules.

“Target Company”

means each of the Company and its direct and indirect Subsidiaries.

“Target Company

Fundamental Representations” means the representations and warranties specified in Section 5.1 (Organization and

Standing), Section 5.2 (Authorization; Binding Agreement); Section 5.3(a) (other than the first sentence of Section 5.3(a))

(Capitalization); Section 5.3(b)(Capitalization); Section 5.6 (Non-Contravention); and Section 5.28 (Finders and

Brokers).

“Tax Return”

means any return, declaration, report, claim for refund, information return or other documents (including any related or supporting schedules,

statements or information) filed or required to be filed in connection with the determination, assessment or collection of any Taxes or

the administration of any Laws or administrative requirements relating to any Taxes.

“Taxes”

means (a) all direct or indirect federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, value-added,

ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, tax collected at source, equalization levy,

payroll, employment, social security and related contributions due in relation to the payment of compensation to employees, excise, severance,

stamp, occupation, premium, property, windfall profits, alternative minimum, estimated, customs, duties or other taxes, fees, assessments

or charges of any kind whatsoever, together with any interest and any penalties, additions to tax or additional amounts with respect thereto,

(b) any Liability for payment of amounts described in clause (a) whether as a result of being a member of an affiliated, consolidated,

combined or unitary group for any period or otherwise through operation of law and (c) any Liability for the payment of amounts described

in clauses (a) or (b) as a result of any tax sharing, tax group, tax indemnity or tax allocation agreement with, or any other express

or implied agreement to indemnify, any other Person.

“Third-Party Payor

Agreement” means any contract between any Target Company (on the one hand) and a Third-Party Payor Program (on the other

hand) under which any Target Company directly or indirectly receives payments for medical services provided to such program’s beneficiaries.

“Third-Party Payor

Programs” means all payment or reimbursement programs sponsored or maintained by any Third-Party Payor.

“Third-Party

Payors” means all Federal Health Care Programs and Private Programs.

“Trade Secrets”

means any trade secrets, confidential business information, concepts, ideas, designs, research or development information, processes,

procedures, techniques, technical information, specifications, operating and maintenance manuals, engineering drawings, methods, know-how,

data, mask works, discoveries, inventions, modifications, extensions, improvements, and other proprietary rights (whether or not patentable

or subject to copyright, trademark, or trade secret protection).

“Trademarks”

means any trademarks, service marks, trade dress, trade names, brand names, internet domain names, designs, logos, or corporate names

(including, in each case, the goodwill associated therewith), whether registered or unregistered, and all registrations and applications

for registration and renewal thereof.

“Transaction Financing”

means a capital raising transaction in connection with the Transactions structured as one or a combination of common equity, preferred

equity, convertible equity or debt, non-redemption or backstop arrangements with respect to the Trust Account, a committed equity facility,

debt facility, and/or other sources of cash or cash equivalents, in each case, whether such investment is into SPAC, the Company or Pubco.

“Trust Account”

means the trust account established by SPAC with the proceeds from the IPO pursuant to the Trust Agreement in accordance with the IPO

Prospectus.

“Trust Agreement”

means that certain Investment Management Trust Agreement, dated as of April 30, 2025, as it may be amended, by and between SPAC and the

Trustee, as well as any other agreements entered into related to or governing the Trust Account.

“Trustee”

means Continental Stock Transfer & Trust Company, in its capacity as trustee under the Trust Agreement.

“Unaudited Financial

Statements” means the unaudited consolidated financial statements of the Target Companies, consisting of the consolidated

balance sheets of the Target Companies and the related consolidated income statements, changes in shareholder equity and statements of

cash flows for the years ended December 31, 2024 and December 31, 2025.

11.2 Section

References. The following capitalized terms, as used in this Agreement, have the respective meanings given to them in the Section

as set forth below adjacent to such terms:

Term

Section

Acquisition Proposal

6.6(a)

Act

Recitals

Agreement

Preamble

Alternative Transaction

6.6(a)

Amended Pubco Charter

7.1(j)

Antitrust Laws

6.9(b)

Audit Delivery Date

6.4(a)

Audited Financials

6.4(a)

Business Combination

9.1

Cayman Registrar

1.7

Change in Recommendation

6.6(b)

Change in Recommendation Notice

6.6(d)

Change in Recommendation Notice Period

6.6(d)

Closing

2.1

Closing Date

2.1

Closing Filing

6.14(b)

Closing Press Release

6.14(b)

CMS

5.26(e)

Common Rule

‎5.26(l)

Company

Preamble

Company Agent

5.26(a)

Company Benefit Plan

5.19(a)

Company Business

Recitals

Company Certificate of Merger

1.3

Company D&O Tail Insurance

6.18(c)

Company Directors

6.17(a)

Company Disclosure Schedules

Article V

Company Financials

6.4(a)

Company IP

5.13(d)

Company IP Licenses

5.13(a)

Company Material Contracts

5.12(a)

Company Merger

Recitals

Company Merger Sub

Preamble

Company Minimum Cash Condition

7.3(f)

Company Permits

5.10

Company Personal Property Leases

5.16

Company Real Property Leases

5.15

Company Registered IP

5.13(a)

Company Special Meeting

6.13

Company Surviving Subsidiary

1.2

Conversion

1.7

Conversion Organizational Documents

1.7

D&O Indemnified Persons

6.18(a)

DGCL

Recitals

DLLCA

1.2

Term

Section

Effective Time

1.3

Employment Agreements

Recitals

Enforceability Exceptions

3.2

Environmental Permits

5.20(a)

Excluded Interests

1.10(b)

Extension

6.3(a)

Extension Expenses

11.1

Financing Agreement

6.20(a)

Federal Securities Laws

6.7

HIPAA

5.25(g)

HIPAA Rules

5.25(g)

Incentive Plan

6.12(a)

Insider Letter Amendment Approval

6.12(a)

Interim Financial Information

6.4

Interim Period

6.1(a)

Investment Company Act

3.15

Lock-Up Agreement

Recitals

Merger Consideration

1.8

Merger Subs

Preamble

Mergers

Recitals

Non-Competition Agreement

Recitals

Off-the-Shelf Software

5.13(a)

OIG

5.26(e)

Outbound IP License

5.13(c)

Outside Date

8.1(b)

Party(ies)

Preamble

PHI

5.25(g)

Post-Closing Equity Plan

6.12(a)

Post-Closing Pubco Board

6.17(a)

Privacy Agreement

5.25(a)

Proxy Statement

6.12(a)

Pubco

Preamble

Public Certifications

3.6(a)

Public Shareholders

9.1

Redemption

6.12(a)

Registration Statement

6.12(a)

Related Person

5.21

Released Claims

9.1

Required Company Member Approval

7.1(b)

Required SPAC Shareholder Approval

7.1(a)

SEC Approval Date

6.12(d)

SEC Reports

3.6(a)

Section 409A Plan

5.19(k)

Security Incident

5.25(d)

Sellers

1.8(a)

Term

Section

Seller Representative

Preamble

Seller Representative Documents

10.14(a)

Signing Filing

6.14(b)

Signing Press Release

6.14(b)

SPAC

Preamble

SPAC Certificate of Merger

1.3

SPAC Board Recommendation

Recitals

SPAC D&O Tail Insurance

6.18(b)

SPAC Directors

6.17(a)

SPAC Disclosure Schedules

Article III

SPAC Extraordinary General Meeting

6.12(a)

SPAC Financials

3.6(c)

SPAC Material Contract

3.13(a)

SPAC Merger

Recitals

SPAC Merger Sub

Preamble

SPAC Minimum Cash Condition

7.2(e)

SPAC Shareholder Approval Matters

6.12(a)

SPAC Representative

Preamble

SPAC Representative Documents

10.13(a)

SPAC Surviving Subsidiary

1.1

Specified Courts

10.4

Surviving Subsidiaries

1.2

Top Customers

5.23

Top Suppliers

5.23

{REMAINDER OF PAGE INTENTIONALLY LEFT BLANK;

SIGNATURE PAGE FOLLOWS}

IN WITNESS WHEREOF, each Party

hereto has caused this Agreement to be signed and delivered as of the date first written above.

SPAC:

COPLEY ACQUISITION CORP

By:

Name:

Title:

Pubco:

IGNITE PROTEOMICS HOLDINGS INC.

By:

Name:

Title:

SPAC Merger Sub:

IGNITE MERGER SUB I INC.

By:

Name:

Title:

Company Merger Sub:

IGNITE MERGER SUB II LLC

By:

Name:

Title:

The Company:

IGNITE PROTEOMICS, LLC

By:

Name:

Jeffrey M. Busch

Title:

Chief Executive Officer

SPAC Representative:

By:

Name:

Chibo Tang

Seller Representative:

By:

Name:

Jeffrey M. Busch

EX-10.1 — FORM OF SELLER SUPPORT AGREEMENT

EX-10.1

Filename: ea029430701ex10-1.htm · Sequence: 3

Exhibit 10.1

FORM OF SELLER SUPPORT AGREEMENT

This Seller Support Agreement

(this “Agreement”) is made as of June ____, 2026 by and among (i) Copley Acquisition Corp, a Cayman Islands

exempted company incorporated with limited liability (together with its successors, including after the Conversion (as defined below),

the “SPAC”), (ii) Ignite Proteomics, LLC, a Delaware limited liability company (the “Company”),

and (iii) the undersigned holders of membership interests and/or interests convertible into membership interests (collectively, the “Holders”

and each, a “Holder”) of the Company. Any capitalized term used but not defined in this Agreement will have

the meaning ascribed to such term in the Business Combination Agreement.

WHEREAS, on or about

the date hereof, (i) the SPAC, (ii) Ignite Proteomics Holdings, Inc., a Delaware corporation (“Pubco”), (iii)

Ignite Merger Sub I Inc., a Delaware corporation and a wholly-owned subsidiary of Pubco (“SPAC Merger Sub”),

(iv) Ignite Merger Sub II LLC, a Delaware limited liability company and a wholly-owned subsidiary of Pubco (“Company

Merger Sub”), (v) the Company, (vi) the SPAC Representative (as therein defined), and (vii) the Seller Representative (as

therein defined), have entered into that certain Business Combination Agreement (as amended from time to time in accordance with the terms

thereof, the “Business Combination Agreement”), pursuant to which, (a) prior to the closing of the transactions

contemplated by the Business Combination Agreement (the “Closing”), the SPAC shall transfer by way of continuation

out of the Cayman Islands and into the State of Delaware so as to convert into and become a Delaware corporation pursuant to the Cayman

Islands Companies Act (as Revised) (the “Act”) and the applicable provisions of the Delaware General Corporation

Law (“DGCL”) (the “Conversion”), and, at the Closing, (b) SPAC Merger Sub will merge

with and into the SPAC, with the SPAC continuing as the surviving entity (the “SPAC Merger”), with the security

holders of the SPAC receiving substantially equivalent security of Pubco, and (c) Company Merger Sub will merge with and into the Company,

with the Company continuing as the surviving entity (the “Company Merger”), with the security holders of the

Company receiving shares of Pubco Common Stock, all upon the terms and subject to the conditions set forth in the Business Combination

Agreement and in accordance with the applicable provisions of the DGCL and the Act; and

WHEREAS, as a condition

to the willingness of the SPAC to enter into the Business Combination Agreement, and as an inducement and in consideration therefor, and

in view of the valuable consideration to be received by each Holder thereunder, and the expenses and efforts to be undertaken by the SPAC

and the Company to consummate the Business Combination Agreement, the Ancillary Documents, the Company Merger and the other transactions

contemplated by any such documents (collectively, the “Transactions”), the SPAC, the Company and such Holder

desire to enter into this Agreement in order for such Holder to provide certain assurances to the SPAC regarding the manner in which such

Holder is bound hereunder to vote any membership interest of the Company or other equity interests of the Company which such Holder beneficially

owns, holds or otherwise has voting power (the “Membership Interests”) during the period from and including

the date hereof through and including the date on which this Agreement is terminated in accordance with its terms (the “Voting

Period”) with respect to the Business Combination Agreement, the Company Merger, the Ancillary Documents and the Transactions.

NOW, THEREFORE, in

consideration of the premises set forth above, which are incorporated in this Agreement as if fully set forth below, and intending to

be legally bound hereby, the parties hereby agree as follows:

1. Covenant to Vote in

Favor of Transactions and Other Actions in Connection with the Transactions. Each Holder agrees, with respect to all of the Membership

Interests:

(a) during

the Voting Period, at each meeting of the members of the Company (the “Company Members”) or any class or series

thereof, and in each written consent or resolutions of any of the Company Members in which such Holder is entitled to vote or consent

as a member of the Company, such Holder hereby unconditionally and irrevocably agrees to be present for such meeting or otherwise be counted

as present thereat for the purpose of establishing a quorum and vote (in person or by proxy), or consent to any action by written consent

or resolution, in accordance with the applicable provisions of the Company’s Operating Agreement dated May 29, 2024, and with respect

to, as applicable, the Membership Interests (i) in favor of, and adopt, the Company Merger, the Business Combination Agreement, the Ancillary

Documents, any amendments to the Company’s Organizational Documents (including the Company Operating Agreement), and all of the

other Transactions (and any actions required in furtherance thereof), (ii) in favor of the other matters set forth in the Business Combination

Agreement, and (iii) to vote the Membership Interests in opposition to: (A) any Acquisition Proposal or Alternative Transaction and any

and all other proposals (x) for the acquisition of the Company, (y) that could reasonably be expected to delay or impair the ability of

the Company to consummate the Company Merger, the Business Combination Agreement or any of the Transactions, or (z) which are in competition

with or materially inconsistent with the Business Combination Agreement or the Ancillary Documents; (B) other than as contemplated by

the Business Combination Agreement or the Ancillary Documents, any material change in (x) the present capitalization of the Company or

any amendment of the Company’s Organizational Documents (including the Company Operating Agreement) or (y) the Company’s limited

liability company structure or business; or (C) any other action or proposal involving any Target Company that is intended, or would reasonably

be expected, to prevent, impede, interfere with, delay, postpone or adversely affect in any material respect the Transactions or would

reasonably be expected to result in any of the conditions to the Closing under the Business Combination Agreement not being fulfilled;

(b) to

promptly execute and deliver all related documentation and take such other action in support of the Company Merger, the Business Combination

Agreement, any Ancillary Documents and any of the Transactions as shall reasonably be requested by Pubco, the Company or the SPAC in order

to carry out the terms and provisions of this Section 1, including, without limitation, (i) execution and delivery to the Company

of a Letter of Transmittal and the Transmittal Documents, (ii) if applicable, delivery of such Holder’s Company Certificate (or

a Lost Certificate Affidavit in lieu of the Company Certificate), duly endorsed for transfer, to Pubco and any similar or related documents

and such other documents as may be reasonably requested by Pubco or the SPAC or the Exchange Agent, (iii) any actions by written consent

of the Company Members presented to such Holder, and (iv) any applicable Ancillary Documents (including, without limitation, a Lock-Up

Agreement and a Non-Competition and Non-Solicitation Agreement), customary instruments of conveyance and transfer, and any consent, waiver,

governmental filing, and any similar or related documents;

to deposit, and to cause their Affiliates not to deposit, except as provided in this Agreement, any Membership Interests owned by such

Holder or his/her/its Affiliates in a voting trust or subject any Membership Interests to any arrangement or agreement with respect to

the voting of such Membership Interests, unless specifically requested to do so by the Company and the SPAC in connection with the Business

Combination Agreement, the Ancillary Documents or the Transactions;

(d) except

as contemplated by the Business Combination Agreement or the Ancillary Documents, not make, or in any manner participate in, directly

or indirectly, a “solicitation” of “proxies” or consents (as such terms are used in the rules of the SEC) or powers

of attorney or similar rights to vote, or seek to advise or influence any Person with respect to the voting of, any Membership Interests

in connection with any vote or other action with respect to the Transactions, other than to recommend that the members of the Company

vote in favor of adoption of the Business Combination Agreement and the Transactions and any other proposal the approval of which is a

condition to the obligations of the parties under the Business Combination Agreement (and any actions required in furtherance thereof

and otherwise as expressly provided by Section 1 of this Agreement);

(e) to

refrain from exercising any dissenters’ rights or rights of appraisal under applicable Law at any time with respect to the Company

Merger, the Business Combination Agreement, the Ancillary Documents and any of the Transactions, including pursuant to the DGCL.

Grant of Proxy. Each Holder, with respect to all of such Holder’s Membership Interests, hereby irrevocably grants to, and

appoints, the SPAC and any designee of the SPAC (determined in SPAC’s sole discretion) as such Holder’s attorney-in-fact and

proxy, with full power of substitution and resubstitution, for and in such Holder’s name, to vote, or cause to be voted (including

by proxy or written consent, if applicable) any Membership Interests owned (whether beneficially or of record) by such Holder as of the

date hereof and as of immediately prior to the Effective Time, with respect to any vote related to approval of the Business Combination

Agreement and the Transactions. The proxy granted by such Holder pursuant to this Section 2 is irrevocable and is granted in consideration

of the SPAC entering into this Agreement and the Business Combination Agreement and incurring certain related fees and expenses. Each

Holder hereby affirms that such irrevocable proxy is coupled with an interest by reason of the Business Combination Agreement and, except

upon the termination of this Agreement in accordance with Section 6(a), is intended to be irrevocable. Each Holder agrees, until

this Agreement is terminated in accordance with Section 6(a), to vote its Membership Interests in accordance with Section 1

above.

3. Other

Covenants.

(a) No

Transfers. Each Holder agrees that during the Voting Period it shall not, and shall cause its Affiliates not to, without the SPAC’s

prior written consent, (A) offer for sale, sell (including short sales), transfer, tender, pledge, encumber, assign or otherwise dispose

of (including by gift) (collectively, a “Transfer”), (B) enter into any contract, option, derivative, hedging

or other agreement or arrangement or understanding (including any profit-sharing arrangement) with respect to, or consent to, a Transfer

of, any or all of the Membership Interests; (C) grant any proxies or powers of attorney with respect to any or all of the Membership Interests;

(D) permit to exist any lien of any nature whatsoever (other than those imposed by this Agreement, applicable securities Laws or the Company’s

Organizational Documents (including the Company Operating Agreement), as in effect on the date hereof) with respect to any or all of the

Membership Interests; or (E) take any action that would have the effect of preventing, impeding, interfering with or adversely affecting

such Holder’s ability to perform its obligations under this Agreement. The Company hereby agrees that it shall not permit any Transfer

of the Membership Interests in violation of this Agreement. Each Holder agrees with, and covenants to, the SPAC that such Holder shall

not request that the Company register the Transfer (book-entry or otherwise) of any certificate or uncertificated interest representing

any Membership Interests during the term of this Agreement without the prior written consent of the SPAC, and the Company hereby agrees

that it shall not effect any such Transfer.

(b) Changes

to Membership Interests. In the event of an equity distribution, or any change in the equity interests of the Company by reason of

any equity distribution, equity split, recapitalization, combination, conversion, exchange of equity interests or the like, the term “Membership

Interests” shall be deemed to refer to and include the Membership Interests as well as all such equity distributions and any securities

into which or for which any or all of the Membership Interests may be changed or exchanged or which are received in such transaction.

Each Holder agrees during the Voting Period to notify the SPAC and the Company promptly in writing of the number and type of any changes

to Holder’s ownership of or voting rights with respect to the Membership Interests, upon Holder’s acquisition or commitment

to acquire any additional Membership Interests or upon any other changes involving Holder relating to the equity interests or securities

convertible or exercisable for equity interests of the Company.

with Business Combination Agreement. Each Holder agrees during the Voting Period not to take or agree or commit to take any action

that would make any representation and warranty of such Holder contained in this Agreement inaccurate in any material respect. Each Holder

further agrees that it shall use its commercially reasonable efforts to cooperate with the SPAC to effect the Company Merger, all other

Transactions, the Business Combination Agreement, the Ancillary Documents and the provisions of this Agreement. During the Voting Period,

each Holder shall not authorize or permit any of its Representatives to, directly or indirectly, cause the Company to, take any action

that the Company is prohibited from taking pursuant to Section 6.2 of the Business Combination Agreement (unless the SPAC shall

have consented thereto).

(d) Registration

Statement. During the Voting Period, each Holder agrees to provide to Pubco, the SPAC, the Company and their respective Representatives

any information regarding such Holder or the Membership Interests that is reasonably requested by Pubco, the SPAC, Company or their respective

Representatives for inclusion in the Registration Statement.

(e) Publicity.

Except for disclosure required by the SEC, Nasdaq or NYSE, which disclosure is hereby expressly authorized, Holder shall not issue any

press release or otherwise make any public statements with respect to the Transactions or the transactions contemplated herein without

the prior written approval of the Company and the SPAC. Each Holder hereby authorizes the Company and the SPAC to publish and disclose

in any announcement or disclosure required by the SEC, NYSE or the Registration Statement (including all documents and schedules filed

with the SEC in connection with the foregoing), such Holder’s identity and ownership of the Membership Interests and the nature

of such Holder’s commitments and agreements under this Agreement, the Business Combination Agreement and any other Ancillary Documents.

4. Representations

and Warranties of Holders. Each Holder hereby represents and warrants to the SPAC and the Company as follows:

(a) Binding

Agreement. Such Holder (i) if a natural person, is of legal age to execute this Agreement and is legally competent to do so and (ii)

if not a natural person, is (A) a corporation, limited liability company, company or partnership duly organized and validly existing under

the laws of the jurisdiction of its organization and (B) has all necessary power and authority to execute and deliver this Agreement,

to perform its obligations hereunder and to consummate the transactions contemplated hereby. If such Holder is not a natural person, the

execution and delivery of this Agreement, the performance of its obligations hereunder and the consummation of the transactions contemplated

hereby by such Holder has been duly authorized by all necessary corporate, limited liability or partnership action on the part of such

Holder, as applicable. This Agreement, assuming due authorization, execution and delivery hereof by the other parties hereto, constitutes

a legal, valid and binding obligation of such Holder, enforceable against such Holder in accordance with its terms (except as such enforceability

may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability

relating to or affecting creditor’s rights, and to general equitable principles). Such Holder understands and acknowledges that

the SPAC is entering into the Business Combination Agreement in reliance upon the execution and delivery of this Agreement by such Holder.

(b) Ownership

of Membership Interests. As of the date hereof, such Holder has beneficial ownership over the Membership Interests set forth under

such Holder’s name on the signature page hereto, is the lawful owner of such Membership Interests, has the sole power to vote or

cause to be voted such Membership Interests (to the extent the Membership Interests have associated voting rights), and has good and valid

title to such Membership Interests, free and clear of any and all pledges, mortgages, encumbrances, charges, proxies, voting agreements,

liens, adverse claims, options, security interests and demands of any nature or kind whatsoever, other than those imposed by this Agreement,

applicable securities Laws or the Company’s Organizational Documents (including the Company Operating Agreement), as in effect on

the date hereof. There are no claims for finder’s fees or brokerage commission or other like payments in connection with this Agreement

or the transactions contemplated hereby payable by such Holder pursuant to arrangements made by such Holder. Except for the Membership

Interests of the Company set forth under such Holder’s name on the signature page hereto, as of the date of this Agreement, such

Holder is not a beneficial owner or record holder of any: (i) equity securities of the Company, (ii) securities of the Company having

the right to vote on any matters on which the holders of equity securities of the Company may vote or which are convertible into or exchangeable

for, at any time, equity securities of the Company or (iii) options, warrants or other rights to acquire from the Company any equity securities

or securities convertible into or exchangeable for equity securities of the Company.

Conflicts. No filing with, or notification to, any Governmental Authority, and no consent, approval, authorization or permit of any

other person is necessary for the execution of this Agreement by such Holder, the performance of its obligations hereunder or the consummation

by it of the transactions contemplated hereby. None of the execution and delivery of this Agreement by such Holder, the performance of

its obligations hereunder or the consummation by it of the transactions contemplated hereby shall (i) conflict with or result in any breach

of the certificate of incorporation, bylaws or other comparable organizational documents of such Holder, if applicable, (ii) result in,

or give rise to, a violation or breach of or a default under any of the terms of any Contract or obligation to which such Holder is a

party or by which such Holder or any of the Membership Interests or its other assets may be bound, or (iii) violate any applicable Law

or Order, except for any of the foregoing in clauses (i) through (iii) as would not reasonably be expected to impair such Holder’s

ability to perform its obligations under this Agreement in any material respect.

(d) No Inconsistent

Agreements. Holder hereby covenants and agrees that, except for this Agreement, Holder (i) has not entered into, nor will enter into

at any time while this Agreement remains in effect, any voting agreement or voting trust with respect to the Membership Interests, (ii)

has not granted, nor will grant at any time while this Agreement remains in effect, a proxy, a consent or power of attorney with respect

to the Membership Interests and (iii) has not entered into any agreement or knowingly taken any action (nor will enter into any agreement

or knowingly take any action) that would make any representation or warranty of Holder contained herein untrue or incorrect in any material

respect or have the effect of preventing Holder from performing any of its material obligations under this Agreement.

5. Waiver

and Release of Claims. Holder covenants and agrees as follows:

(a) Subject

to and conditioned upon the Closing, effective as of the Closing (and subject to the limitations set forth in paragraph (d) below), Holder,

on behalf of itself and its Affiliates and its and their respective successors, assigns, representatives, administrators, executors and

agents, and any other person or entity claiming by, through, or under any of the foregoing (each a “Releasing Party”

and, collectively, the “Releasing Parties,” provided, for the avoidance of doubt, that the SPAC, shall not be

deemed a Releasing Party hereunder), does hereby unconditionally and irrevocably release, waive and forever discharge Pubco, the SPAC,

the Company, and each of their past and present directors, officers, employees, agents, predecessors, successors, assigns, and Subsidiaries,

from any and all past or present claims, demands, damages, judgments, causes of action and liabilities of any nature whatsoever, whether

or not known, suspected or claimed, arising directly or indirectly from any act, omission, event or transaction occurring (or any circumstances

existing) at or prior to the Closing, in each case to the extent arising out of or relating to Holder’s capacity as a current or

former member of the Company or holder of any other equity securities of the Company (or securities convertible into equity securities

of the Company) (each a “Claim” and, collectively, the “Claims”).

(b) Holder

acknowledges that it may hereafter discover facts in addition to or different from those which it now knows or believes to be true with

respect to the subject matter of this Agreement, and that it may hereafter come to have a different understanding of the law that may

apply to potential claims which it is releasing hereunder, but it affirms that, except as is otherwise specifically provided herein, it

is its intention to fully, finally and forever settle and release any and all Claims. In furtherance of this intention, Holder acknowledges

that the releases contained herein shall be and remain in effect as full and complete general releases with respect to the specified subject

matter notwithstanding the discovery or existence of any such additional facts or different understandings of law.

that Holder has the right not to release existing Claims of which Holder is not aware, unless Holder voluntarily chooses to waive this

right. Having been so apprised, Holder elects to assume all risks for Claims that exist, existed or may hereafter exist in its favor,

known or unknown, suspected or unsuspected, arising out of or related to claims or other matters purported to be released pursuant to

this Section 5, in each case, effective as of the Closing. Holder acknowledges and agrees that the foregoing waiver is an essential

and material term of the release provided pursuant to this Section 5 and that, without such waiver, the SPAC and the Company would

not have agreed to the terms of this Agreement.

(d) Notwithstanding

the foregoing provisions of this Section 5 or anything to the contrary set forth herein, the Releasing Parties do not release or

discharge, and each Releasing Party expressly does not release or discharge: (i) any Claims that arise under or are based upon the terms

of the Business Combination Agreement, this Agreement, any of the Ancillary Documents, or any other document, certificate or Contract

executed or delivered in connection with the Business Combination Agreement, as each such agreement or instrument may be amended in accordance

with its terms and the terms set forth in (A) the Business Combination Agreement or (B) this Agreement or the other Ancillary Documents

(if and to the extent applicable), (ii) any rights with respect to the Membership Interests of the Company or the SPAC owned by such Releasing

Party, (iii) any Claims for indemnification, contribution, set-off, reimbursement or similar rights pursuant to any organizational document

of the Company or any indemnity or similar agreements by the Company with or for the benefit of a Releasing Party solely to the extent

(in each case) contemplated by Section 6.18 of the Business Combination Agreement, (iv) any Claims for compensation, reimbursement of

expenses or benefits payable to such Holder in his, her or its capacity as an officer, director, employee, consultant or contractor of

the Company or any of its Subsidiaries; or (v) any Claims for obligations pursuant to, or other rights set forth in, any employment or

similar agreement between Holder, on the one hand, and the Company or any Subsidiary of the Company, on the other hand, together with

any other agreements, documents, instruments or certificates contemplated by the foregoing, as well as any other employment related rights

that such Holder has by Contract or pursuant to applicable Law.

6. Miscellaneous.

(a) Termination.

Notwithstanding anything to the contrary contained herein, this Agreement shall automatically terminate, and none of the SPAC, the Company

or any Holder shall have any rights or obligations hereunder, upon the earliest to occur of (i) the mutual written consent of the SPAC

and the Company, (ii) the Effective Time (following the performance of the obligations of the parties hereunder required to be performed

at or prior to the Effective Time), and (iii) the date of termination of the Business Combination Agreement in accordance with its terms.

The termination of this Agreement shall not prevent any party hereunder from seeking any remedies (at law or in equity) against another

party hereto or relieve such party from liability for such party’s breach of any terms of this Agreement. Notwithstanding anything

to the contrary herein, the provisions of this Section 6 shall survive the termination of this Agreement.

(b) Binding

Effect; Assignment. This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the parties

hereto and their respective permitted successors and assigns. This Agreement and all obligations of Holder are personal to Holder and

may not be assigned, transferred or delegated by operation of Law or otherwise without the prior written consent of the SPAC and the Company

(and after the Closing, Pubco), and any purported assignment, transfer or delegation without such consent shall be null and void; provided

that no such assignment shall relieve the assigning party of its obligations hereunder. Each of the Company and the SPAC may freely assign

any or all of its rights under this Agreement, in whole or in part, to any successor entity (whether by merger, consolidation, equity

sale, asset sale or otherwise) without obtaining the consent or approval of Holder.

Parties. Nothing contained in this Agreement or in any instrument or document executed by any party in connection with the transactions

contemplated hereby shall create any rights in, or be deemed to have been executed for the benefit of, any person that is not a party

hereto or thereto or a successor or permitted assign of such a party.

(d) Governing

Law; Jurisdiction. This Agreement and any dispute or controversy arising out of or relating to this Agreement shall be governed by

and construed in accordance with the Laws of the State of New York without regard to the conflict of laws principles thereof. All Actions

arising out of or relating to this Agreement shall be heard and determined exclusively in any state or federal court located in New York,

New York (or in any appellate court thereof) (the “Specified Courts”). Each party hereto hereby (a) submits

to the exclusive jurisdiction of any Specified Courts for the purpose of any Action arising out of or relating to this Agreement brought

by any party hereto and (b) irrevocably waives, and agrees not to assert by way of motion, defense or otherwise, in any such Action,

any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from

attachment or execution, that the Action is brought in an inconvenient forum, that the venue of the Action is improper, or that this Agreement

or the transactions contemplated hereby may not be enforced in or by any Specified Courts. Each party agrees that a final judgment in

any Action shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.

Each party irrevocably consents to the service of the summons and complaint and any other process in any other Action relating to the

transactions contemplated by this Agreement, on behalf of itself, or its property, by personal delivery of copies of such process to such

party at the applicable address set forth in Section 6(g) (and in the case of Holder, the address set forth on such Holder’s

signature page). Nothing in this Section 6(d) shall affect the right of any party to serve legal process in any other manner permitted

by applicable law.

(e) WAIVER

OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO

A TRIAL BY JURY WITH RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS

CONTEMPLATED HEREBY. EACH PARTY HERETO (i) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE,

THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (ii) ACKNOWLEDGES THAT IT AND THE

OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION

6(e).

(f) Interpretation.

The titles and subtitles contained in this Agreement are solely for the purpose of reference, are not part of the agreement of the parties

and shall not in any way affect the meaning or interpretation of this Agreement. In this Agreement, unless the context otherwise requires:

(i) any pronoun used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns,

pronouns and verbs, including any defined terms, include the plural and vice versa; (ii) “including” (and with correlative

meaning “include”) means including without limiting the generality of any description preceding or succeeding such term and

shall be deemed in each case to be followed by the words “without limitation”; (iii) the words “herein,” “hereto,”

and “hereby” and other words of similar import in this Agreement shall be deemed in each case to refer to this Agreement as

a whole and not to any particular section or other subdivision of this Agreement; (iv) the word “if” and other words of similar

import when used herein shall be deemed in each case to be followed by the phrase “and only if”; and (v) the term “or”

means “and/or”. The parties have participated jointly in the negotiation and drafting of this Agreement. Consequently, in

the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the

parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any

provision of this Agreement.

(g) Notices.

All notices, consents, waivers and other communications hereunder shall be in writing and shall be deemed to have been duly given when

delivered (i) in person, (ii) by electronic means (including email), with affirmative confirmation of receipt, (iii) one Business Day

after being sent, if sent by reputable, nationally recognized overnight courier service or (iv) three (3) Business Days after being mailed,

if sent by registered or certified mail, pre-paid and return receipt requested, in each case to the applicable party at the following

addresses (or at such other address for a party as shall be specified by like notice):

If to the SPAC, to:

Copley Acquisition Corp.

Suite 4005-4006, 40/F, One Exchange Square

8 Connaught Place, Central, Hong Kong

Attn: [***]

Email: [***]

with a copy (which will not constitute notice) to:

Winston Taylor LLP

800 Capitol St., Suite 2400

Houston, Texas 77002

Attn: [***]

Telephone No.: [***]

Email: [***]

If to the Company, to:

Ignite Proteomics, LLC

[***]

Attn: [***]

Telephone No.: [***]

Email: [***]

with a copy (which will not constitute notice) to:

Meister Seelig & Schuster PLLC

125 Park Avenue, 7th Floor

New York, New York 10017

Attn: Louis Lombardo

Telephone No.: [***]

Email: [***]

If to a Holder, to: the address set forth under such Holder’s name on the signature page hereto, with a copy (which will not constitute notice) to, if not the party sending the notice, each of the Company and the SPAC (and each of their copies for notices hereunder).

(h) Amendments

and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally

or in a particular instance, and either retroactively or prospectively) only with the written consent of the SPAC, the Company and each

Holder. No failure or delay by a party in exercising any right hereunder shall operate as a waiver thereof. No waivers of or exceptions

to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further

or continuing waiver of any such term, condition, or provision.

(i) Severability.

In case any provision in this Agreement shall be held invalid, illegal or unenforceable in a jurisdiction, such provision shall be modified

or deleted, as to the jurisdiction involved, only to the extent necessary to render the same valid, legal and enforceable, and the validity,

legality and enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby nor shall the validity,

legality or enforceability of such provision be affected thereby in any other jurisdiction. Upon such determination that any term or other

provision is invalid, illegal or incapable of being enforced, the parties will substitute for any invalid, illegal or unenforceable provision

a suitable and equitable provision that carries out, so far as may be valid, legal and enforceable, the intent and purpose of such invalid,

illegal or unenforceable provision.

(j) Specific

Performance. Each Holder acknowledges that its obligations under this Agreement are unique, recognizes and affirms that in the event

of a breach of this Agreement by such Holder, money damages will be inadequate and the Company and the SPAC will not have an adequate

remedy at law, and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed

by such Holder in accordance with their specific terms or were otherwise breached. Accordingly, the Company and the SPAC shall be entitled

to seek an injunction or restraining order to prevent breaches of this Agreement by any such Holder and to enforce specifically the terms

and provisions hereof, without the requirement to post any bond or other security or to prove that money damages would be inadequate,

this being in addition to any other right or remedy to which such party may be entitled under this Agreement, at law or in equity.

(k) Expenses.

Each party shall be responsible for its own fees and expenses (including the fees and expenses of investment bankers, accountants and

counsel) in connection with the entering into of this Agreement, the performance of its obligations hereunder and the consummation of

the transactions contemplated hereby; provided, that in the event of any Action arising out of or relating to this Agreement, the non-prevailing

party in any such Action will pay its own expenses and the reasonable documented out-of-pocket expenses, including reasonable attorneys’

fees and costs, reasonably incurred by the prevailing party.

(l) No

Partnership, Agency or Joint Venture. This Agreement is intended to create a contractual relationship among the Holders, the Company

and the SPAC, and is not intended to create, and does not create, any agency, partnership, joint venture or any like relationship among

the parties hereto or among any other Company Members entering into voting agreements with the Company or the SPAC. No Holder is affiliated

with any other holder of Membership Interests entering into a voting or support agreement with the Company or the SPAC in connection with

the Business Combination Agreement and Holder has acted independently regarding its decision to enter into this Agreement. Nothing contained

in this Agreement shall be deemed to vest in the Company or the SPAC any direct or indirect ownership or incidence of ownership of or

with respect to any Membership Interests.

(m) Further

Assurances. From time to time, at another party’s request and without further consideration, each party shall execute and deliver

such additional documents and take all such further action as may be reasonably necessary or desirable to consummate the transactions

contemplated by this Agreement.

(n) Entire

Agreement. This Agreement (together with the Business Combination Agreement to the extent referred to herein) constitutes the full

and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement

relating to the subject matter hereof existing between the parties is expressly canceled; provided, that, for the avoidance

of doubt, the foregoing shall not affect the rights and obligations of the parties under the Business Combination Agreement or any Ancillary

Document. Notwithstanding the foregoing, nothing in this Agreement shall limit any of the rights or remedies of the SPAC or any of the

obligations of any Holder under any other agreement between such Holder and the SPAC or any certificate or instrument executed by such

Holder in favor of the SPAC, and nothing in any other agreement, certificate or instrument shall limit any of the rights or remedies of

the SPAC or any of the obligations of such Holder under this Agreement.

(o) Counterparts.

This Agreement may be executed and delivered (including by electronic signature or by email in portable document format) in two or more

counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original

but all of which taken together shall constitute one and the same agreement.

[Remainder of Page Intentionally Left Blank;

Signature Page Follows]

IN WITNESS WHEREOF, the parties have executed

this Agreement as of the date first written above.

The SPAC:

COPLEY ACQUISITION CORP

By:

Name:

Title:

The Company:

IGNITE PROTEOMICS, LLC

By:

Name:

Title:

[Signature Pages Continue]

{Signature Page to Seller Support Agreement}

Holder:

By:

Name:

Total Membership Interests:

Number and class of Units of the Company: ______________

Address for Notice:

Address:

Telephone No.:

Email:

{Signature Page to Seller Support Agreement}

EX-10.2

Filename: ea029430701ex10-2.htm · Sequence: 4

Exhibit 10.2

AMENDMENT TO LETTER AGREEMENT

THIS AMENDMENT TO LETTER

AGREEMENT (this “Amendment”) is made and entered into as of [__], 2026, and shall be effective as of the

Closing (defined below), by and among (i) Copley Acquisition Corp, a Cayman Islands exempted company incorporated with limited

liability (“Company” or the “SPAC”), (ii) Copley Acquisition Sponsors, LLC,

a Delaware limited liability company (the “Sponsor”), (iii) [Ignite Holdings, Inc.], a Delaware corporation

(“Pubco”), (iv) Ignite Proteomics, LLC, a Delaware limited liability company (the “Target

Company”), and (v) the undersigned individuals, each of whom is a member of the Company’s board of directors and/or

management team and who, along with the Sponsor and other transferees of the applicable Company securities, is referred to as an “Insider”

pursuant to the terms of the Letter Agreement (as defined below). Capitalized terms used but not otherwise defined herein shall have the

respective meanings assigned to such terms in the Original Letter Agreement (as defined below) (and if such term is not defined in the

Original Letter Agreement, then in the Business Combination Agreement (as defined below)).

RECITALS

WHEREAS, Company, the

Sponsor and the other undersigned Insiders are parties to that certain Letter Agreement, dated as of April 30, 2025 (the “Original

Letter Agreement” and, as amended by this Amendment, the “Letter Agreement”), pursuant to which

the Sponsor and the undersigned Insiders agreed, among other matters, to (i) waive their redemption rights with respect to their

Ordinary Shares that they may have in connection with the consummation of the proposed Business Combination, (ii) waive their rights

to liquidating distributions from the Trust Account with respect to their Founder Shares (although they will be entitled to liquidating

distributions from the trust account with respect to any Offering Shares), (iii) vote any Ordinary Shares owned by it, him or her

in favor of any proposed Business Combination for which the Company seeks approval, and (iv) certain transfer restrictions with respect

to the Founder Shares, Private Placement Warrants and Working Capital Warrants (and the Ordinary Shares underlying such Private Placement

Warrants and Working Capital Warrants);

WHEREAS, on or about

the date hereof, the Company, Pubco, the Target Company, [Ignite Merger Sub I Inc.], a Delaware corporation (“SPAC

Merger Sub”) and [Ignite Merger Sub II LLC], a Delaware limited liability company and a wholly-owned subsidiary of

Pubco (“Company Merger Sub”), and the other parties thereto, entered into that certain Business Combination

Agreement (the “Business Combination Agreement”);

WHEREAS, pursuant to

the Business Combination Agreement, subject to the terms and conditions thereof, among other matters, the SPAC shall continue out of the

Cayman Islands and into the State of Delaware so as to convert into and become a Delaware corporation pursuant to the Cayman Islands Companies

Act (as Revised) (the “Act”) and the applicable provisions of the Delaware General Corporation Law (the “DGCL”)

and, upon the consummation of the transactions contemplated by the Business Combination Agreement (the “Closing”):

(a) SPAC Merger Sub will merge with and into SPAC, with SPAC continuing as the surviving entity (the “SPAC Merger”)

and each issued and outstanding security of the SPAC immediately prior to the effective time of the SPAC Merger shall no longer be outstanding

and shall automatically be cancelled, in exchange for the issuance to the holder thereof of a substantially equivalent Pubco security;

(b) Company Merger Sub will merge with and into the Target Company, with the Target Company continuing as the surviving entity (the “Company

Merger” and together with the SPAC Merger, the “Mergers”) and each issued and outstanding security

of the Target Company immediately prior to the effective time of the Company Merger shall no longer be outstanding and shall automatically

be cancelled, in exchange for the issuance to the holder thereof of shares of common stock of Pubco; and (c) as a result of the Mergers,

the SPAC and the Target Company will become wholly-owned subsidiaries of Pubco and Pubco will become a publicly traded company, all in

accordance with the applicable provisions of the DGCL and the Act;

WHEREAS, the parties

hereto desire to amend the Original Letter Agreement (i) to add Pubco and the Target Company as parties to the Letter Agreement, (ii)

to revise the terms thereof in order to reflect the transactions contemplated by the Business Combination Agreement, including without

limitation the issuance of shares of Pubco Common Stock and Pubco Warrants in exchange for the Company’s Ordinary Shares and Warrants,

respectively, and (iii) to amend the terms of the lock-up set forth in Section 5 of the Original Agreement; and

WHEREAS, pursuant to

Section 13 of the Original Letter Agreement, the Original Letter Agreement can be amended with the written consent of each Insider,

the Sponsor and Company.

NOW, THEREFORE, in

consideration of the premises and the mutual promises herein made, and in consideration of the representations, warranties and covenants

herein contained, and intending to be legally bound hereby, the parties hereto agree as follows:

1. Addition

of Pubco and the Target Company as Parties to the Letter Agreement. The parties hereby agree to add Pubco and the Target Company as

parties to the Letter Agreement. The parties further agree that, from and after the Closing, (i) all of the rights and obligations of

the Company under the Letter Agreement shall be, and hereby are, assigned and delegated to Pubco as if it were the original “Company”

party thereto, and (ii) all references to the Company under the Letter Agreement relating to periods from and after the Closing shall

instead be a reference to Pubco. By executing this Amendment, Pubco hereby agrees to be bound by and subject to all of the terms and conditions

of the Letter Agreement, as amended by this Amendment, from and after the Closing as if it were the original “Company” party

thereto.

2. Amendments

to the Letter Agreement. The parties hereby agree to the following amendments to the Letter Agreement:

(a) The

defined terms in this Amendment, including without limitation in the preamble and recitals hereto, and the definitions incorporated by

reference from the Business Combination Agreement, are hereby added to the Letter Agreement as if they were set forth therein.

(b) The

parties hereby agree that (i) the terms “Offering Shares,” “Class A Ordinary Shares,” “Class B Ordinary

Shares,” “Ordinary Shares,” and “Founder Shares”, as used in the Letter Agreement shall include without

limitation any and all shares of Pubco Common Stock into which any such securities will convert in the Mergers, and (ii) the terms “Private

Placement Warrants” and “Working Capital Warrants” shall include without limitation any and all Pubco Private Warrants

into which such securities will convert in the Mergers. The parties further agree that from and after the Closing, any reference in the

Letter Agreement to the terms “Private Placement Warrants” and “Working Capital Warrants” will instead refer to

Pubco Private Warrants (and any warrants of Pubco or any successor entity issued in consideration of or in exchange for any of such warrants).

upon the Closing, Section 5(a) of the Original Letter Agreement is hereby deleted in its entirety and replaced with the following:

“(a) any Founder

Shares or the Class A Ordinary Shares issuable upon conversion of the Founder Shares (the “Founder Shares Lock-up”)

until the earlier of (i) 90 days following the consummation of the Business Combination; or (ii) the date on which the Company completes

a liquidation, merger, share exchange, reorganization or other similar transaction after the initial Business Combination, that results

in all of the Company’s shareholders having the right to exchange their Ordinary Shares for cash, securities or other property (the

“Founder Shares Lock-up Period”); and”

3. Effectiveness.

Notwithstanding anything to the contrary contained herein, this Amendment shall become effective upon the Closing. In the event that the

Business Combination Agreement is terminated in accordance with its terms prior to the Closing, this Amendment and all rights and obligations

of the parties hereunder shall automatically terminate and be of no further force or effect.

4. Miscellaneous.

Except as expressly provided in this Amendment, all of the terms and provisions in the Original Letter Agreement are and shall remain

in full force and effect, on the terms and subject to the conditions set forth therein. This Amendment does not constitute, directly or

by implication, an amendment or waiver of any provision of the Original Letter Agreement, or any other right, remedy, power or privilege

of any party thereto, except as expressly set forth herein. Any reference to the Letter Agreement in the Original Letter Agreement or

any other agreement, document, instrument or certificate entered into or issued in connection therewith shall hereinafter mean the Letter

Agreement, as amended by this Amendment (or as the Letter Agreement may be further amended or modified in accordance with the terms thereof

and hereof). The terms of this Amendment shall be governed by, enforced and construed and interpreted in a manner consistent with the

provisions of the Original Letter Agreement, including without limitation Section 13 thereof.

{REMAINDER OF PAGE INTENTIONALLY LEFT BLANK;

SIGNATURE PAGES FOLLOW}

IN WITNESS WHEREOF,

each party hereto has signed or has caused to be signed by its officer thereunto duly authorized this Amendment as of the date first above

written.

Sincerely,

COPLEY ACQUISITION SPONSORS, LLC

By:

Name:

Title:

COPLEY ACQUISITION CORP

By:

Name:

Title:

IGNITE HOLDINGS, INC.

By:

Name:

Title:

IGNITE PROTEOMICS, LLC

By:

Name:

Title:

{Signature Page to Amendment to Letter Agreement}

Name:

Francis Chi Yin Ng

Name:

Chibo Tang

Name:

Menghan “Henry” Zhang

Name:

Tok Li

Name:

Chun Kit Chu

Name:

Tsz Chiu Guan

Name:

Jean-Baptiste Djebbari

Name:

Ying Shirley Meng

Name:

Rebecca Fannin

Name:

Robert J. Whitsitt

{Signature Page to Amendment to Letter Agreement}

EX-10.3 — SIDE LETTER AND GUARANTY AGREEMENT, DATED JUNE 10, 2026, BY AND AMONG ADITXT, INC. AND COPLEY ACQUISITION CORP

EX-10.3

Filename: ea029430701ex10-3.htm · Sequence: 5

Exhibit 10.3

SIDE LETTER AND GUARANTY AGREEMENT

This Side Letter and Guaranty

Agreement (this “Guaranty”) is made and entered into as of June 9, 2026, by and between Aditxt Inc., a Delaware corporation

(“Guarantor”), and Copley Acquisition Corp, an exempted company incorporated under the laws of the Cayman Islands (“SPAC”).

RECITALS

WHEREAS, SPAC, Ignite

Proteomics Holdings, Inc., a Delaware corporation (“Pubco”), Ignite Merger Sub I Inc., a Delaware corporation, Ignite

Merger Sub II LLC, a Delaware limited liability company, Jeffrey M. Busch, as Seller Representative, Chibo Tang, as SPAC Representative,

and Ignite Proteomics, LLC, a Delaware limited liability company (the “Company”), have entered into that certain Business

Combination Agreement, dated as of [●], 2026 (as may be amended, restated, supplemented or otherwise modified from time to time,

the “Business Combination Agreement”);

WHEREAS, the Company

is a direct subsidiary of Guarantor;

WHEREAS, as a condition

to and in consideration of SPAC’s willingness to enter into and perform its obligations under the Business Combination Agreement,

SPAC has required that Guarantor execute and deliver this Guaranty; and

WHEREAS, Guarantor

has determined that the execution, delivery and performance of this Guaranty is in the best interests of Guarantor because Guarantor will

derive substantial direct and indirect benefits from the transactions contemplated by the Business Combination Agreement.

NOW, THEREFORE, in

consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

the parties hereto agree as follows:

1. Defined

Terms. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Business Combination

Agreement.

2. Guaranty.

(a) Guarantor

hereby absolutely, unconditionally and irrevocably guarantees to SPAC, as primary obligor and not merely as surety, the full, complete

and punctual payment, performance and discharge of each and every obligation of the Company arising under or in connection with the Business

Combination Agreement and all Ancillary Documents to which the Company is a party (collectively, the “Guaranteed Obligations”),

including, without limitation: (i) the payment of all Expenses required to be paid by or on behalf of the Company pursuant to the

Business Combination Agreement; (ii) the repayment, forgiveness, discharge or other satisfaction in full of all Indebtedness of the

Company as required by Section 7.3(g) of the Business Combination Agreement; (iii) the performance of all covenants and agreements

of the Company contained in the Business Combination Agreement, including under Article VI thereof; (iv) any reimbursement or

indemnification obligations of the Company arising under the Business Combination Agreement; and (v) any other monetary or performance

obligations of the Company arising under the Business Combination Agreement or any Ancillary Document to which the Company is a party.

(b) If

the Company shall fail to pay, perform or discharge any Guaranteed Obligation when due (whether at stated maturity, by acceleration, demand

or otherwise), Guarantor shall, promptly upon demand by SPAC, pay, perform or discharge, or cause to be paid, performed or discharged,

such Guaranteed Obligation. Each failure by the Company to pay, perform or discharge a Guaranteed Obligation shall give rise to a separate

cause of action hereunder and separate suits may be brought hereunder as each cause of action arises.

3. Nature

of Guaranty. This Guaranty is an absolute, unconditional and continuing guaranty of the full and punctual payment, performance and

discharge of the Guaranteed Obligations. This Guaranty is in no way conditioned upon any requirement that SPAC first attempt to collect

any Guaranteed Obligation from the Company or resort to any security or other means of obtaining payment of any Guaranteed Obligation

that SPAC now has or may acquire after the date hereof, or upon any other contingency whatsoever. Should the Company default in the payment,

performance or discharge of any Guaranteed Obligation, the obligations of Guarantor hereunder with respect to such Guaranteed Obligation

shall become immediately due and performable by Guarantor regardless of any defense, right or claim that the Company may have against

SPAC. This Guaranty shall not be discharged except by complete payment and performance of the Guaranteed Obligations.

4. Waivers.

(a) Guarantor

hereby unconditionally and irrevocably waives, to the fullest extent permitted by applicable Law:

(i) any

defense arising by reason of any claim or defense based upon an election of remedies by SPAC;

(ii) any

defense based upon any statute or rule of law that provides that the obligation of a surety must be neither larger in amount nor in other

respects more burdensome than that of the principal;

(iii) any

duty on the part of SPAC to disclose to Guarantor any matter, fact or thing relating to the business, condition (financial or otherwise),

operations, performance, properties or prospects of the Company now known or hereafter known by SPAC;

(iv) notice

of acceptance of this Guaranty, notice of any Guaranteed Obligation incurred, notice of any action at any time taken or omitted by SPAC,

and generally all demands and notices of every kind;

(v) any

right to require SPAC to (A) proceed against the Company, (B) proceed against or exhaust any security held from the Company,

or (C) pursue any other remedy in SPAC’s power whatsoever;

(vi) any

defense based on or arising out of any defense of the Company other than the defense of full payment and performance of all Guaranteed

Obligations;

(vii) any

defense based on any right of set-off or counterclaim against or in respect of the obligations of Guarantor hereunder;

(viii) diligence,

presentment, demand of performance, filing of any claim, any right to require any proceeding first against the Company, protest, notice

(except as specifically required herein) and all other demands and notices whatsoever with respect to the Guaranteed Obligations;

(ix) any

defense based upon the incapacity, lack of authority, or any disability or other defense of the Company, including any defense based on

or arising out of the lack of validity or the unenforceability of the Guaranteed Obligations or any agreement or instrument relating thereto;

and

(x) the

benefit of any statute of limitations affecting Guarantor’s liability hereunder or the enforcement hereof, to the extent permitted

by applicable Law.

(b) Guarantor

consents and agrees that SPAC may, at any time and from time to time, without notice to or further consent of Guarantor, and without impairing

or releasing the obligations of Guarantor hereunder: (i) agree with the Company to make any change in the terms of any Guaranteed

Obligation; (ii) take or fail to take any action of any kind in respect of any security for any Guaranteed Obligation; (iii) exercise

or refrain from exercising any rights against the Company or others; or (iv) compromise or subordinate any Guaranteed Obligation,

including any security therefor.

5. Reinstatement.

Guarantor agrees that this Guaranty shall continue to be effective or shall be reinstated, as the case may be, if at any time any payment

made or value received with respect to a Guaranteed Obligation is rescinded or must otherwise be returned by SPAC upon the insolvency,

bankruptcy or reorganization of the Company or otherwise, all as though such payment had not been made or value received.

6. No

Subrogation. Notwithstanding anything to the contrary herein, Guarantor shall not exercise any right of subrogation, contribution,

reimbursement, indemnification or similar right against the Company by reason of this Guaranty or any payment or performance hereunder

until the date on which all Guaranteed Obligations have been indefeasibly paid and performed in full.

7. Representations

and Warranties of Guarantor. Guarantor hereby represents and warrants to SPAC that:

(a) Guarantor

is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware.

(b) Guarantor

has all requisite corporate power and authority to execute and deliver this Guaranty and to perform its obligations hereunder. The execution,

delivery and performance of this Guaranty have been duly authorized by all necessary corporate action on the part of Guarantor.

Guaranty has been duly executed and delivered by Guarantor and constitutes the legal, valid and binding obligation of Guarantor, enforceable

against Guarantor in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium

and similar Laws affecting creditors’ rights generally and subject, as to enforceability, to general principles of equity.

(d) The

Company is a direct or indirect subsidiary of Guarantor.

(e) The

execution, delivery and performance of this Guaranty by Guarantor does not and will not (i) violate the organizational documents

of Guarantor, (ii) violate any applicable Law or Order, or (iii) result in a breach of any material agreement to which Guarantor

is a party.

8. Notices.

All notices, requests, demands, claims and other communications hereunder shall be in writing and shall be deemed to have been duly given

when delivered in accordance with the notice provisions set forth in Section 10.1 of the Business Combination Agreement, with notices

to Guarantor to be delivered to the following address:

Aditxt, Inc.

15000 West 6th Avenue, Suite 400

Golden, Colorado 80401

Attn: [***]

Email: [***]

with a copy (which will not constitute

notice) to:

Meister Seelig & Schuster PLLC

125 Park Ave, 7th Floor

New York, New York 10017

Attn: [***]

Email: [***]

and notices to SPAC to be delivered as set forth

in Section 10.1 of the Business Combination Agreement.

9. Governing

Law. This Guaranty shall be governed by, construed and enforced in accordance with the Laws of the State of Delaware without regard

to the conflict of laws principles thereof.

10. Jurisdiction.

All Actions arising out of or relating to this Guaranty shall be heard and determined exclusively in any state court located in Wilmington,

Delaware or federal court located in the State of Delaware (or in any appellate court thereof) (the “Specified Courts”).

Each party hereto hereby (a) submits to the exclusive jurisdiction of any Specified Court for the purpose of any Action arising out

of or relating to this Guaranty brought by any party hereto and (b) irrevocably waives, and agrees not to assert by way of motion,

defense or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that

its property is exempt or immune from attachment or execution, that the Action is brought in an inconvenient forum, that the venue of

the Action is improper, or that this Guaranty may not be enforced in or by any Specified Court.

11. WAIVER

OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL

BY JURY WITH RESPECT TO ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS GUARANTY OR THE TRANSACTIONS

CONTEMPLATED HEREBY. EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE,

THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND

THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS GUARANTY BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN

THIS SECTION 11.

12. Amendments.

No amendment, modification or waiver of any provision of this Guaranty shall be effective unless the same shall be in writing and signed

by each of SPAC and Guarantor. No waiver by any party of any default, misrepresentation or breach of warranty or covenant hereunder, whether

intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant

hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence.

13. Successors

and Assigns. This Guaranty shall be binding upon Guarantor and its successors and assigns and shall inure to the benefit of SPAC and

its successors and assigns. Guarantor shall not assign its obligations hereunder without the prior written consent of SPAC, and any purported

assignment without such consent shall be null and void.

14. Entire

Agreement. This Guaranty constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and supersedes

all prior agreements and undertakings, both written and oral, between the parties with respect to the subject matter hereof. For the avoidance

of doubt, this Guaranty is in addition to, and does not limit, modify or supersede, any obligation of the Company under the Business Combination

Agreement.

15. Severability.

In the event that any provision of this Guaranty or the application thereof becomes or is declared by a court of competent jurisdiction

to be illegal, void or unenforceable, the remainder of this Guaranty shall continue in full force and effect and the application of such

provision to other Persons or circumstances shall be interpreted so as reasonably to effect the intent of the parties hereto.

16. Counterparts.

This Guaranty may be executed in one or more counterparts (including by facsimile, .pdf or other electronic transmission), each of which

shall be deemed an original but all of which taken together shall constitute one and the same instrument.

17. Specific

Performance. Each party hereto acknowledges that the other party would be irreparably harmed by any breach of this Guaranty and that

monetary damages may not be an adequate remedy therefor. Accordingly, each party hereto shall be entitled to seek specific performance

and injunctive or other equitable relief as a remedy for any breach or threatened breach of this Guaranty, without the necessity of proving

actual damages or posting any bond or other security, and such remedies shall not be deemed to be the exclusive remedies for a breach

of this Guaranty but shall be in addition to all other remedies available at law or in equity.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties

hereto have caused this Guaranty to be duly executed and delivered as of the date first written above.

GUARANTOR:

ADITXT INC.

By:

Name:

Title:

SPAC:

COPLEY ACQUISITION CORP

By:

Name:

Chibo Tang

Title:

Co-CEO

EX-99.1 — PRESS RELEASE, DATED JUNE 9, 2026

EX-99.1

Filename: ea029430701ex99-1.htm · Sequence: 6

Exhibit 99.1

Aditxt Signed Definitive Agreement Valuing

Ignite Proteomics at Approximately $150 Million

Transaction values Ignite Proteomics at approximately

$150 million and is expected to position Ignite as an independent NYSE-listed functional proteomics company, while Aditxt continues as

a separate Nasdaq-listed company

MOUNTAIN VIEW, CA, GOLDEN, CO and HONG KONG

— June 9, 2026 — Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a qualified acquisition corp and Ignite Proteomics,

LLC (“Ignite”, or “Ignite Proteomics”), a functional proteomics company and 100%-owned subsidiary of Aditxt, today

announced that Ignite and strategic counterparty agreed to sign a definitive business combination agreement.

The transaction values Ignite at an implied equity

value of approximately $150 million, subject to the terms and conditions of the business combination agreement. Upon closing, Ignite

is expected to separate from Aditxt and become an independent publicly traded company through a newly formed public holding company expected

to be named Ignite Proteomics , Inc. (“Ignite Holdings, Inc,”, or “Pubco”).

Following closing, the acquisition corp. and Ignite

are expected to become wholly owned subsidiaries of the newly formed public holding company. Pubco’s common stock and public warrants

are expected to be listed on the New York Stock Exchange, subject to approval of the listing application and satisfaction of customary

closing conditions.

For Aditxt, the transaction is expected to unlock

value in its 100%-owned Ignite subsidiary while allowing Aditxt to continue operating as a separate Nasdaq-listed public company, subject

to continued compliance with Nasdaq listing requirements.

Strategic Value Creation for Aditxt

Aditxt acquired Ignite as part of its strategy

to identify, acquire and advance differentiated health innovation platforms. The proposed business combination is intended to provide

Ignite with a dedicated public-company platform, greater visibility and access to growth capital, while highlighting the value of Ignite

within Aditxt’s portfolio.

“Today’s announcement represents an

important milestone for Aditxt and Ignite,” said Jeff Busch, Interim Chief Executive Officer of Aditxt and Chief Executive Officer

of Ignite Proteomics. “Aditxt owns 100% of Ignite, a differentiated precision oncology asset, and this transaction is expected

to unlock that value through a business combination that values Ignite at approximately $150 million. At the same time, Aditxt is expected

to continue as a separate Nasdaq-listed company focused on advancing its broader health innovation strategy.”

Mr. Busch continued, “For Ignite, becoming

an independent public company is expected to provide the focus, visibility and access to capital needed to accelerate commercialization,

expand clinical evidence generation and pursue broader adoption of its functional proteomics platform in oncology.”

Advancing Functional Proteomics in Precision

Oncology

Ignite is developing and commercializing a functional

proteomics platform designed to help physicians better understand the biological activity driving a patient’s tumor. Unlike traditional

approaches that may infer protein activity from genomic information, Ignite’s platform is designed to directly measure protein and

phosphoprotein signaling activity from tumor tissue, providing a functional view of tumor biology that may support more informed therapy

selection.

Ignite’s current commercial focus is in

breast cancer, with a broader development strategy intended to support expansion into additional tumor types and treatment settings over

time. The company believes its platform may be particularly relevant as oncology treatment continues to shift toward increasingly targeted

therapeutic classes, including antibody-drug conjugates, immunotherapies and targeted therapies.

Platform Positioned for Commercial and Clinical

Expansion

Ignite’s growth strategy is expected to

focus on expanding clinical adoption, scaling commercial operations, supporting additional clinical evidence generation and pursuing collaborations

with academic institutions, oncology networks, payors and biopharmaceutical partners.

Net proceeds from the transaction, including cash

remaining in the acquisition corp trust account after redemptions and any additional transaction financing, are expected to support Ignite’s

commercialization initiatives, clinical evidence generation, working capital needs and general corporate purposes.

Transaction Overview

The transaction is expected to result in Ignite

becoming an independent publicly listed company through a business combination with the acquisition corp. Following closing, the acquisition

corp. and Ignite are expected to become wholly owned subsidiaries of a newly formed public holding company.

The transaction values Ignite at an implied equity

value of approximately $150 million, with Ignite equity holders expected to receive newly issued shares of Pubco common stock based

on a $10.00 per share reference price, subject to the terms and conditions of the business combination agreement.

The boards of directors / managers of the applicable

parties have approved the transaction. Closing is subject to customary conditions, including approval by acquisition corp. shareholders,

approval by Ignite equity holders, effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission,

approval for listing of Pubco’s common stock and public warrants on the NYSE, satisfaction of applicable regulatory and third-party

consent requirements, and satisfaction of minimum cash / financing conditions.

Following closing, the combined company is expected

to be led by Ignite’s management team. Pubco’s board of directors is expected to consist of seven directors designated by

Ignite, including a majority of independent directors.

About Ignite Proteomics

Ignite Proteomics is a functional proteomics company

focused on advancing precision oncology through direct measurement of protein expression and pathway activation. The company’s Reverse

Phase Protein Array platform is designed to measure functional protein and phosphoprotein activity from tumor tissue to support therapy-selection

insights across oncology.

Ignite’s current commercial focus is in

breast cancer, with a broader development strategy intended to support future expansion into additional tumor types, therapeutic classes

and data-driven clinical applications.

For more information, visit https://igniteproteomics.com/

About Aditxt, Inc.

Aditxt, Inc. (NASDAQ: ADTX) is a public company

focused on developing and commercializing health innovation platforms. Ignite Proteomics is currently a 100%-owned subsidiary of Aditxt.

Through the proposed business combination, Aditxt

expects to unlock value in Ignite at an implied equity value of approximately $150 million, while Ignite is expected to become

an independent publicly traded company. Aditxt is expected to continue as a separate Nasdaq-listed public company, subject to continued

compliance with Nasdaq listing requirements.

About the Acquisition Corp

The undisclosed acquisition corp is a special

purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization

or similar business combination with one or more businesses.

Advisors

Ladenburg Thalmann & Co. Inc. is serving as

financial advisor to the newly formed public holding company and Ignite Proteomics, LLC, and Meister Seelig & Schuster PLLC is serving

as legal counsel.

Additional Information and Where to Find It

In connection with the proposed transaction, Pubco

intends to file with the SEC a registration statement on Form S-4, which will include a proxy statement / prospectus of the acquisition

corp. and Pubco. The acquisition corp., Pubco, Aditxt and Ignite urge investors, shareholders and other interested persons to read, when

available, the preliminary and definitive proxy statement / prospectus, as well as other documents filed with the SEC, because these documents

will contain important information about the acquisition corp., Pubco, Aditxt, Ignite and the proposed transaction.

Investors and security holders will be able to

obtain free copies of the proxy statement / prospectus and other documents filed with the SEC by the acquisition corp, Pubco, Aditxt and

Ignite through the website maintained by the SEC at www.sec.gov.

Participants in the Solicitation

The acquisition corp., Pubco, Aditxt, Ignite and

their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation

of proxies from the acquisition corp. shareholders in connection with the proposed transaction. Information regarding the persons who

may, under SEC rules, be deemed participants in the solicitation of the acquisition corps shareholders in connection with the proposed

transaction will be set forth in the registration statement / proxy statement / prospectus when filed with the SEC.

No Offer or Solicitation

This press release is for informational purposes

only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote, consent

or approval, in any jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of

applicable securities laws.

Forward-Looking Statements

This press release contains forward-looking statements

within the meaning of applicable federal securities laws, including statements regarding the proposed business combination, the anticipated

benefits of the transaction, the expected separation of Ignite from Aditxt, the expected listing of the combined company’s securities

on the NYSE, the implied equity value of Ignite, Aditxt’s expected continued Nasdaq listing, expected use of proceeds, Ignite’s

business strategy, clinical and commercial expansion plans, and the timing and ability of the parties to consummate the transaction.

These forward-looking statements are subject to

risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including

risks related to the parties’ ability to satisfy closing conditions, obtain required shareholder and regulatory approvals, complete

any contemplated financing, satisfy NYSE and Nasdaq listing requirements, satisfy continued Nasdaq listing requirements applicable to

Aditxt, and execute their respective business and commercialization strategies. The parties undertake no obligation to update any forward-looking

statements, except as required by law.

Media Contact:

IR@aditxt.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.1

Cover

Jun. 10, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 10, 2026

Entity File Number

001-39336

Entity Registrant Name

ADITXT, INC.

Entity Central Index Key

0001726711

Entity Tax Identification Number

82-3204328

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2569 Wyandotte Street

Entity Address, Address Line Two

Suite

101

Entity Address, City or Town

Mountain

View

Entity Address, State or Province

Entity Address, Postal Zip Code

94043

City Area Code

650

Local Phone Number

870-1200

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

ADTX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration